The return of a sign, symptom, or disease after a remission.
| Excerpt | Reference |
|---|
| "The problem of recurrence is addressed." | ( McCarthy, DM, 1979) |
| "The prevention of relapses is a problem." | ( Gnädinger, MC, 1977) |
| "Tetanus relapses are caused by reactivated tetanus spores which have remained in the region of the wound, and made possible by unsatisfactory immunisation during a tetanus infection." | ( Nerke, O; Stöhr, M, 1976) |
| "This recurrence is attributed to chief-cell hyperplasia as the pathology in one third to one half of all patients." | ( Beahrs, OH; Purnell, DC; Scholz, DA, 1977) |
| "Relapses are frequent, but it could be shown that their number can be reduced by more aggressive therapy." | ( Hahnloser, P; Jadoul, D; Petropoulos, P, 1976) |
| "Recurrence is directly related to basal acidity in both tests but is not related to stimulated acid levels preoperatively." | ( Hood, JM; Kennedy, T; MacRae, KD; Spencer, EF, 1976) |
| "This relapse is postulated to be due to localized cerebral vasculitis which was not treated for a sufficient period of time during the initial course of therapy." | ( Feldman, WE; Laupus, WE; Ledaal, P, 1976) |
| "Recurrence is seldom related to hypercalciuria or urinary infection except when infection is caused by or associated with B." | ( Blandy, JP; De Saintonge, MC; Marshall, V; Tresidder, GC; White, RH, 1975) |
| "Relapse is usually clinically milder than the first phase, with variable liver function abnormalities and a tendency toward more marked cholestatic features." | ( Galun, E; Glikson, M; Oren, R; Shouval, D; Tur-Kaspa, R, 1992) |
| "The relapse is discussed taking into account the mechanism of action of ACV, the age of the patient and the immunological response profile." | ( Badoual, J; Boccara, JF; Francoual, C; Houang, M; Le Gall, MA; Lebon, P, 1992) |
| "Relapse is a central problem in the treatment of addictive behaviour, and a specific problem in the out-patient treatment of the opiate withdrawal syndrome." | ( Gossop, M; Strang, J; Unnithan, S, 1992) |
| "Prevention of recurrence is now the main therapeutic problem in the management of duodenal ulcer disease." | ( Soulé, JC, 1991) |
| "Relapse is one of the main complications." | ( Devergie, A; Esperou-Bourdeau, H; Gluckman, E; Ribaud, P; Socie, G; Traineau, R, 1991) |
| "Relapse is a frequent problem for recovered alcoholics since up to 80% do so within 6 months of completing treatment." | ( Kadlec, KE; Naranjo, CA, 1991) |
| "Relapse is common even after apparently adequate therapy and may be seen in up to 25% of cases that involve streptomycin-resistant strains." | ( Dietrich, KA; Dixon, WA; Landau, SW; Miller, WC; Sacher, HL; Sacher, ML, 1991) |
| "Gallstone recurrence is a major problem in the medical treatment of gallstones (treatment with UDCA/CDCA, ESWL, local MTBE lysis)." | ( Leiss, O; von Bergmann, K, 1991) |
| "Recurrences are common and require culture specimens from sexual partners and appropriate antifungal therapy." | ( Horowitz, BJ, 1991) |
| "We conclude that recurrence is predominantly seen in very young children and occurs even under CsA immunosuppression." | ( Ingulli, E; Tejani, A, 1991) |
| "b) Duodenal ulcer recurrence is correlated with persistence of C." | ( Gabriel, P; Kalantzis, N; Kallimanis, G; Mavrogiannis, H; Mouzas, IA; Papantoniou, P, 1990) |
| "Recurrence is one of the major complications of pericarditis." | ( Bayés de Luna, A; Cosín, J; de Miguel Diaz, MA; Guindo, J; Perez Ayuso, MJ; Ramió, J; Rodriguez de la Serna, A; Subirana, MT, 1990) |
| "Recurrences are common and affect up to one third of patients." | ( Hunter, JA; Kemmett, D, 1990) |
| "If recurrences are frequent and at short intervals, antibiotic prophylaxis may be effective, using penicillin V (Oracillin) 250,000 IU daily throughout the entire cold period." | ( Grenier, B, 1990) |
| "Relapse is common once ganciclovir is stopped and maintenance therapy may be required for sustained benefit." | ( Balfour, HH; Fletcher, CV, 1989) |
| "Recurrence is a fundamental reality of the major affective disorders and must be considered in treatment planning." | ( Goodwin, FK, 1989) |
| "Recurrence is a major problem in the medical treatment of gallstones but its extent is still uncertain." | ( Barbara, L; Bazzoli, F; Festi, D; Frabboni, R; Mazzella, G; Roda, E; Taroni, F; Villanova, N, 1989) |
| "The majority of relapses are endocarditis and occur within ten weeks after completion of therapy." | ( Ehni, WF; Reller, LB, 1989) |
| "Duodenal ulcer recurrences are also common in nonsmokers because treatments fail to correct underlying pathogenetic mechanisms of ulcer disease." | ( Orlando, RC, 1987) |
| "Some herpetic recurrences are associated with erythema multiforme and some are not and episodes of erythema multiforme are not always associated with clinical herpetic recurrences." | ( Huff, JC, 1988) |
| "Recurrence is an important problem following operations for hydatid disease in man." | ( Morris, DL; Taylor, DH, 1988) |
| "Early relapses are probably due to insufficient treatment, and late relapses to persisting bacilli or to reinfection." | ( Bourland, J; De Muynck, A; Grillone, S; Groenen, G; Grossetete, G; Husser, JA; Janssens, L; Pattyn, SR, 1988) |
| "Chemoresistant relapse is unlikely to be cured and the high probability of a transient response does not justify the procedure in such cases." | ( Biron, P; Favrot, M; Hartmann, O; Patte, C; Philip, I; Philip, T; Pinkerton, R, 1986) |
| "Relapse is a common sequel of antibiotic-associated colitis due to Clostridium difficile." | ( Bayley, N; McDonald, MI; St John, DJ; Ward, P; Young, GP, 1986) |
| "The site of relapse is discussed in detail in the text." | ( Chan, PY; Hintz, BL; Kagan, AR; McMahon, J; Nussbaum, H; Rao, AR; Ryoo, MC; Wollin, M, 1987) |
| "10%), recurrences are possible." | ( Eichler, I; Götz, M; Wagner, U, 1986) |
| "The chance of recurrence is about 60 percent." | ( Swinker, ML, 1986) |
| "Systemic relapse is still a major problem after multiple CNS relapse and in those in whom the CNS relapse follows or is simultaneous with relapse at other sites." | ( Galicich, J; Jereb, B; Steinherz, P, 1985) |
| "Late recurrence is common." | ( Friedland, GH; Harris, CA; Klein, RS; Small, CB, 1985) |
| "This fall during a relapse is most pronounced when the patient suffers from universal colitis and is least marked in cases of distal colitis." | ( Azad Khan, AK; Truelove, SC, 1980) |
| "The mechanism of recurrence is yet not fully elucidated and therapy still remains a problem." | ( Fanta, D, 1981) |
| "Recurrence is emerging as an important aspect which needs a solution." | ( Thistle, JL, 1983) |
| "Recurrence is of special clinical importance in the following conditions: Membranoproliferative GN type I (in 33%, often severe) and type II (= dense deposit disease, recurrence in 90%, often minor), focal segmental glomerulosclerosis (in 48% of patients with a rapid course (less than 3 years) and in 12% of patients with a longer duration of the original disease; often severe), membranous nephropathy (recurrence rather rare, but often serious), and primary hyperoxaluria (in 100%)." | ( Briner, J; Leumann, EP, 1984) |
| "Forty-nine recurrences are known to have occurred in 228 patients." | ( Lennon, DR; Newman, JE; Wong-Toi, W, 1984) |
| "Ulcer recurrences are as frequent after antacid as after cimetidine." | ( Ippoliti, AF, 1982) |
| "This high rate of relapse is viewed as indicating the need for continued medication in most chronic schizophrenic patients." | ( Aderounmu, AF; Odejide, OA, 1982) |
| "Recurrence is usually not a generalized process occurring throughout the skeleton, but remains restricted to one or several lesions." | ( Bijvoet, OL; Frijlink, WB; Pauwels, EK; Vellenga, CJ, 1981) |
| "Such recurrences are rare." | ( Bujara, K, 1980) |
| "Relapse is frequent in many forms of vasculitis." | ( Conn, DL; Hall, S, 1995) |
| "Relapse is still a common problem after bone marrow transplant (BMT) and teh value of adding etoposide to standard conditioning agents is being tested." | ( Bernstein, E; Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Mullaney, R; Resnick, K; Styler, MJ; Topolsky, D, 1995) |
| "Relapse is always preceded by a positive PCR result." | ( Gadner, H; Heinz, R; Karlic, H; Koller, E; Krieger, O; Lutz, D; Michlmayr, G; Mistrik, M; Pittermann, E, 1995) |
| "The pattern of relapses is described in a consecutive series of 150 patients with vasculitis." | ( Adu, D; Bacon, PA; Emery, P; Gordon, M; Greaves, I; Luqmani, RA; Michael, J; Richards, N, 1993) |
| "During treatment, relapse is correlated with number of pretreatment stones." | ( Coe, FL; Parks, JH, 1994) |
| "Crohn's recurrence is the appearance of objective signs--defined radiologically, endoscopically or pathologically--of Crohn's disease in the bowel of a patient who has previously had a resection of all macroscopically diseased tissue." | ( Rutgeerts, P, 1994) |
| "We conclude that relapse is frequently observed following cyclophosphamide withdrawal in lupus patients with diffuse proliferative glomerulonephritis initially responsive to this therapy." | ( Gomez-Reino, JJ; Gutierrez-Millet, V; Pablos, JL, 1994) |
| "Vulnerability to relapse is a central issue in the biology of schizophrenia." | ( Akiyama, K; Kanzaki, A; Tsuchida, K; Ujike, H, 1994) |
| "Over 80% of recurrences are infrequent and can be treated when they occur n 20% of ulcer patients have 3 recurrences/yr, ulcer complications, or such poor health that recurrence might prove fatal." | ( McCarthy, DM, 1993) |
| "Early recurrence is associated with an increased risk of graft failure." | ( Barnes, RD; Moyes, AL; Musch, DC; Sugar, A, 1994) |
| "This high risk of relapse is not observed when the dose of cyclophosphamide is increased to 200 mg/kg." | ( Bernaudin, F; Blaise, D; Bordigoni, P; Esperou-Bourdeau, H; Gluckman, E; Jouet, JP; Michel, G; Pico, JL; Reiffers, J; Thuret, I, 1994) |
| "Relapses are one of the most serious complications of exudative pericarditis." | ( Puchala, M, 1993) |
| "However, relapses are unlikely to occur five years post therapy." | ( Advani, SH; Gopal, R; Kurkure, PA; Nadkarni, KS; Nair, CN; Pai, SK; Pai, VR; Parikh, PM; Saikia, TK; Vaidya, SJ, 1996) |
| "Recurrence is rare, but metastases disease or death attributable to these lesions is not." | ( Bisceglia, M; Devaney, K; Wenig, BM, 1995) |
| "Prevention of recurrence is difficult, as the recurrence rate is high, treatment duration is potentially long, and residual thoracic pain during menstruation is sometimes seen." | ( Bruggisser, D; Hamacher, J; Mordasini, C, 1996) |
| "Postoperative recurrence is a significant problem but is significantly reduced by the prophylactic use of 5-aminosalicylic acid." | ( Mcleod, RS, 1996) |
| "Recurrences are common, Symptoms are more severe in AIDS patients, with the diarrhea being more watery." | ( Blagburn, BL; Dubey, JP; Lindsay, DS, 1997) |
| "The risk of relapse is probably less than 10%, and this may be prevented by a further course of terbinafine should the expected increasing length of unaffected nail growth stall or cultures become positive." | ( Hull, PR, 1997) |
| "Recurrence is common when cysts rupture during surgical removal." | ( Babuna, O; Canbaz, B; Erdinçler, P; Kaynar, MY, 1997) |
| "The pathogenesis of recurrence is still unknown." | ( Caprilli, R; Taddei, G; Viscido, A, 1995) |
| "Relapse is strikingly rapid among those reporting high levels of craving following cessation." | ( Fortmann, SP; Killen, JD, 1997) |
| "Often, relapse is related to the failure of maintenance therapy." | ( Miner, PB, 1997) |
| "Low-grade relapse is not uncommon in patients who initially presented with diffuse large cell lymphoma." | ( Connors, JM; Gascoyne, RD; Hoskins, PJ; Klasa, R; Le, N; O'Reilly, S; Shenkier, T, 1997) |
| "As recurrence is common, patients should be fully investigated and followed up long term." | ( Campistol, J; Cardo, E; Kirkham, F, 1997) |
| "Recurrence is common, although antiarrhythmic drugs often effectively decrease the number and duration of recurrent AF episodes." | ( Duytschaever, M; Haerynck, F; Jordaens, L; Tavernier, R, 1998) |
| "Ten patients who relapsed are alive a median of 31 months (range, 6-47) after relapse." | ( Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B, 1998) |
| "Postsurgical ulcer recurrence is a challenging problem." | ( Hirschowitz, BI; Lanas, A, 1998) |
| "Crohn's recurrence is the appearance of objective signs defined radiologically, endoscopically or pathologically of Crohn's disease in the bowel of a patient who has previously had a resection of all macroscopically diseased tissue." | ( Rutgeerts, P; Vermeire, S, 1998) |
| "The cause of the recurrence is usually unknown, although in some cases it may be traced to viral infection or may be a consequence of coronary artery bypass grafting." | ( Adler, Y; Bayes de Luna, A; Bayes-Genis, A; Finkelstein, Y; Guindo, J; Rodriguez de la Serna, A; Sagie, A; Shoenfeld, Y; Spodick, DH, 1998) |
| "Late relapse is a quite common event in DLCL lymphomas, with those patients achieving more frequently a second CR and having better survival than early relapsed patients." | ( Bladé, J; Bosch, F; Campo, E; Cervantes, F; Cobo, F; Esteve, J; López-Guillermo, A; Martínez, C; Montoto, S; Montserrat, E; Nomdedeu, B; Perales, M; Sanz, L, 1998) |
| "Recurrences are exceptional." | ( Bourrat, C; Caudie, C; Riche, G; Vial, C, 1998) |
| "Recurrence is frequent, but prognosis is good." | ( Demedts, M; Lamont, J; Verbeken, E; Verschakelen, J, 1998) |
| "Multiple recurrences are not a contraindication." | ( Alton, DJ; Daneman, A; Ein, SH; Gravett, J; Kim, P; Lobo, E, 1998) |
| "Relapses are frequent after treatment withdrawal." | ( Gajdos, P, 1999) |
| "Recurrences are common." | ( Akaraphanth, R; Douglass, MC; Lim, HW, 2000) |
| "However, recurrence is quite common and eradication of infection is difficult." | ( Ratna S, WV, 1999) |
| "Since relapse is frequent when medication is stopped long-term treatment (at least until seroconversion of HBeAg) is warranted." | ( Erhardt, A; Häussinger, D; Heintges, T; Petry, W, 2000) |
| "Risk for recurrence is highest during the first 4 years after the first stone episode." | ( Strohmaier, WL, 2000) |
| "Since relapses are frequent, these patients should be evaluated frequently." | ( Gothefors, L; Malmer, B; Müller Wiefel, DE; Nilsson, K; Stegmayr, BG; Sundelin, B, 2000) |
| "Recurrence is common and may be seen in more than 50% of the patients." | ( Madhan, KK; Symmans, P; Te Strake, L; van Der Merwe, W, 2000) |
| "Relapses are common in children with idiopathic nephrotic syndrome, and this prospective study looks into the possibility of decreasing the frequency of relapses in a selected group of such patients." | ( Mahmoud, MA; Mattoo, TK, 2000) |
| "Recurrences are more frequent in cases with ectopic tumors and in those with a low plasma epinephrine to total catecholamine ratio." | ( Duclos, JM; Gimenez-Roqueplo, AP; La Batide Alanore, A; Plouin, PF; Salenave, S, 2000) |
| "Local recurrence is rarely seen following complete resection of an intact cyst and is usually the result of spillage of live parasites or leaving a residual cyst wall containing germinal epithelium, daughter cysts, or protoscolices during surgery." | ( Langer, B; Sielaff, TD; Taylor, B, 2001) |
| "The relapses are 53." | ( Tsenov, D, 2000) |
| "Relapses are common and become increasingly worse and less responsive to treatment." | ( Carminati, G; Carrera, C; Pinzani, R; Plebani, A; Rancilio, L; Salvini, F, 1997) |
| "Relapse is defined as the re-emergence of Cushing's disease more than one year after operation." | ( Chee, GH; James, RA; Kendall-Taylor, P; Mathias, DB, 2001) |
| "The 2 patients with recurrences are now successfully treated with a calcium channel blocker, an approach, to our knowledge, never before reported for adult-onset nesidioblastosis." | ( Costa, EA; Kaplan, EL; Koka, MR; Straus II, FH; Sugg, SL; Witteles, RM, 2001) |
| "Smoking relapse is common after successful pharmacologic treatment for smoking cessation." | ( Buist, AS; Durcan, MJ; Gonzales, D; Hays, JT; Hurt, RD; Johnston, JA; Niaura, R; Rigotti, NA; Sachs, DP; White, JD; Wolter, TD, 2001) |
| "Alcohol relapse is a major problem in the treatment of alcohol abuse and alcoholism." | ( Le, AD; McBride, WJ; Noronha, A, 2002) |
| "Autoimmune diabetes recurrence is in part responsible for islet graft destruction in type 1 diabetic individuals." | ( Bouillon, R; Gysemans, C; Mathieu, C; Overbergh, L; Van Etten, E; Verstuyf, A; Waer, M, 2002) |
| "The risk of relapse is 6." | ( Chen, X; Feng, S; Huo, W; Li, X; Li, Z; Lu, C; Wu, Q; Ye, G; Yin, Y; Yu, H; Yu, Y; Zhang, L, 2002) |
| "Disease recurrence is less well described." | ( Barsoum, NR; Bunnapradist, S; Jordan, SC; Mougdil, A; Toyoda, M; Vo, A, 2002) |
| "Recurrence is caused by recrudescence rather than re-infection." | ( Banda, HT; Boeree, MJ; Corkill, JE; Gilks, CF; Gondwe, M; Gordon, MA; Gordon, SB; Hart, CA; Molyneux, ME; Walsh, AL, 2002) |
| "Because the risk of recurrence is high, the standard of care is prolonged and high-intensity warfarin (INR near 3) after a venous thromboembolic event, together with the management of associated vascular risk factors." | ( Arvieux, J; Hachulla, E, 2002) |
| "Seizure recurrence is high after a first acute symptomatic seizure due to NC, but this seems related to persistence of active brain lesions." | ( Carpio, A; Hauser, WA, 2002) |
| "Recurrence is uncommon and occurs mainly within the first 24 months, being related to the presence and grade of prolapse as well as to its location, but bears little relation to the rest of factors analysed." | ( Arroyo Sebastián, A; Calpena Rico, R; Candela Polo, F; Costa Navarro, D; Fernández Frías, A; Ferrer Riquelme, R; Lacueva Gómez, FJ; Oliver García, I; Pérez Vicente, F; Serrano Paz, P, 2003) |
| "The recurrences are attributed more to inadequate technique than to the shortcoming of the procedure." | ( Cambal, M; Fillo, J; Labas, P; Ohradka, B; Reis, R, 2003) |
| "Early relapse is common after opiate withdrawal and deprives addicts of important opportunities to develop new, opiate-free cognitive-behavioural habits." | ( Brewer, C; Foster, J; Steele, T, 2003) |
| "Recurrence is common, particularly at sites that are difficult to access." | ( Aktaou, S; El-Bardouni, A; El-Manouar, M; Fizazi, M; Hajjaj-Hassouni, N; Hassikou, H; Loudiye, H; Tazi, A, 2003) |
| "True PEH recurrences are uncommon and frequently asymptomatic." | ( Andujar, JJ; Birdas, T; Caushaj, PF; Gagné, DJ; Keenan, RJ; Landreneau, RJ; Papasavas, PK; Raftopoulos, Y; Robke, J, 2004) |
| "Therefore, recurrence is a problem for many patients." | ( Cox, JT; Petry, KU; Roy, M; Rylander, E, 2004) |
| "If tumor recurrence is suspected, other imaging modalities including positron emission tomography (PET) with (18)F-deoxyglucose (FDG) are often used." | ( Döbert, N; Grünwald, F; Hamscho, N; Matic, V; Menzel, C; Vasvatekis, S; Wördehoff, N; Zaplatnikov, K, 2004) |
| "The risk of recurrence is low if thrombosis was provoked by a major reversible risk factor such as surgery; 3 months of treatment is usually adequate for such patients." | ( Kearon, C, 2004) |
| "Recurrences are common." | ( Püst, B, 2004) |
| "HSV recrudescence is common after routine dental treatment." | ( Avdiushko, SA; Cunningham, LL; Lindroth, JE; Miller, CS, 2004) |
| "pylori, and relapse is effectively prevented by H." | ( Backman, M; Befrits, R; Hedenborg, L; Leijonmarck, CE; Sjöstedt, S; Tour, R, 2004) |
| "Recurrences are exceptional with Miller Fisher syndrome." | ( Bhargavan, PV; Madhavan, S, 2004) |
| "Relapses are relatively uncommon in newly diagnosed patients, but are the rule in patients with more advanced disease." | ( Deininger, MW; Druker, BJ; O'Hare, T; Walters, DK, 2005) |
| "Of course, recurrence is always possible but the recurrence rate is not unacceptable." | ( Bourelle, S; Chotel, F; Cottalorda, J; de Gauzy, JS; Diméglio, A; Kohler, R; Lefort, G; Louahem, D, 2005) |
| "Relapse is a common clinical problem in individuals with substance dependence." | ( Paulus, MP; Schuckit, MA; Tapert, SF, 2005) |
| "Relapses are treated with corticosteroids." | ( Mattle, HP, 2005) |
| "It is known that recurrence is very rare after successful steroid treatment." | ( Choi, WB; Kim, MH; Lee, SK; Lee, SS; Pyun, DK; Seo, DW; Yun, JP, 2005) |
| "No vasculitis relapse is found during the follow-up after withdrawal of PTU." | ( Gao, Y; Guo, XH; Ye, H; Zhao, MH, 2005) |
| "Relapse is the primary cost driver in schizophrenia and is closely related to levels of adherence (compliance) with therapy." | ( Haycox, A, 2005) |
| "Craving and relapse are core symptoms of drug addiction and alcoholism." | ( Bachteler, D; Borchardt, T; Gass, P; Sanchis-Segura, C; Spanagel, R; Sprengel, R; Vengeliene, V; Zghoul, T, 2006) |
| "Once treated, relapses are rare." | ( Kapoor, S; Sharma, A, 2006) |
| "Recurrences are frequent and discourage both the practitioner and the patient." | ( Bignami, M; Castelnuovo, P; De Bernardi, F; De Zen, M; Delù, G; Latorre, P; Maretti, D; Padoan, G; Palma, P, 2005) |
| "pylori recurrence is higher during the first year, which suggests that most recurrences during this period are recrudescence and not true reinfections." | ( Castro-Fernández, M; Cosme, A; Gisbert, JP; Gómez, B; Herrerías, JM; Luna, M; Monés, J; Olivares, D; Pajares, JM; Sánchez-Pobre, P, 2006) |
| "However, recurrences are frequent and corticosteroid requirements are highly variable among patients." | ( Cid, MC; Elkin, M; García-Martínez, A; Grau, JM; Hernández-Rodríguez, J; Hoffman, MP; Kleinman, HK; Pla-Campo, M; Sánchez, M; Segarra, M; Vilardell, C, 2006) |
| "Relapses are rare, but side effects are common, limiting the use of haloperidol in some patients." | ( Honkaniemi, J; Liimatainen, S; Rainesalo, S; Sulavuori, S, 2006) |
| "Remission and relapse are clinical outcomes of increasing interest in schizophrenia." | ( Alonso, J; Haro, JM; Lépine, JP; Novick, D; Ratcliffe, M; Suarez, D, 2006) |
| "Recurrence is almost inevitable, but the mechanisms of recurrence are not fully understood." | ( Folz, BJ; Werner, JA, 2007) |
| "Recurrence is probably the most troublesome complication, characterized by a return of pericardial pain after recovery from an episode of typical acute pericarditis." | ( Martin y Porras, M; Piérard, L; Waleffe, A, 2007) |
| "Once recurrence is diagnosed patients should be treated with an increased dosage of steroid in addition to standard immunosuppressives." | ( Strecker, T; Wiest, GH; Zimmermann, I, 2007) |
| "The risk of disease relapse is affected by several factors, of which the most prominent is nonadherence to maintenance therapy." | ( Boltri, JM; Tindall, WN; Wilhelm, SM, 2007) |
| "These relapses are usually treated with cyclophosphamide (CYC) and glucocorticoids, but the repeated use of CYC carries a risk of substantial toxicity that may limit or prohibit its use in some patients." | ( Fervenza, FC; Geetha, D; Seo, P; Specks, U, 2007) |
| "Recurrence is frequent because of HPV persistence in perilesional skin." | ( Aubin, F; Guerrini, JS, 2007) |
| "However, HCV recurrence is universal and this immediately occurs following LT, which endangers both the graft and patient survival." | ( Ahn, CS; Choi, KM; Chung, YH; Hwang, S; Kim, KH; Lee, SG; Lee, YS; Moon, DB; Park, JI; Suh, DJ, 2007) |
| "Relapse is short-lived and may be induced by the withdrawal of interferon alfa therapy." | ( Cacoub, P; Fois, E; Halfon, P; Landau, DA; Marcellin, P; Martinot-Peignoux, M; Saadoun, D, 2008) |
| "Relapse is common despite cotrimoxazole maintenance therapy." | ( Carel, O; de Castro, N; Delcey, V; Lagrange-Xélot, M; Magnier, JD; Molina, JM; Porcher, R; Sarfati, C, 2008) |
| "The risk of relapse is associated with several factors, of which the foremost is patient nonadherence to prescribed medical therapy." | ( Lichtenstein, GR; Rubin, DT; Sabesin, SM; Velayos, FS; Vitat, P, 2008) |
| "Relapses are also a frequent problem: they may occur despite antibiotic treatment given according to the results of microbiological tests." | ( Kohler, BM; Türoff, A; Vollnberg, H, 2008) |
| "Atrial fibrillation recurrence is a main factor contributing to enlargement of the LA." | ( Chen, Y; Du, H; Lan, X; Ling, Z; Liu, Z; She, Q; Su, L; Wu, J; Yin, Y, 2008) |
| "MCNS relapses are associated with an activation of the immune system, including an expansion of T and B cell compartments and production of growth factors as well as many cytokines." | ( Audard, V; Lang, P; Sahali, D, 2008) |
| "Delayed relapse is not infrequent, even in patients who maintain VR for 1 year after LMV discontinuation." | ( Bak, YT; Byun, KS; Choi, JH; Joo, MK; Jung, YK; Kim, CH; Kim, JH; Kim, JS; Lee, SJ; Park, JJ; Yeon, JE; Yim, HJ, 2009) |
| "The risk of recurrence is more frequent in men, in patients with thrombophilia especially in antithrombin deficiency, and in patients with cancer, residual venous obstruction, or elevated D dimer." | ( Fontcuberta, J, 2008) |
| "Management of relapses is not always straightforward." | ( Thrower, BW, 2009) |
| "Relapse is frequent and must be distinguished from reinfection." | ( Bujanda, L; Cosme, A, 2009) |
| "BV recurrence is common." | ( Behets, F; Hoke, TH; Rasolofomanana, JR; Turner, AN; Van Damme, K; Yotebieng, M, 2009) |
| "Recurrence is common but complications are infrequent and self-limited." | ( Hattori, K; Kumai, T; Sugimoto, K; Takakura, Y; Tanaka, Y; Taniguchi, A, 2009) |
| "Relapse is the major cause of treatment failure in acute lymphoblastic leukemia (ALL), yet there is no established treatment for relapsed ALL." | ( Ahn, HS; Kang, HJ; Kim, EK; Park, JA; Shin, HY; Yoon, JH, 2009) |
| "Relapse is more common when ANCA levels are high but, although elevated, ANCA levels are lower in relapse than at presentation." | ( Hayman, M; Pollock, W; Savige, J; Trevisin, M, 2009) |
| "Relapse is infrequent and generally mild with acid secreting status closely monitored." | ( Fineberg, N; Hirschowitz, BI; Mohnen, J; Wilcox, CM; Worthington, J, 2010) |
| "Recrudescence is essential for the transmission of de-novo resistance." | ( Aguas, R; Day, NP; Dondorp, AM; Lee, SJ; Maude, RJ; Pongtavornpinyo, W; Saralamba, S; Stepniewska, K; White, LJ; White, NJ, 2009) |
| "Relapse is a common and distressing aspect of substance dependence mediated by several biological and psychosocial factors." | ( Anjaiah, M; Chakrabarti, S; Mattoo, SK, 2009) |
| "Relapse is one of the main challenges facing the current treatment of cocaine addiction." | ( Huang, Z; Steketee, JD; Sun, W; Xue, Y, 2010) |
| "A second recurrence is most likely seen in a supernumerary gland." | ( Fornos, JS; Goday, A; Gonzalez, JM; Paricio, PP; Perez, NM; Salmeron, MD; Sancho Insenser, J; Serra, AS; Zambudio, AR, 2010) |
| "The treatment of recurrence is still controversial, and most reports related to use of plasma exchange have been uncontrolled trials with relatively small groups of patients and conflicting results." | ( Canaud, G; Legendre, C; Mamzer, MF; Martinez, F; Niaudet, P; Noël, LH, 2010) |
| "Indeed recurrence is almost the rule in patients with mutations in genes encoding factor H or factor I, whereas patients with a mutation in membrane-cofactor-protein gene have a good transplant outcome." | ( Noris, M; Remuzzi, G, 2010) |
| "Recurrence is a major cause of treatment failure after allogeneic transplantation for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), and treatment options are very limited." | ( Braun, TM; Champlin, R; de Lima, M; de Padua Silva, L; Garcia-Manero, G; Giralt, S; Jones, RB; Komanduri, K; Nguyen, HQ; Thall, PF, 2010) |
| "However, the recurrence is still an unsolved problem." | ( Choi, SI; Chung, WS; Han, KE; Kim, BY; Kim, EK; Kim, TI, 2010) |
| "However, recurrences are possible after early treatment interruption." | ( Ayari, S; Carrabin, L; Couloigner, V; Cox, A; Denoyelle, F; Fayoux, P; Froehlich, P; Garabédian, EN; Leboulanger, N; Lescanne, E; Marianowski, R; Marie, JP; Mom, T; Mondain, M; Nicollas, R; Roger, G; Teissier, N; Triglia, JM; Van Den Abbeele, T, 2010) |
| "Early recurrence is not uncommon and usually involves arteries previously unaffected by dissection, while the risk of late recurrence is low." | ( Ballotta, E; Baracchini, C; Meneghetti, G; Tonello, S, 2010) |
| "Relapse is a hallmark of cocaine addiction." | ( Rebec, GV; Steketee, JD; Sun, W; Xue, Y, 2011) |
| "Ocular relapse is rare in MM." | ( Bolaman, Z; Dayanir, V; Dayanir, Y; Kadikoylu, G; Kocaturk, T; Yavasoglu, I, 2010) |
| "Breast cancer recurrence is often suspected on tumor marker rising in asymptomatic patients." | ( Alberini, JL; Bellet, D; Brain, E; Champion, L; Edeline, V; Giraudet, AL; Le Stanc, E; Madar, O; Pecking, A; Wartski, M, 2011) |
| "Recurrence is a major challenge in management." | ( Abd-Rashid, R; Hussein, A; Naik, VR; Shatriah, I; Yunus, R, 2011) |
| "Mostly, recurrences are caused by identical Candida strains suggesting C." | ( Beikert, FC; Clad, A; Koeninger, A; Le, MT; Technau, K, 2011) |
| "Relapse is a highly prevalent phenomenon in addiction." | ( Sinha, R, 2011) |
| "Early relapse is a parameter that affects clinical outcomes in relapsed diffuse large B cell lymphoma (DLBCL)." | ( Aoki, T; Imahashi, N; Kitamura, K; Nishiyama, T, 2012) |
| "HCV recurrence is more severe and progresses more rapidly in HCV+ recipients who receive grafts from DCD compared with those who receive grafts from DBD." | ( Chandok, N; Croome, KP; Dale, C; Hernandez-Alejandro, R; Levstik, MA; Marotta, P; Mawardi, M; McAlister, V; Quan, D; Wall, W, 2011) |
| "Relapse is a hallmark of drug addiction and a daunting challenge facing the clinical treatment of the disease." | ( Sun, W, 2011) |
| "A high rate of relapse is a daunting challenge facing clinical treatment of cocaine addiction." | ( Lu, L; Rebec, GV; Steketee, JD; Sun, W; Xue, Y, 2012) |
| "Risk of relapse is more likely as age increases, partly because aging confers lower resilience." | ( Benvenuti, A; Calugi, S; Cassano, GB; Fagiolini, A; Frank, E; Kupfer, DJ; Maggi, L; Miniati, M; Rucci, P; Wallace, M, 2011) |
| "Recurrences are the most common complication, but the overall prognosis is related to the etiology, usually benign in idiopathic pericarditis." | ( Imazio, M, 2011) |
| "However, recurrence is not uncommon and eradication of disease can be particularly difficult in patients with diabetes and a mastoid cavity." | ( Cao, W; Chi, F; Jia, X; Liang, Q, 2012) |
| "Among those who do, recurrence is common, and metabolic profile and composition are varied as in the general stone-forming population." | ( Gettman, MT; Krambeck, AE; McPhail, EF; Patterson, DE; Rangel, LJ, 2012) |
| "Recurrence is less frequent with fidaxomicin than with vancomycin." | ( Bliss, D; Butler, M; Drekonja, DM; Filice, GA; MacDonald, R; Rector, TS; Wilt, TJ, 2011) |
| "Recurrence is also more common in pregnant women, and therapeutic responses are reduced." | ( Aydin, M; Güzel, AB; Ilkit, M; Kalkanci, A; Khalil, II; Kuştimur, S, 2012) |
| "In type 1 AIP relapses are common." | ( Chari, ST; Clain, JE; Gleeson, FC; Hart, PA; Klebig, RR; Levy, MJ; Pearson, RK; Petersen, BT; Smyrk, TC; Sugumar, A; Takahashi, N; Topazian, MD; Vege, SS; Witzig, TE, 2013) |
| "Stroke recurrence is an important public health concern." | ( Abu-Hegazy, M; Azzam, H; El-Mitwalli, A; Gomaa, M; Wasel, Y, 2013) |
| "Relapse is common (10%-20%) in the first 6 months after immunosuppression is stopped, and patients need to be followed up regularly to allow early diagnosis and treatment of relapse." | ( Collins, PW, 2012) |
| "Fewer relapses are expected, although there is no consensus on the best salvage regimen." | ( Gisselbrecht, C, 2012) |
| "However, recurrence is common, and there is no reliable prognostic biomarker." | ( Gu, B; Liang, L; Liu, H; Ma, J; Wen, W; Zhang, H, 2013) |
| "Cirrhosis recurrence is frequent after orthotopic liver transplantation for hepatitis C virus (HCV)." | ( Abraldes, JG; Berzigotti, A; Bosch, J; Carrión, JA; Forns, X; García-Pagán, JC; García-Valdecasas, JC; Navasa, M; Schepis, F; Vukotic, R, 2013) |
| "Most EC relapses are either pelvic or distant metastases and occur within the first three years after hysterectomy." | ( Basso, SM; Bertozzi, S; Capobianco, G; Lumachi, F; Pasqual, EM; Re, GL; Santeufemia, DA; Tumolo, S, 2013) |
| "Relapses are frequent, especially in patients with anti-myeloperoxidase antibodies and baseline eosinophilia <3000/mm(3)." | ( Cohen, P; Devilliers, H; Guillevin, L; Mouthon, L; Pagnoux, C; Puéchal, X; Ribi, C; Samson, M; Stern, M, 2013) |
| "Identification of relapses is based on the claims in the database rather than on a clinical assessment." | ( Agashivala, N; Balderston McGuiness, C; Bergvall, N; Capkun, G; Karkare, SU; Korn, JR; Lahoz, R; Makin, C; Petrilla, A; Pradhan, A, 2013) |
| "Target aneurysm recurrence is a promising clinical outcome measure that correlates well with established angiographic measurements." | ( Barnwell, SL; Bonafe, A; Carroll, K; Chaloupka, JC; Dowd, CF; Fox, AJ; Gholkar, A; Imm, SJ; Johnston, SC; Massó Romero, J; McDougall, CG; Tampieri, D; Turk, AS; Vazquez Suarez, JC; Wakhloo, AK, 2014) |
| "Preventing relapse is a basic goal in the treatment of DVT and requires investigation of risk factors for recurrence of deep venous thrombosis (DVT) in the lower extremities." | ( Fu, Q; Fu, Z; Li, Z; Ren, W, 2014) |
| "Relapse is a primary obstacle in the treatment of addiction disorders, and as such, understanding this phenomenon is a major effort of clinical and preclinical studies of cocaine addiction." | ( Feltenstein, MW; Moorman, DE; See, RE; Waters, RP; Young, AB, 2014) |
| "Nodal relapse is also associated with a high mortality rate." | ( Heij, HA; Merks, JH; Spronk, P; Terwisscha van Scheltinga, CE; van Baren, R; van Noesel, MM; van Rosmalen, J; Wijnen, MH; Wijnen, RM, 2014) |
| "Relapse is defined as any use of MA with time as the number of months of continuous MA abstinence after treatment discharge until relapse." | ( Brecht, ML; Herbeck, D, 2014) |
| "Identification of relapses is based on database claims rather than on clinical assessment." | ( Bergvall, N; Korn, JR; Lahoz, R; Reynolds, T, 2014) |
| "Recurrence is scarce." | ( Carnicero Iglesias, M; Holgado, S; Mateo, L; Olivé, A; Pego-Reigosa, JM; Tejera Segura, B, 2014) |
| "That relapse is highest among addicts who have less education and who report lower grades is a factor that can be useful when considering treatment type and controlled for when comparing treatment outcomes." | ( Blum, K; Braverman, ER; Giordano, J; Han, D; Madigan, MA; Oscar-Berman, M; Schoenthaler, SJ, 2014) |
| "Drug resistance and recurrence are the major obstacles to bladder cancer chemotherapy." | ( Hu, H; Lei, T; Meng, Q; Zhang, M, 2015) |
| "Disease recurrence is the major and most common complication of pericarditis and its prevention may reduce morbidity and management costs." | ( Adler, Y; Belli, R; Brucato, A; Ferro, S; Forno, D; Imazio, M; Trinchero, R, 2014) |
| "Disease relapses are frequent in antineutrophil cytoplasmic antibody-associated vasculitis (AAV)." | ( Allen, NB; Brunetta, P; Ding, L; Fervenza, FC; Geetha, D; Hoffman, GS; Iklé, D; Jepson, B; Kallenberg, CG; Keogh, K; Kissin, EY; Langford, CA; Merkel, PA; Miloslavsky, EM; Monach, PA; Peikert, T; Seo, P; Specks, U; Spiera, R; St Clair, EW; Stegeman, C; Stone, JH; Tchao, NK; Villarreal, M; Viviano, L; Ytterberg, SR, 2014) |
| "Recurrence is rare and it can be addressed efficiently with the administration of a second course of antibiotics." | ( Aygen, E; Kırkıl, C; Yiğit, MV, 2014) |
| "Relapses are frequent in patients with PR and can be partially prevented by a longer tapering period." | ( Agraz, I; Arroyo, D; Caro, J; Espinosa, M; Fernández, L; Frutos, MÁ; Goicoechea, M; Gutiérrez-Solís, E; Hernández, Y; Juárez, GF; Martín, M; Ocaña, J; Oliet, A; Perea, L; Praga, M; Rabasco, C; Ramos, N; Rojas-Rivera, J; Romera, A; Segarra, A; Valera, A, 2015) |
| "While clinical relapse is noted frequently following drug withdrawal, there are few published data on predictive factors." | ( Ahmad, T; Al-Hilou, H; Arnott, ID; Cummings, JR; Dattani, R; Felwick, R; Gambles, CJ; Gaya, DR; Harris, R; Irving, PM; Kalla, R; Kennedy, NA; Lamb, CA; Lees, CW; Lindsay, JO; Lobo, AJ; Mansfield, J; Marriott, S; Musy, R; Nayee, H; Parkes, M; Reynolds, S; Satsangi, J; Senanayake, SM; Smith, M; Warner, B, 2014) |
| "Recurrence is a frequent complaint of patients with vulvovaginal candidiasis (VVC)." | ( Banco, R; De Leo, R; De Santo, D; De Seta, F; Inglese, S; Maso, GP; Parazzini, F; Restaino, S; Sartore, A; Stabile, G; Tonon, M, 2014) |
| "Patients suffering recurrence are known to have faster times to fibrosis and consequently higher rates of graft failure." | ( Firpi, RJ; Hilgenfeldt, E, 2015) |
| "Recurrence is rare and occurs most commonly in children." | ( Aldemir-Kocabaş, B; Çiftçi, E; Fitöz, S; İnce, E; Kcal, MM; Ramoğlu, MG; Tutar, E, 2014) |
| "The risk of recurrence is elevated and the lesions can lead to severe pediatric diseases." | ( Blöcker, T; Feist, H; Hussein, K, 2015) |
| "Although recurrence is likely, the timing of onset is variable and close follow-up is mandatory to identify it." | ( Albiger, NM; Barbot, M; Boscaro, M; Ceccato, F; Fassina, A; Iacobone, M; Mantero, F; Occhi, G; Rizzati, S; Scaroni, C; Zilio, M, 2015) |
| "Nonsevere relapses are more common than severe relapses in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but their clinical course and treatment outcomes remain largely unexamined." | ( Brunetta, P; Ding, L; Fervenza, FC; Hoffman, GS; Iklé, D; Kallenberg, CG; Langford, CA; Lim, N; Merkel, PA; Miloslavsky, EM; Monach, PA; Seo, P; Specks, U; Spiera, R; St Clair, EW; Stone, JH; Tchao, NK; Villareal, M, 2015) |
| "Recurrence is a concern with both modalities." | ( Garg, VK; Goel, K; Sardana, K, 2015) |
| "In-field recurrence is associated with widespread tumor dissemination and poor pathological response to neoadjuvant treatment." | ( Boterberg, T; Ceelen, W; Pattyn, P; Thoen, H; Van Daele, E, 2015) |
| "Since the risk of recurrence is considered to be low in TTC, this case report is of high interest." | ( Böttiger, BW; Brinker, G; Hinkelbein, J; Mey, C; Pfister, R, 2015) |
| "Stone recurrence is a common late adverse event after ERCP in patients with common bile duct stones (CBDS)." | ( Dong, J; Guo, X; Liu, Z; Lu, G; Luo, H; Pan, Y; Tao, Q; Wang, X; Zhang, R; Zhao, L, 2015) |
| "Relapse is the leading cause of mortality in children with acute lymphoblastic leukemia (ALL)." | ( Bai, Y; Chen, H; Chen, J; Chen, S; Chen, Y; Ding, J; Ding, L; Du, A; Ferrando, A; Gu, L; Huang, X; Jin, L; Kang, H; Kirschner-Schwabe, R; Li, B; Li, H; Li, W; Liang, H; Lu, G; Lu, H; Ma, X; Shen, S; Tang, J; Tzoneva, G; von Stackelberg, A; Wang, S; Wu, T; Yang, JJ; Yang, M; Zhang, J; Zhou, BB, 2015) |
| "A high rate of relapse is a defining characteristic of substance use disorder for which few treatments are available." | ( Briggs, SB; Miller, CA; Young, EJ, 2015) |
| "Hepatitis C recurrence is the main cause of graft loss in liver transplant patients co-infected with human immunodeficiency virus (HII)." | ( Barcan, LA; Gadano, AC; Galdame, OA; Marciano, S, 2015) |
| "The risk of PTC recurrence is mainly related to the presence of lymph node metastases and extrathyroidal invasion, whereas no impact of BRAF V600E mutation has been demonstrated." | ( Chmielik, E; Czarniecka, A; Handkiewicz-Junak, D; Jarzab, B; Jarzab, M; Kowal, M; Krajewska, J; Lange, D; Maciejewski, A; Oczko-Wojciechowska, M; Poltorak, S; Rusinek, D; Sacher, A; Stobiecka, E; Zebracka-Gala, J; Zembala-Nozynska, E, 2015) |
| "Disease relapse is the major causes of treatment failure after allogeneic stem cell transplantation (SCT) in patients with acute myeloid leukemia (AML)." | ( Buka, R; Byrne, J; Craddock, C; Crawley, C; Dennis, M; Ferguson, P; Goodyear, O; Hazlewood, P; Jilani, N; Khan, J; Malladi, R; Nagra, S; Russell, N; Siddique, S; Snowden, J; Tholouli, E; Vyas, P; Ward, J; Yap, C, 2016) |
| "Recurrences are particularly prevalent in people with low urinary citrate levels." | ( Biyani, CS; Hanchanale, VS; Myatt, A; Nabi, G; Phillips, R; Somani, B, 2015) |
| "Recurrence is related to diabetes mellitus, perianal collections, tract abscesses and multiple tracts and a second LIFT procedure may be feasible and efficient." | ( Gomes, RM; Palanivelu, C; Parthasarathi, R; Praveenraj, P; Rajapandian, S; Sathiamurthy, R; Senthilnathan, P, 2016) |
| "Relapses are frequent but no reliable predictive indicator has emerged in this study." | ( Biedermann, E; Flegel, T; Tipold, A, 2016) |
| "Recurrence is a major problem following the treatment of aggressive central giant cell granuloma (CGCG)." | ( Amanpour, S; Fardisi, S; Karagah, T; Tabrizi, R; Zamiri, B, 2016) |
| "vivax relapse is a major global public health concern." | ( Rishikesh, K; Saravu, K, 2016) |
| "A recrudescence is thought to originate from circulating Plasmodium blood stages which do not cause fever before a certain level of a microscopically detectable parasitemia is reached." | ( Franken, G; Holtfreter, MC; Labisch, A; Mehlhorn, H; Richter, J; Walter, S, 2016) |
| "Disease relapse is the most common cause of treatment failure after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes, yet treatment options for such patients remain extremely limited." | ( Blaise, D; Bourhis, JH; Chevallier, P; Craddock, C; Finke, J; Hallek, M; Kröger, N; Labopin, M; Luft, T; Mohty, M; Nagler, A; Robin, M; Sengelov, H; Yakoub-Agha, I, 2016) |
| "ReLApsE is a randomized, open, multicenter phase III trial in a planned study population of 282 RMM patients." | ( Baertsch, MA; Fenk, R; Goerner, M; Goldschmidt, H; Graeven, U; Haenel, M; Hielscher, T; Hillengaß, J; Ho, AD; Hose, D; Jauch, A; Klein, S; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Martin, H; Merz, M; Nogai, A; Noppeney, R; Raab, MS; Reimer, P; Salwender, H; Scheid, C; Schlenzka, J; Schmidt-Hieber, M; Schmidt-Wolf, IG; Weisel, K; Wuchter, P, 2016) |
| "Post-transplant relapse is a major factor influencing the long-term outcome in alcoholic liver disease (ALD) patients." | ( Bhangui, P; Choudhary, NS; Gautam, D; Goja, S; Kumar, N; Mehrotra, S; Rai, R; Ramachandra, SK; Rastogi, A; Rastogi, V; Raut, V; Saigal, S; Saraf, N; Soin, AS; Yadav, SK, 2016) |
| "Relapses are a hallmark of MS and are often associated with significant functional impairment and decreased quality of life." | ( Berkovich, RR, 2016) |
| "Treatment of MS relapses is important as it helps to shorten the duration of disability associated with their course." | ( Berkovich, RR, 2016) |
| "Relapse is distressingly common after the first episode of psychosis, yet it is poorly understood and difficult to predict." | ( Chan, SK; Chang, WC; Chen, EY; Honer, WG; Hui, CL; Lam, SY; Lee, EH; Li, AW; Li, YK; Sham, P; Thornton, AE, 2016) |
| "The risk of disease recurrence is highest among patients with idiopathic focal segmental glomerulosclerosis (FSGS), presumably due to a circulating permeability factor." | ( Arnol, M; Battelino, N; Kandus, A; Novljan, G; Ponikvar, R, 2016) |
| "Stroke recurrence is associated with not only the number of MESs but also the size of the MES, which can theoretically be estimated by monitoring the MES intensity via transcranial doppler (TCD)." | ( Chen, C; Deng, QQ; Fu, JH; Huang, YN; Markus, H; Ratanakorn, D; Tang, J; Wong, KS; Zhao, H, 2016) |
| "Relapses are important contributors to illness and morbidity in Plasmodium vivax and P." | ( Chu, CS; White, NJ, 2016) |
| "The recurrence is common after surgical excision, and the lesion can be exacerbated by surgery." | ( Choi, HJ; Kim, MK; Lee, HK; Oh, JY; Wee, WR, 2016) |
| "Relapse is a two-component process consisting of a highly motivated drug-seeking phase that, if successful, is followed by a drug-using phase resulting in temporary satiation." | ( Garcia-Keller, C; Heinsbroek, JA; Kalivas, PW; Mulvaney, M; Roberts-Wolfe, D; Sorrell, A; Spencer, S, 2017) |
| "The management of recurrence is adapted to the individual situation and the patient's needs." | ( Pillukat, T; Stüber, R; van Schoonhoven, J; Walle, L; Windolf, J, 2017) |
| "Prevention of relapse is a major challenge in schizophrenia, a disease characterized by poor adherence to antipsychotic medication leading to multiple rehospitalizations and a substantial burden-of-care." | ( Biagi, E; Brambilla, G; Capuzzi, E; Clerici, M; Colmegna, F; Mascarini, A; Ornaghi, A; Santambrogio, J, 2017) |
| "Frequent relapses are observed in co-infected HIV who can benefit of a second cycle." | ( Esposito, S; Pagliano, P, 2017) |
| "The recurrences are common after such treatment." | ( Abeygunasekera, AM; Balagobi, B; Sutharshan, K, 2017) |
| "Recurrence is frequent among patients cured of a CR-KP BSI and is associated with higher long-term mortality." | ( Ambretti, S; Bartoletti, M; Berlingeri, A; Cristini, F; Giannella, M; Girometti, N; Graziano, E; Lewis, RE; Marconi, L; Tedeschi, S; Tumietto, F; Viale, P, 2017) |
| "Postpartum smoking relapse is a highly prevalent public health problem." | ( Allen, A; Allen, S; Carlson, S; Tosun, N, 2018) |
| "Relapse is a frequent problem in PD, and long-term treatment does not protect these patients in the long run." | ( Amrein, R; Arias-Carrión, O; Carta, MG; Dias, GP; Freire, RC; Machado, S; Mochcovitch, MD; Nardi, AE; Versiani, M, 2017) |
| "Rapid virological relapse is universal and clinical relapse is common after stopping antiviral therapy in patients with immune-tolerant chronic hepatitis B." | ( Chan, HL; Chan, RS; Chim, AM; Hui, AJ; Lo, AO; Wong, GL; Wong, VW, 2018) |
| "Relapse is a common factor within the behavior change process." | ( Becoña, E; Fernández Del Río, E; López-Durán, A; Martínez, Ú; Martínez-Vispo, C; Míguez, MC; Piñeiro, B; Rodríguez-Cano, R, 2017) |
| "However, relapses are common when prednisolone is tapered." | ( Castañeda, S; González-Gay, MA; Matteson, EL, 2017) |
| "Its effect on relapses is comparable to fingolimod and its effect on disability accrual is comparable to interferon β and fingolimod." | ( Barnett, M; Butler, E; Butzkueven, H; Duquette, P; Fabis-Pedrini, M; Ferraro, D; Girard, M; Grammond, P; Grand'Maison, F; Havrdova, E; Hodgkinson, S; Horakova, D; Hupperts, R; Jokubaitis, V; Kalincik, T; Kermode, A; Lechner-Scott, J; Lugaresi, A; McCombe, P; Prat, A; Prevost, J; Shaw, C; Slee, M; Sola, P; Solaro, C; Spelman, T; Terzi, M; Trojano, M, 2018) |
| "The risk of recurrence is elevated in patients with high-risk cytogenetic or molecular abnormalities, as well as when allo-HCT is performed in patients with refractory disease or with persistent molecular or radiological (PET-CT scan) residual disease." | ( Bazarbachi, A; Beckerich, F; Bulabois, CE; Chevallier, P; Daguindau, É; Dumesnil, C; Guillaume, T; Huynh, A; Levrat, SM; Menard, AL; Michallet, M; Pautas, C; Poiré, X; Ravinet, A; Yafour, N; Yakoub-Agha, I, 2017) |
| "Relapse is especially likely when recovering addicts encounter risk factors like small "priming" doses of drug, stress, or drug-associated cues and locations." | ( Farrell, MR; Mahler, SV; Schoch, H, 2018) |
| "However, disease relapse is common in long-term follow-up, despite a successful initial treatment response." | ( Cho, DH; Jun, JH; Kim, MH; Lee, HW; Lee, SK; Lee, SS; Moon, SH; Nam, K; Park, DH; Seo, DW; Song, TJ, 2018) |
| "The risk for recurrence is particularly high in VTE events that occurred without provoking risk factor, with minor provoking factors and in cases with persistent risk factors such as active cancer." | ( Bauersachs, R, 2018) |
| "In the second case, relapse is a consequence of failures to inhibit prepotent responses." | ( Dos Santos, C; Martínez, K; Reyes-Huerta, HE, 2018) |
| "Due to the results recurrences are common after both oestrogen and manual separations." | ( Ekmark, AN; Stenström, P; Wejde, E, 2018) |
| "Recurrent relapse is a major problem in treating opiate addiction." | ( Bailey, A; Bailey, CP; Georgiou, P; Heal, DJ; Wonnacott, S; Wright, VL, 2019) |
| "Posttreatment relapse is a major challenging clinical issue." | ( AlSwafeeri, H; ElKenany, W; Karam, S; Mowafy, M, 2018) |
| "Vivax malaria relapses are predominantly delayed by chloroquine but prevented by primaquine." | ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018) |
| "Relapses are common in type 1 AIP after steroid treatment." | ( Hao, L; Hu, LH; Li, ZS; Lin, H; Liu, PP; Meng, QQ; Pan, J; Qian, W; Wang, LW; Xin, L, 2018) |
| "However, relapse is the main reason for treatment failure, also after hematopoietic stem cell transplantation (HSCT)." | ( Calafiore, V; Cupri, A; Di Raimondo, F; Leotta, S; Martino, EA; Mauro, E; Milone, G; Pirosa, MC; Sapienza, G; Scalise, L; Spadaro, A; Stella, S; Vigneri, P, 2018) |
| "Its high rate of relapse is mainly attributable to the difficulties of avoidance." | ( Bouschon, P; D'Incan, M; Le Bouëdec, MF; Pereira, B; Schmutz, JL; Waton, J, 2019) |
| "Opioid-primed relapse is a global burden." | ( He, Y; Huang, Z; Kong, E; Lu, Y; Shen, Y; Sun, Y; Wu, F; Xu, X; Yu, W, 2019) |
| "However, its recurrence is not rare, sometimes bothersome." | ( Byun, JS; Choi, JK; Choi, YJ; Jung, JK, 2019) |
| "However, late recurrences are more common compared to paroxAF." | ( Benák, A; Bencsik, G; Herczeg, A; Kohári, M; Makai, A; Pap, R; Sághy, L, 2019) |
| "Early detection of recurrence is of high clinical importance, since there are several effective second line therapies that may have curative potential in some patients." | ( Appold, S; Bandurska-Luque, A; Hoberück, S; Kohler, A; Kotzerke, J; Löck, S; Schreiber, A; Zips, D; Zöphel, K, 2019) |
| "Early (<6 months) relapse is associated with dismal outcome, while the majority of relapses occur early after transplantation." | ( Biemond, BJ; de Jong, G; Hazenberg, MD; Janssen, JJWM; Meijer, E; Nur, E; Ossenkoppele, GJ; Visser, O; Zeerleder, SS, 2019) |
| "Alcohol relapse is a treatment goal for alcohol dependence and the target for medications' development." | ( Kreek, MJ; Zhou, Y, 2019) |
| "Tumor recurrence is the main cause of poor prognosis of GBM." | ( Li, P; Liu, J; Pan, J; Sun, Z; Tan, N; Zhao, W, 2019) |
| "Although 90% of BRD relapses are reported to receive retreatment with a different class of antimicrobial, studies examining the impact of antimicrobial selection (i." | ( Coetzee, JF; Cooper, VL; Engelken, TJ; Follett, L; Kleinhenz, MD; Krull, AC; Magstadt, DR; O'Connor, AM; Schuler, AM; Sidhu, PK, 2019) |
| "Orthodontic relapse is a physiologic process that involves remodelling of the alveolar bone and principle periodontal ligament fibres." | ( Azami, N; Chen, PJ; Dutra, EH; Kalajzic, Z; Mehta, S; Nanda, R; Yadav, S, 2020) |
| "Relapse is common in treatment for opioid use disorders (OUDs)." | ( Burns, GL; McPherson, S; Tragesser, S; Vest, NA, 2020) |
| "Recurrence is more common in younger patients, and can be ipsilateral, contralateral, or bilateral." | ( Bae, JH; Choi, H; Kim, HY; Kim, JH; Kim, TY; Kim, YS; Koh, SH; Kwon, HS; Lee, KY; Lee, YJ, 2020) |
| "As relapses are frequent on discontinuation, a minimum effective dose of TXA that can be used safely for long time remains unknown." | ( Chauhan, PS; Chowdhary, B; Kumar, P; Mahajan, VK; Mehta, KS; Sharma, A; Sharma, V; Vashist, S, 2021) |
| "Hump recurrence is a commonly encountered problem following dorsal preservation (DP) rhinoplasty when surgeons are learning the procedure." | ( Aydogdu, IO; Kurt, A; Tuncel, U, 2021) |
| "Glioblastoma relapse is associated with activation of phosphatidylinositol 3-kinase (PI3K) signalling pathway." | ( Campone, M; Chinot, O; Clement, PM; DeGroot, J; Donnet, V; El-Hashimy, M; Gan, H; Gil-Gil, MJ; Idbaih, A; Mason, W; Mills, D; Pineda, E; Raizer, J; Rosenthal, M; Wen, PY, 2020) |
| "vivax recurrences are attributable to relapses or late recrudescences, rather than new infections that could be prevented by reducing malaria exposure during pregnancy." | ( Corder, RM; Davenport, MP; de Lima, ACP; Docken, SS; Ferreira, MU; Khoury, DS, 2020) |
| "Relapse is frequent in MCD in adults." | ( Erickson, SB; Fervenza, FC; Heybeli, C; Hogan, MC; Leung, N; Zand, L, 2021) |
| "Relapse is a major cause of treatment failure in Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ALL) undergoing allogeneic hematopoietic cell transplantation (allo-HCT)." | ( Deng, L; Fan, Z; Huang, F; Jin, H; Li, X; Liang, X; Lin, D; Lin, R; Liu, H; Liu, Q; Ma, L; Nie, D; Sun, J; Xu, D; Xu, N; Xuan, L; Ye, J; Zhang, Y, 2021) |
| "Relapse is one of the main features of multiple sclerosis (MS)." | ( Baghbanian, SM; Bazi, A; Ghazaeian, M; Hendoiee, N; Saeedi, M, 2021) |
| "Disease recurrence is a common finding for those who undergo successful treatment." | ( Guo, W; Silverstein, D; Stevens, G; Zhu, C, 2021) |
| "Relapses are common in patients with PMR." | ( Atienza-Mateo, B; Blanco, R; Castañeda, S; González-Gay, MA; Prieto-Peña, D, 2021) |
| "Relapses are common in PMR being observed in approximately half of the patients." | ( Atienza-Mateo, B; Blanco, R; Castañeda, S; González-Gay, MA; Prieto-Peña, D, 2021) |
| "Clinical relapses are common in patients with ANCA-associated vasculitis (AAV)." | ( He, LJ; He, P; Hu, JP; Huang, C; Sun, SR; Tian, XJ, 2021) |
| "Relapses are an indicator of MDT effectiveness and can reflect Mycobacterium leprae persistence or re-infection." | ( Hacker, MAVB; Illarramendi, X; Maia, RC; Moraes, MO; Nery, JAC; Sales, AM; Sarno, EN, 2021) |
| "Recurrence is the main complication, so correct treatment of the risk factors is crucial." | ( Amorim, I; Caetano, M; Rodrigues, MA; Selores, M, 2021) |
| "Relapse is the most common cause of treatment failure following allogeneic blood or marrow transplantation (alloBMT) for AML or MDS." | ( Dezern, AE; Gojo, I; Jones, RJ; Morrow, J; Prince, GT; Showel, M; Smith, BD; Symons, H; Webster, JA; Yogarajah, M; Zahurak, M, 2021) |
| "Recurrence is the most frequent complication following acute pericarditis and may occur in 30% patients, rising to 50% in case of multiple recurrences, lack of colchicine treatment or use of glucocorticoids." | ( Andreis, A; Avondo, S; Biondi-Zoccai, G; Casula, M; Imazio, M, 2021) |
| "Long-term recurrence is high (>80% at 10 years) and might appear at any time after healing." | ( Almela, P; Espi, A; Ferriols, FL; Granero, EG; Hernandez, V; Herreros, B; Mínguez, M; Montón Rodriguez, C; Mora, F; Sanchiz, V, 2021) |
| "Seizure relapses are the leading cause of admission to emergency rooms (ER) in people with epilepsy." | ( Bernal Cobo, R; Giraldo Castrillón, YM; Giraldo Tapias, LM; Gómez Escobar, T; Rojas-Gualdrón, DF; Rueda Cárdenas, LF; Vásquez Trespalacios, EM; Zapata Berruecos, JF, 2022) |
| "Malaria relapses are caused by Plasmodium vivax-induced latent liver stage hypnozoites, and relapses contribute significantly to the total disease burden." | ( Mohan, M; Nain, M; Sharma, A, 2022) |
| "Relapse is common after discontinuation of infliximab." | ( Beattie, K; Cox, G; Hambly, N; Khalidi, N; Kolb, M; Kouranos, V; Larche, M; Morar, N; Renzoni, EA; Sakkat, A, 2022) |
| "Relapse is a major cause of treatment failure after allogeneic hematopoietic cell transplantation (allo-HCT) in myeloid malignancies." | ( Beauvais, D; Chauvet, P; Coiteux, V; Drumez, E; Duhamel, A; Magro, L; Quesnel, B; Srour, M; Wattebled, KJ; Yakoub-Agha, I, 2022) |
| "Early recurrence is high, and is concentrated in the first 7 days, in patients with minor stroke or TIA." | ( Bourand, N; Brorson, JR, 2022) |
| "AML relapse is attributed to the persistence of drug-resistant leukemia stem cells (LSCs)." | ( Buettner, R; Burnett, J; Ghoda, L; Hoang, DH; Kuo, YH; Marcucci, G; Nguyen, LXT; Pullarkat, V; Rosen, ST; Valerio, M; Zhang, B, 2022) |
| "Recurrence is likely caused by spores in the gastrointestinal tract that germinate after antibiotic therapy." | ( Budi, ND; Godfrey, JJ; Rose, WE; Safdar, N; Shukla, SK, 2023) |
| "Recurrence is described as 4% to 10%." | ( Dy, B; Foster, T; Fyffe-Freil, R; Huang, CT; Kearns, A; Lyden, M; McKenzie, T; Mirande, M; Singh, R; Szabo Yamashita, T; Thompson, G; Wermers, RA, 2023) |
| "Relapse is a defining feature of smoking and a significant challenge in cessation management." | ( Ding, ZM; Neslund, E; Tan, X, 2022) |
| "Disease recurrence is common within 2 years from the time of initial diagnosis." | ( Ashwathanarayana, AG; Bansal, H; Dewangan, V; Goyal, V, 2022) |
| "Relapse is a major problem in treating methamphetamine use disorder." | ( Baker, R; Caccamise, AJ; Engeln, KA; Funke, JR; Hwang, EK; Milovanovic, M; Murray, CH; Wolf, ME; Wunsch, AM, 2023) |
| "Relapses are associated with increased exposure to immunosuppressive medications, the accrual of damage and increased morbidity and mortality." | ( Al-Jayyousi, R; Andrews, J; Bond, S; Bruchfeld, A; Camilleri, B; Carette, S; Cheung, CK; Derebail, V; Doulton, T; Ferraro, A; Forbess, L; Fujimoto, S; Furuta, S; Gewurz-Singer, O; Harper, L; Ito-Ihara, T; Jayne, D; Jones, RB; Khalidi, N; Klocke, R; Koening, C; Komagata, Y; Langford, C; Lanyon, P; Luqmani, R; McAlear, C; Merkel, PA; Moreland, LW; Mynard, K; Nachman, P; Nodale, M; Pagnoux, C; Peh, CA; Pusey, C; Ranganathan, D; Rhee, RL; Smith, RM; Specks, U; Spiera, R; Sreih, AG; Tesar, V; Walters, G; Wroe, C, 2023) |
| "Recurrence is common with any monotherapy which prompted a comprehensive, multidimensional approach." | ( Cai, XN; Ji, YC; Wang, MM, 2023) |
| "Relapse is the most common cause of mortality in acute myeloid leukemia (AML) patients after allogeneic stem cell transplant (SCT)." | ( Amaya, M; Bosma, G; Gutman, JA; Kent, A; Marciano, K; McMahon, C; Pollyea, DA; Rezac, R; Schwartz, M; Smith, CA; Tobin, J, 2023) |
| "Recurrence is due to autoinflammatory processes in the pericardium." | ( Andel, PM; Atar, D; Aukrust, P; Gleditsch, J; Gude, E; Haugeberg, G; Høie, S; Salte, T; Steine, K, 2023) |
| "Alcohol relapse is a main limitation for the treatment of alcohol use disorders." | ( Adasme, S; Herrera-Marschitz, M; Morales, P; Quilaqueo, ME; Quintanilla, ME; Rivera-Meza, M; Solís-Egaña, F; Vásquez, D, 2023) |
| "Relapse is common following treatment interruption however some patients may be suitable for limited-duration treatment." | ( Abdel-Wahab, O; Diamond, EL; Durham, BH; Francis, JH; Lacouture, ME; Panageas, KS; Petrova-Drus, K; Rampal, RK; Reiner, AS; Rotemberg, V; Yabe, M, 2023) |
| "Relapse is now the most frequent cause of transplant failure." | ( Balaguer-Roselló, A; Montoro, J; Sanz, J, 2023) |
| "Relapse is common in PCNSV and an increased dose of steroids is often given, sometimes with a change in therapy." | ( Bays, AM, 2024) |
| Excerpt | Reference |
|---|
| "No patient showed recurrence of disease during treatment with cytotoxic agents." | ( Fauci, AS; Haynes, BF; Katz, P; Wolff, SM, 1979) |
| "It was found that: (1) no patient had a recurrence of ventricular fibrillation after aprindine therapy was begun, except as a terminal event subsequent to the development of acute myocardial infarction and cardiogenic shock or refractory congestive heart failure; (2) 6 patients experienced ventricular tachycardia after the loading dose, but with continued aprindine therapy the ventricular tachycardia was suppressed in 3 of these 6 patients, and a fourth patient was asymptomatic during brief paroxysms of ventricular tachycardia; (3) in 2 patients, aprindine was ineffective and was discontinued; (4) electrical cardioversion was not required in any patient receiving aprindine; (5) premature ventricular extrasystoles were decreased in 18 of the 23 patients treated with aprindine; (6) aprindine was discontinued in 1 patient because of intolerable side effects, although ventricular arrhythmias were suppressed in this patient; and (7) 5 patients died from acute myocardial infarction or severe heart failure while receiving aprindine." | ( Fasola, AF; Noble, RJ; Zipes, DP, 1977) |
| "The case of a patient with a recurrence of gonorrhoea due to a concomitant gonorrhoic infection of a paraurethral duct, which was not healed by the initial routine penicillin treatment, is reported." | ( Konrad, K, 1976) |
| "In cases with recurrence without changes in the morphological characteristics, positive effects were achieved with 1 to 4 repeated courses of therapy." | ( Koch, HF, 1978) |
| "Although total recurrence rates were not significantly affected by endolymphatic therapy, recurrence in the lymph nodes was largely prevented." | ( , 1979) |
| "Both metastases and local recurrences were more frequent in those patients submitted to segmental bone resection (7/8) than in those treated by more radical surgery (22/47)." | ( Bacci, G; Campanacci, M; Pagani, P; Picci, P, 1979) |
| "In order to reduce the recurrence rate of bladder tumours, 78 patients with bladder tumours have been treated since November 1973 with topical Thio-TEPA bladder instillations." | ( Dobrzecki, W; Kaczmarek, A, 1977) |
| "Comparison of the recurrence rates of soft tissue sarcomas treated by radiotherapy (14 patients) or radiotherapy and synchronous administration of razoxane (19 patients) has shown a statistically significant benefit for those patients treated by the combination." | ( Hellmann, K; James, SE; Jones, S; Macdonald, E; Newton, KA; Ryall, RD, 1978) |
| "There were no recurrences at 1 month; after 6 months, however, Giardia infection was found in 13% of both treatment groups." | ( Kavousi, S, 1979) |
| "There was no difference in the recurrence rates after single-dose treatment and treatment for 10 days or more." | ( Källenius, G; Winberg, J, 1979) |
| "From the results it is concluded that recurrence occurs in patients after slow healing and (or) previous cimetidine treatment if long-term prophylaxis with cimetidine is not carried out." | ( Blum, AL; Kiene, K; Pelloni, S; Peter, P; Sonnenberg, A; Strohmeyer, G; Weber, KB; Wienbeck, M, 1979) |
| "In Group C, the rate of recurrence of pneumothorax was 23% during the first year following treatment." | ( Derrick, JR; Larrieu, AJ; O'Neill, MJ; Tyers, GF; Williams, EH, 1979) |
| "Stoma recurrences can be prevented by immediate postoperative megavoltage radiotherapy when the stoma is included in the irradiated volume." | ( Jesse, RH; Lindberg, RD; Schneider, JJ, 1975) |
| "After discontinuation of drug therapy, recurrence was variable but less than expected." | ( Miller, JM; Niemann, KM; Stover, SL, 1976) |
| "Under this treatment relapses were observed in only 19 % of the cases." | ( Hahnloser, P; Jadoul, D; Petropoulos, P, 1976) |
| "Retreatment in three cases of recurrence was successful." | ( Rutherford, AM, 1976) |
| "In the next three months, two recurrences of this syndrome were verified and successfully treated in a similar manner." | ( Ginsberg-Fellner, F; Primack, WA, 1975) |
| "The patient later had a brief recurrence of urticaria following oral erythromycin and tetracycline therapy but did not develop lesions at sites of insulin injection." | ( Kyle, GC; Shelley, WB; Shore, RN, 1975) |
| "Both of these are also useful in the treatment of relapses." | ( Chan, AC; Mak, MH, 1976) |
| "Risk factors for arrhythmia recurrence despite amiodarone therapy were low left ventricular ejection fraction, inducible ventricular tachycardia by programmed electrical stimulation or persisting ventricular tachycardia on Holter monitoring, and cardiac arrest before the institution of amiodarone therapy." | ( Burckhardt, D, 1992) |
| "Cumulative recurrence rates during the 2 years of long-term therapy were lower (17." | ( Arnold, R; Blum, AL; Classen, M; Fischer, M; Goebell, H; Koop, H, 1992) |
| "Treated animals experienced fewer recurrences during the treatment period but the results were not significantly different from results with controls." | ( Ashton, WT; Bourne, N; Bravo, FJ; Karkas, JD; Meurer, LC; Stanberry, LR; Tolman, RL, 1992) |
| "After withdrawal from maintenance treatment, a relapse of cytomegalovirus retinitis occurred, which was again successfully treated with ganciclovir." | ( Geier, SA; Goebel, FD; Klauss, V; Kronawitter, U; Matuschke, A, 1992) |
| "Forty-four percent remained free of recurrences until they died (for up to 15 months); 56% had 1 to 4 recurrences, altogether 35 episodes, of which 14 occurred after withdrawal of therapy." | ( Fabricius, EM; Popescu, M; Schmitz, K, 1992) |
| "Nineteen (95%) of the 20 placebo-treated patients relapsed after they sampled alcohol, while only eight (50%) of 16 naltrexone-treated patients exposed to alcohol met relapse criteria." | ( Alterman, AI; Hayashida, M; O'Brien, CP; Volpicelli, JR, 1992) |
| "Further, the mean duration of treatment in the relapsed patients was not significantly different from that for patients who went into remission (9." | ( Cho, BY; Koh, CS; Lee, HK; Min, HK; Shong, MH; Yi, KH, 1992) |
| "Proportions of patients reporting recurrences, recurrence frequency, and mean duration of lesions during breakthrough recurrences in each treatment group during a 6 month treatment period; time to first recurrence during treatment and follow-up after treatment cessation." | ( De Maubeuge, J; Engst, R; Foidart, JM; Kinghorn, GR; Thin, RN; Woolley, PD, 1992) |
| "The mean time to first recurrence after treatment cessation did not differ between the two groups." | ( De Maubeuge, J; Engst, R; Foidart, JM; Kinghorn, GR; Thin, RN; Woolley, PD, 1992) |
| "Treatment of hernial recurrence is a troublesome goal for surgeons." | ( Campli, M; De Toma, G; Gabriele, R; Mazzocconi, G; Sgarzini, G, 1992) |
| "The risk of gallstone recurrence following non-surgical treatment has been overestimated in the past for two reasons: (1) diagnosis of primary gallstone dissolution was based on oral cholecystography; and (2) gallstone recurrence was expressed as a cumulative recurrence rate." | ( Lanzini, A; Northfield, TC, 1992) |
| "The stone-recurrence rate is about 15% after two years, and thus lower compared to that after oral dissolution therapy alone." | ( Adamek, HE; Riemann, JF, 1992) |
| "The prevention of the occurrence and recurrence of PCP is a cornerstone in the treatment of patients infected with the human immunodeficiency virus." | ( Beall, GN; Beck, K; Cox, PH; Martin, MA; Styer, CM, 1992) |
| "Frequent catheter blockade (7/9) and recurrence of bleeding (3/9) were also seen with alum therapy." | ( Praveen, BV; Sankaranarayanan, A; Vaidyanathan, S, 1992) |
| "The probability of recurrence for patients who received triple therapy plus ranitidine was significantly lower than that for patients who received ranitidine alone: for patients with duodenal ulcer, 12% (95% CI, 1% to 24%) compared with 95% (CI, 84% to 100%); for patients with gastric ulcer, 13% (CI, 4% to 31%) compared with 74% (44% to 100%)." | ( Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM; Malaty, HM; Saeed, ZA, 1992) |
| "The relationship between recurrence of esophageal varices after endoscopic injection sclerotherapy (EIS) and changes of the blood pool of portosystemic collaterals was studied in 36 patients with liver cirrhosis." | ( Azuma, M; Fujita, S; Kashiwagi, T; Kimm, H; Koizumi, T; Matsuda, H; Mitsutani, N; Naito, M; Ohata, H; Okuno, A, 1992) |
| "In order to prevent recurrence of pterygium after excision we treated 21 patients postoperatively with Mitomycin-C-eye drops 0." | ( Goder, GJ; Möller, DE, 1992) |
| "At present the only treatment if a recurrence does occur is to terminate the pregnancy." | ( Berthier, M; Bonneau, D; de Giacomoni, P; Deshayes, M; Kibler, MP; Magnin, G; Plocoste, V, 1992) |
| "Ten of 33 recurrences were diagnosed within 6 months, and 32/33 recurrences were diagnosed within 5 years of treatment." | ( Buatti, JM; Cassady, JR; Harari, PM; Kittelson, JM; Rogoff, EE; Shimm, DS; Wilder, RB, 1992) |
| "Migraine recurrence within 48 h was a feature of 46% of attacks treated by patients with either treatment." | ( , 1991) |
| "Spontaneous ocular recurrences were reduced during therapy, compared to saline-treated controls." | ( Bobek, M; Cheng, YC; Dutschman, GE; Kaufman, HE; Thompson, HW; Varnell, ED, 1991) |
| "Because of the high likelihood of recurrence, long-term treatment, such as repeated sclerotherapy, propranolol therapy, or shunt surgery, is necessary." | ( Marshall, JB, 1991) |
| "Median time to recurrence or progression of the effusion was 32 days for tetracycline-treated patients and at least 46 days for bleomycin-treated patients (p = 0." | ( Einhorn, LH; Keller, JH; Koeller, J; Lee, JY; Losada, M; Mandelbaum, I; Moores, D; Ruckdeschel, JC; Weiss, GR, 1991) |
| "Careful follow-up detects early recurrences that are then treated with injection consisting of 40 mg/mL of triamcinolone acetonide (Kenalog), 150 mg of hyaluronidase (Wydase), and 2% lidocaine via a dermajet." | ( Shaw, GY; Stucker, FJ, 1992) |
| "The treatment of each recurrence with topical or oral acyclovir is of limited benefit." | ( Mindel, A, 1991) |
| "Initial treatment and relapse therapy were similar in all patients according to the BFM- and CoALL-protocols (front line: 38 patients according to BFM-protocols and 13 patients according to CoALL-protocols; relapse: 12 patients in study ALL-REZ-BFM 83, 17 in ALL-REZ-BFM 85, 20 in ALL-REZ-BFM 87, and two in ALL-REZ-BFM 90)." | ( Bender-Götze, C; Dopfer, R; Ebell, W; Ehninger, G; Friedrich, W; Gadner, H; Henze, G; Klingebiel, T; Peters, C; Riehm, H, 1991) |
| "Percentages of depressive relapses and recurrences were also evaluated in the sub-sample of patients treated with tianeptine alone." | ( Deniker, P; Dufour, H; Ganry, G; Kamoun, A; Lôo, H; Malka, R; Olié, JP, 1991) |
| "Episode recurrence in bipolar disorder following discontinuation of stable maintenance treatment with lithium salts was analyzed from 14 studies involving 257 patients with bipolar I disorder." | ( Baldessarini, RJ; Faedda, GL; Suppes, T; Tohen, M, 1991) |
| "Thus, combined failure and recurrence occurred in 12 loracarbef-treated patients and four amoxicillin-clavulanate-treated patients (P = 0." | ( Gan, VN; Kusmiesz, H; Nelson, JD; Shelton, S, 1991) |
| "Two patients had to stop because of two recurrences but, in contrast to earlier recurrences, they responded to local corticosteriod treatment within a few days." | ( Pleyer, U; Thiel, HJ; Waetjen, R; Weidle, EG; Zierhut, M, 1991) |
| "In 1 cat, recurrence of clinical signs after initiating treatment was attributed to relapse of the inflammatory intestinal disease, but was found to be attributable to relapsing toxoplasmosis secondary to immunosuppressive drug therapy." | ( Dieringer, T; Floyd, E; Lappin, MR; Lees, GE; Peterson, JL; Willard, MD, 1991) |
| "Gallstone recurrence is a major problem in the medical treatment of gallstones (treatment with UDCA/CDCA, ESWL, local MTBE lysis)." | ( Leiss, O; von Bergmann, K, 1991) |
| "The difference in recurrence rates between healed colloidal bismuth subcitrate-treated and healed cimetidine-treated patients was statistically significant at 3 months (3." | ( Chen, SH; Liao, CH; Lien, GS; Pan, SA, 1991) |
| "Parasite recrudescence following treatment (median 21 days) occurred in seven of 23 patients (30%) who had mefloquine serum concentrations indicative of regular prophylaxis (greater than 500 ng/ml)." | ( Edstein, MD; Kowinwiphat, W; Panpunnung, S; Shanks, GD; Suriyamongkol, V; Watanasook, C; Watt, G; Webster, HK, 1991) |
| "Patients treated for relapse episodes responded as well as they did to the first course of treatment, whether the relapse occurred after discontinuation of mesalamine or during a tapering of the dose." | ( Biddle, WL; Miner, PB, 1990) |
| "6 of 11 untreated patients relapsed within 3 months of ANCA rise." | ( Hené, RJ; Huitema, MG; Kallenberg, CG; Sluiter, WJ; Tervaert, JW; The, TH; van der Hem, GK, 1990) |
| "Fourteen of 24 patients (58%) had recurrence of endoscopic esophagitis documented between 26 and 300 days from the time of starting maintenance therapy." | ( Beck, IT; Da Costa, LR; Marciano-D'Amore, DA; Paterson, WG, 1990) |
| "Of the 13 recurrences, 10 have been re-treated with surgery and a second course of beta irradiation with excellent results." | ( Beyer, DC, 1991) |
| "Comparison of the recurrence rates during maintenance treatment with those during periods without active anti-ulcer therapy, using life table and incidence density analysis, showed a significant difference in favour of maintenance treatment." | ( Penston, JG; Wormsley, KG, 1990) |
| "When recurrences did occur in the thyroxine treated group they were small and easily managed by increasing the dose of thyroxine." | ( Anderson, PE; Hurley, PR; Rosswick, P, 1990) |
| "To determine whether recurrence rates for group A beta-hemolytic streptococcal (GABHS) pharyngitis are related to the time of initiation of antibiotic therapy, we randomly assigned 113 patients with GABHS pharyngitis either to a group that began a 10-day course of penicillin V at the time of diagnosis or to a group that began the same antibiotic regimen after a dealy of 48 hours." | ( DeMeo, KK; Gerber, MA; Kaplan, EL; Randolph, MF, 1990) |
| "After treatment, only one patient had recurrence in one treatment site." | ( McElroy, JA; Mehregan, DA; Roenigk, RK, 1990) |
| "Although there is no explanation for recurrence in most cases of CRCV, intermittent treatment schedules can be used to treat but not to cure these patients." | ( Merkus, JM; van Heusden, AM, 1990) |
| "In patients who relapsed, the ulcer recurrence tended to occur early on placebo and to be evenly distributed over the year on active therapy." | ( Salim, AS, 1990) |
| "The rate of recurrence of the ulcer within six months after the initial treatment (84." | ( Nair, KV; Rajindranath, T; Ramachandran, TM; Thomas, V, 1990) |
| "However, nine of these relapsed with recurrence of respiratory failure after steroid therapy was withdrawn." | ( Farber, BF; Kaplan, MH; Schiff, MJ, 1990) |
| "Treatment of recurrence is often difficult, and immunosuppressive drugs or surgery may be necessary." | ( Bayés de Luna, A; Cosín, J; de Miguel Diaz, MA; Guindo, J; Perez Ayuso, MJ; Ramió, J; Rodriguez de la Serna, A; Subirana, MT, 1990) |
| "However, it is noticeable that recurrence occurred when patients were treated with a combination of chloroquine and quinine." | ( Shimada, K; Tanabe, K, 1990) |
| "The effect on the recurrence of gastric ulcers after suppression of Helicobacter pylori by combined treatment with cimetidine and the antimicrobial drug cefixime was investigated." | ( Iishi, H; Ishikawa, H; Okuda, S; Tatsuta, M; Yokota, Y, 1990) |
| "To evaluate the rate of recurrence of focal segmental glomerulosclerosis (FSGS) in renal transplant patients treated with cyclosporine, we reviewed the outcome of 25 renal Tx performed in 24 patients who had FSGS as their original renal disease." | ( Banfi, G; Colturi, C; Montagnino, G; Ponticelli, C, 1990) |
| "In the controls, no recurrence was observed after a post-therapy period averaging 3." | ( Ammann, RW; Cotting, J; Eckert, J; Hirsbrunner, R; Jacquier, P; Steiger, U, 1990) |
| "Four of the five recurrences were in patients treated with doses of 1,000-1,500 cGy (P less than ." | ( Amendola, BE; Brady, LW; Campbell, OR, 1990) |
| "In the untreated group ulcer recurrence seemed to occur earlier (median relapse time = 2 months) in the patients with severe non-stenosing bulb deformity, and later in those with normal or mildly deformed bulb (median relapse time = 8 months); ranitidine treatment delayed relapse in deformed bulb patients (median relapse time = 14 months) and almost eliminated it in those with normal duodenal bulb morphology." | ( Greco, L; Mazzacca, G; Minieri, M; Piai, G; Sabbatini, F; Sollazzo, R, 1990) |
| "Variceal recurrence was found in 11 patients (73%; 95% confidence limits, 45-92%) treated with sclerotherapy only and in 2 patients (15%; 95% confidence limits, 2-43%; p less than 0." | ( Jensen, LS; Krarup, N, 1990) |
| "There were no recurrences of ventricular arrhythmias, and patients did not require antiarrhythmic drug therapy." | ( Barker, RA; Gardner, MA; Landymore, RW; McIntyre, AJ, 1990) |
| "The frequency of such recurrences is not known, but they may be related to krypton laser treatment." | ( Bindley, C; Kim, YM; Myers, FL; Wallow, IH, 1985) |
| "The time to first recurrence and frequency of subsequent recurrences were similar in the three treatment groups." | ( Allason-Jones, E; Barton, I; Faherty, A; Jeavons, M; Kinghorn, G; Mindel, A; Patou, G; Williams, P; Woolley, P, 1987) |
| "The visual results and recurrence rates in treated extrafoveal NVMs of 70 patients with AMD and 21 patients with OHS were similar to those reported by the Macular Photocoagulation Study Group, in which all treated patients received argon blue-green laser photocoagulation after the administration of retrobulbar anesthesia." | ( Alexander, MF; Chamberlin, JA; Fine, SL; Jost, BF; Maguire, MG; Murphy, RP, 1988) |
| "Pain recurrence was observed in about half of the patients in each group 1 year after treatment suspension." | ( Arcaini, L; Bianchi, S; Candiani, GB; Fedele, L; Vercellini, P, 1989) |
| "Consistent with this rate of recurrence, new warts developed in a third of the subjects in each group at sites remote from the treatment site." | ( Artman, NN; Beutner, KR; Conant, MA; Friedman-Kien, AE; Illeman, M; King, DH; Thisted, RA, 1989) |
| "During acyclovir therapy recurrences were completely prevented in 24 (77%) and were reduced in both frequency and duration in the remainder compared with those occurring during treatment with placebo." | ( Fiddian, AP; Gabrielsen, BO; Halsos, AM; Hovi, T; Lassus, A; Salo, OP; Tjøtta, EA, 1985) |
| "There was a 25% recurrence rate, mostly associated with treatment by enucleation, cysts that were parakeratinized or difficulty in removing the lesion." | ( Papanicolaou, S; Triantafyllou, D; Zachariades, N, 1985) |
| "Questionnaires about stone recurrence after treatment with percutaneous nephrolithotripsy (PNL) or extracorporeal shock wave lithotripsy (ESWL) were sent to 11 hospitals in the central section of Japan." | ( Yasukawa, S, 1989) |
| "Mel-B was used to treat 55 relapses after suramin therapy with 1." | ( Abinya, A; Chumo, DA; Dola, S; Mbwabi, D; Reardon, MJ; Siongok, TA; Smith, DH; Wanyama, L; Wellde, BT, 1989) |
| "The mean number of recurrences for patients on acyclovir therapy was 1." | ( Baker, DA; Blythe, JG; Hale, R; Kaufman, R; Portnoy, J, 1989) |
| "During acyclovir therapy, recurrences were completely prevented in 17 patients (71%) and the remaining seven patients had nine recurrences as compared to 18 recurrences while receiving placebo." | ( Andersen, LP; Kroon, S; Petersen, CS; Rasmussen, LP; Vestergaard, BF, 1989) |
| "Congenital ocular toxoplasmosis with recurrences must be treated by Spiramycin destroys trophozoites when they escape from the true cysts." | ( Comte, P; Le Bras, M; Verin, P, 1989) |
| "A symptomatic toxin-positive recurrence then developed after the subsequent course of systemic chemotherapy." | ( Hancock, KC; Harrison, CR; Satin, AJ; Zahn, CM, 1989) |
| "The rate and magnitude of late recurrences however was unaffected by the pleurodesis treatment, although recurrence in the chemically treated group was later than in the conventional drainage group." | ( Staelens, I; van den Brande, P, 1989) |
| "A patient in whom recurrence of Graves' disease after treatment with carbimazole was diagnosed after a disease-free interval of 31 years." | ( Lewis, NP, 1989) |
| "After stopping treatment, a recurrence is observed in about 50% of cases within 5 years." | ( Erlinger, S, 1989) |
| "The time to first recurrence in patients who commenced therapy on 400 mg twice a day was statistically significantly shorter than those on 200 mg four times a day (p less than 0." | ( Carney, O; Faherty, A; Freris, M; Mindel, A; Patou, G; Williams, P, 1988) |
| "The cumulative recurrence rate after 1 year of maintenance treatment was 48%." | ( Boyd, EJ; Johnston, DA; Penston, JG; Wormsley, KG, 1988) |
| "Weekly analysis of recurrences showed that treatment with 5 X 10(4) U of rIL-2 was effective only during the first 3 weeks of use and that 2." | ( Konrad, M; Merigan, TC; Weinberg, A, 1987) |
| "Breakthrough recurrences while on maintenance therapy are not uncommon, but can be successfully treated with more aggressive treatment with ganciclovir." | ( Causey, DM; Freeman, WR; Henderly, DE; Rao, NA, 1987) |
| "Patients with frequent recurrences of genital herpes were treated with oral acyclovir tablets, 800 mg, or placebo once daily for two years." | ( Drucker, JL; Marr, JJ; Mayfield, JL; Mostow, SR, 1988) |
| "The rate of subsequent recurrence of genital herpes was not altered by acyclovir treatment: 24 of 32 acyclovir recipients (75 percent) experienced one or more recurrences during a mean follow-up of 14 months compared with 19 of 27 placebo recipients (70 percent)." | ( Bryson, YJ; Durack, DT; Friedman-Kien, AE; Gnann, JW; Kaplowitz, LG; Klein, RJ; Lovett, M; Peacock, JE; Sparling, PF; Whitley, RJ, 1988) |
| "Of 30 women given such treatment, 13 relapsed within three months." | ( Bushell, TE; Evans, EG; Meaden, JD; Milne, JD; Warnock, DW, 1988) |
| "No significant rebound in recurrence has been observed during follow-up for 12 months after short-term 100- and 200-micrograms qid misoprostol treatment." | ( Herting, RL; Nissen, CH, 1986) |
| "The 39% recurrence rate of hyperprolactinemia and persistent abnormalities in pituitary-hypothalamic regulation of PRL secretion after transsphenoidal surgery raise important questions about the choice of primary therapy for patients with PRL-secreting tumors." | ( Chapler, FK; Schlechte, JA; Sherman, BM; VanGilder, J, 1986) |
| "The proven ulcer recurrence rate was lower in the treated group." | ( Byth, K; Gellatly, R; Piper, DW; Pym, BM; Seville, P; Toy, S, 1986) |
| "Five patients (15%) had full recurrence during acyclovir treatment and 31 (94%) while receiving placebo." | ( Bäck, O; Blom, I; Egelrud, T; Frödin, T; Hellbe, L; Johannisson, G; Malmros-Enander, I; Molin, L, 1986) |
| "The cumulative rate of recurrences (irrespective of T-type) within 2 months from the start of therapy was 55% among patients treated with phenoxymethylpenicillin for 5 days, 24% among those treated for 10 days with this drug and 19% among patients receiving cefadroxil." | ( Cars, O; Schwan, A; Strömberg, A, 1988) |
| "In the TMP group one recurrence and in the CNO group two recurrences occurred during treatment, two recurrences being observed in each group during the follow-up period of 4-6 weeks." | ( Seppänen, J, 1988) |
| "During follow-up, two patients without recurrence after saline treatment and six patients without recurrence after tetracycline treatment developed solid cold nodules." | ( Hansen, JM; Hegedüs, L; Juul, N; Karstrup, S; Torp-Pedersen, S, 1988) |
| "Life table estimates of duodenal ulcer recurrence during the 2-year period showed no significant difference between the two forms of treatment." | ( Billington, B; Bolin, TD; Davis, AE, 1987) |
| "The effect of cimetidine on ulcer recurrence, however, was confined to smokers; relapse risk among nonsmokers did not differ significantly between the treatment groups." | ( Adami, HO; Bates, S; Brodin, U; Fagerström, KO; Gustavsson, S; Lööf, L; Nyberg, A; Nyrén, O, 1987) |
| "The median time to recurrence in the cimetidine-treated group was 17 weeks among smokers, compared to 43 weeks among non-smokers (p less than 0." | ( Carling, L; Glise, H; Hallerbäck, B; Hallgren, T; Kagevi, I; Solhaug, JH; Svedberg, LE; Wählby, L, 1987) |
| "Early recurrence occurred in 36% of patients treated with TCAA and in 39% of those treated with cryotherapy." | ( Bradbeer, CS; Gellan, M; Godley, MJ; Thin, RN, 1987) |
| "Symptomatic relief and ulcer recurrence did not differ between the treatments." | ( Carling, L; Glise, H; Hallerbäck, B; Kagevi, I; Solhaug, JH; Svedberg, LE; Wahlby, L, 1987) |
| "Three surgery patients developed a recurrence which was then also treated medically." | ( Henn, V; Pichert, G, 1987) |
| "Cure and recurrence rates were not different in the three treatment groups, with or without simultaneous treatment of the male partner." | ( Bisschop, MP; Merkus, JM; Scheygrond, H; van Cutsem, J, 1986) |
| "We assessed gallstone recurrence rate in 42 patients diagnosed as having complete gallstone dissolution on bile acid therapy." | ( Jazrawi, RP; Joseph, AE; Kupfer, RM; Lanzini, A; Maudgal, DP; Northfield, TC, 1986) |
| "The hypothesis of a recurrence of sarcoidosis was evoked, and, after a few days course of corticosteroid, the patient recovered; he had no functional sequelae, and did not present any recurrence 2 years after having stopped the treatment." | ( Leys, D; Parent, M; Petit, H, 1986) |
| "Seasonal accumulation of duodenal ulcer recurrences suggests that maintenance therapy could be limited to the more risky periods." | ( Butruk, E; Gabryelewicz, A; Gibiński, K; Habior, A; Hasik, J; Klinoewicz, H; Kosidło, S; Marlioz, K; Nowak, A; Starzyńska, T, 1987) |
| "This procedure was developed to prevent recurrence which has been the biggest problem in the treatment regardless the surgical methods employed." | ( Lehto, M; Nieminen, S, 1986) |
| "The successful anti-recurrence treatment and the maintenance of lasting sinus rhythm after regularization in 90." | ( Karastanev, I; Kozareva, M, 1986) |
| "Four bitches (40%) had recurrence of pyometra within one year of treatment, and these same bitches had another recurrence after an additional prostaglandin treatment." | ( Flickinger, GL; Goldschmidt, MH; Meyers-Wallen, VN, 1986) |
| "Thirty VT recurrences occurred in the first 4 weeks of amiodarone therapy (total incidence, 61%), with the majority (55%) in the first 3 weeks of treatment." | ( Lavery, D; Saksena, S, 1987) |
| "Of 14 symptomatic recurrences of acute otitis media, eight (57 percent) occurred within one week of discontinuing antibiotic therapy." | ( Grundfast, KM; Hayden, GF; Rodriguez, WJ; Schwartz, RH, 1987) |
| "The treatment does not prevent recurrences after the medication is stopped." | ( Salo, OP, 1985) |
| "No difference in recurrence rates was found between the two groups six months after therapy." | ( Clapp-Channing, NE; Finn, AL; Gehlbach, SH; Hanlon, JT; Prentice, RD; Wu, LR, 1985) |
| "A significantly higher ulcer crater recurrence was observed in incompletely healed ulcer patients, even when cimetidine or placebo treatment groups were considered separately." | ( Carratù, R; Paoluzi, P; Proietti, F; Ricotta, G; Ripoli, F; Torsoli, A; Zaccardelli, E, 1985) |
| "Two consecutive recurrences were treated with either oral acyclovir 200 mg or matching placebo five times daily for five days." | ( Andersson, B; Eriksson, G; Hersle, K; Hillström, L; Lövhagen, GB; Mobacken, H; Ruhnek-Forsbeck, M; Sandström, E; Svensson, L, 1985) |
| "Each treatment began during a recurrence and continued for a maximum of 84 days or until the onset of the next recurrence, when the alternate medication was started." | ( Abeywickreme, I; Barton, IG; Hickmott, EA; Jeavons, M; Kinghorn, GR; Potter, CW; Rowland, M, 1985) |
| "In patients with recurrence of arrhythmia compared with asymptomatic patients, administration of amiodarone caused a longer ventricular effective refractory period (296 +/- 8 versus 271 +/- 7 ms, p less than 0." | ( Duncan, G; Fineberg, NS; Heger, JJ; Naccarelli, GV; Prystowsky, EN; Zipes, DP, 1985) |
| "Patient 1 has been free of recurrence for 11 years, six of them without treatment." | ( Bohn, T; Ho, AD; Hunstein, W, 1985) |
| "The effects on the recurrence rate of stones were compared with the effects on the recurrence rate in 43 calcium stone patients who were given similar advice on diet and fluid intake but were not treated with allopurinol." | ( Backman, U; Danielson, BG; Fellström, B; Holmgren, K; Johansson, G; Lindsjö, M; Ljunghall, S; Wikström, B, 1985) |
| "The stone recurrence rate of all of the 111 cases showed significant decrease during prophylactic treatment with allopurinol (p less than 0." | ( Ebisuno, S; Itatani, H; Koide, T; Morimoto, S; Ohkawa, T; Oka, T; Okada, Y; Sakaguchi, H; Sonoda, T; Yoshida, O, 1985) |
| "Ulcer recurrence rates were in 19, 24, and 35 percent for the ranitidine-treated patients and 44, 54, and 60 percent for patients taking placebo at four, eight, and 12 months, respectively (p less than 0." | ( Silvis, SE, 1984) |
| "In 21 of these 25 patients (84%) the recurrence was observed within 2 years of treatment being stopped." | ( Dowling, RH; Ruppin, DC, 1982) |
| "The mean recurrence rate per month of treatment was 1." | ( Adler, MW; Faherty, A; Fiddian, AP; Hindley, D; Mindel, A; Sutherland, S; Weller, IV, 1984) |
| "This rapid recurrence of apathetic hyperthyroidism represents evidence against the concept that this disorder represents "burnt-out," or exhaustion of, body reserves in long-standing, untreated hyperthyroidism." | ( Peake, RL, 1981) |
| "In the present study the recurrence rate of two groups of patients, treated according to two different concepts in the surgical management of keratocysts, are compared." | ( Stoelinga, PJ; van Haelst, UJ; Voorsmit, RA, 1981) |
| "The end-point of the trial was recurrence within 3 years of treatment with one or the other drug of a fatal or non-fatal cerebral infarction." | ( Dehen, H; Dordain, G; Doyon, F, 1984) |
| "The mechanism of recurrence is yet not fully elucidated and therapy still remains a problem." | ( Fanta, D, 1981) |
| "Subsequent untreated recurrences of genital herpes were associated with seroconversion to gD, IIg80, and vp66." | ( Ashley, RL; Corey, L, 1984) |
| "The median time to the first clinical recurrence was 18 days in placebo recipients, compared with over 120 days in both acyclovir-treated groups (P less than 0." | ( Benedetti, J; Connor, JD; Corey, L; Critchlow, C; Douglas, JM; Fahnlander, A; Hintz, MA; Mertz, GJ; Remington, M; Winter, C, 1984) |
| "Three patients had recurrence of infection within 4 days after the end of treatment and were successfully treated in each case with a second course of acyclovir." | ( Meyers, JD; Newton, B; Shepp, DH; Wade, JC, 1984) |
| "The rate of recurrence of duodenal ulcers during the 2nd year of follow-up study was 18% in ranitidine-treated individuals and 87% in those receiving placebo." | ( Boyd, EJ; Wilson, JA; Wormsley, KG, 1984) |
| "The incidences of recurrence/reinfection and treatment failures were comparable in the two groups." | ( Ford, LC; Goldman, L; Lebherz, TB; Mason, D; Wiesmeier, E, 1983) |
| "Treatment of such recurrences was more difficult than treatment of the initial attack." | ( Chapman, C; McGill, J, 1983) |
| "This study was done to determine the recurrence rate after successful medical treatment and cessation of chenodiol therapy; compare the efficacy and safety of low-dose chenodiol, as compared to placebo, for prophylaxis against recurrence; and identify factors predictive of recurrence." | ( Baum, RA; Habig, RL; Hanson, RF; Hersh, T; Hightower, NC; Hofmann, AF; Lachin, JM; Lan, SP; Lasser, EC; Marks, JW, 1984) |
| "The frequency of ulcer recurrence in smokers was significantly reduced by treatment with cimetidine (from 72 per cent to 34 per cent, P less than 0." | ( Archambault, A; Belsito, A; Cohen, N; Davis, W; Farley, A; Graham, DY; Grunt, R; Kinnear, D; Sontag, S; Weiss, J, 1984) |
| "Those with recurrence during treatment had a lower citrate excretion than other patients." | ( Ahlstrand, C; Hellgren, E; Larsson, L; Tiselius, HG, 1984) |
| "The rate of recurrence of ulcer during and after medical treatment was 54% while after surgery it was 10%." | ( Gear, MW, 1983) |
| "The difference in the recurrence rate between the eyes submitted to Beta therapy and those not submitted is considered statistically significant." | ( Barishak, YR; Monselise, M; Politi, F; Schwartz, M, 1984) |
| "Two patients with recurrences of sustained VT in this group were later successfully treated with propafenone, 900 mg/day; overall, 8 of 9 patients with recurrences of sustained VT were successfully treated with 900 mg/day." | ( Ambrosioni, E; Bracchetti, D; Marchesini, B; Naccarella, F; Palmieri, M, 1984) |
| "Percentage of recurrences in phenobarbital treated cases (4 +/- 0,6 mg/Kg/d) was 18,67%, versus 55,89% in untreated children (p less than 0." | ( Blanco, A; Cilleruelo, ML; Palencia, R; Tresierra, F, 1983) |
| "The rate of recurrence formation was found to be in a significant correlation with general symptoms, age, size of the largest cluster of involved lymph nodes, combination of drugs and type of consolidating therapy." | ( Kharatishvili, ZV; Kolygin, BA, 1983) |
| "There was no significant difference in recurrence rates between patients without mediastinal mass and patients with a small mass, and in these patients adjuvant chemotherapy MOPP after radiotherapy showed an evident benefit in reducing the relapse rate." | ( Baccarani, M; Cantore, M; Dominici, G; Emiliani, E; Faedi, M; Fiacchini, M; Frezza, G; Lauria, F; Mazza, P; Sciascia, R, 1983) |
| "Therefore, in stone recurrence prevention, the administration of Milurit 300 is recommended." | ( Balogh, A; Brundig, P; Fünfstück, R; Schneider, HJ; Stein, G; Traeger, A, 1983) |
| "No early ulcer recurrence or increased rebound acid secretion was noted after cessation of the cimetidine treatment." | ( Danielsson, A; Ek, B; Steen, L, 1981) |
| "Analysis of the recurrence of seizures suggested that the first year of treatment may be crucial in determining the long-term prognosis." | ( Reynolds, EH; Shorvon, SD, 1982) |
| "This recurrence of phlebitis resolved slowly over seven days, with warm soaking and aspirin therapy." | ( Brandstetter, RD; Gotz, VP, 1983) |
| "Ulcer recurrence was markedly reduced in sucralfate patients as compared to control when the pretreatment ulcers had healed slowly (P less than 0." | ( Ariyoshi, J; Miyake, T; Oishi, M; Sakai, M; Suzaki, T; Ueda, S, 1980) |
| "The post-treatment relapse study was markedly hampered by a low compliance of patients to cooperate in the long-term follow-up." | ( Domschke, W; Rösch, W; Schenk, J; Schmack, B, 1980) |
| "An early recurrence within the two months following the completion of treatment occurred in two children in each treatment group." | ( Helin, I, 1981) |
| "The incidence of recurrences was much greater in the initial 4 months but there was no difference between the 2 treatments." | ( Carmalt, M; Cockel, R; Green, I; Low-Beer, T; Roden, S, 1981) |
| "After three weeks of treatment, relapse or reinfection of the eye occurred in four of 19 patients (21%) in the topical therapy group and in three of 22 patients (13." | ( Faust, KL; Kusmiesz, HT; Nelson, JD; Patamasucon, P; Rettig, PJ, 1982) |
| "To date, gallstone recurrence has been detected in 14 patients (30%), 3 months to 5 years after discontinuing treatment with CDCA." | ( Dowling, RH; Iser, JH; Maton, PN; Murphy, GM; Reuben, A; Saxton, HM, 1982) |
| "Of the 31 recurrences, 14 had not been treated at the time of follow-up." | ( Geerdsen, JP; Hee, P, 1982) |
| "During a follow-up period of one year recurrences occurred in two of the five patients on antacids, but in none of the six treated with cimetidine." | ( Grönniger, J; Herzog, P; Holtermüller, KH; Rothmund, M; Weis, H, 1982) |
| "Two weeks after therapy, recrudescences of parasites invariably occurred." | ( Lewis, D; Purnell, RE; Young, ER, 1981) |
| "To date, there has been only one recurrence in the patients treated with tetracycline which consisted of mild conjunctival hyperemia." | ( Brown, SI; Zaidman, GW, 1981) |
| "Subsequent courses of treatment after relapse were equally effective in again inducing remission, but the probability of another relapse increased after each successive therapy and was 86% after three treatments." | ( Ammon, HV; Czaja, AJ; Summerskill, WH, 1980) |
| "Twenty-four consecutive women with recurrence and/or metastasizing carcinoma of the cervix were treated with adriamycin and methotrexate." | ( Grundsell, H; Johnsson, JE; Mattsson, W; Tropé, C, 1980) |
| "In contrast, of 17 patients with recurrence of TD 3 1/2 to 11 years (median, 6 years) after treatment, at least 15 had demonstrable pain on pinprick in the neuralgic areas." | ( Ecker, A, 1980) |
| "Two of the patients treated had relapses after vancomycin, while the other 2 were experiencing the first episodes." | ( Bartlett, JG; Chang, TW; Gorbach, SL; Saginur, R, 1980) |
| "Out of 125 patients treated, 83 relapsed, of whom 21 defaulted." | ( Bardhan, KD, 1980) |
| "In patients with frequent recurrences, suppressive therapy with oral aciclovir should be considered." | ( de Ruiter, A; Thin, RN, 1994) |
| "The time between the two treatments, age at relapse, and higher doses of radiotherapy all correlated with cognitive outcome, with girls showing greater impairments than boys." | ( Battin, M; Chessells, J; Christie, D; Leiper, AD; Neville, BG; Vargha-Khadem, F, 1994) |
| "There was no further recurrence during successful treatment with full doses of rifampicin and pyrazinamide for 1 year." | ( Chan, HS; Chan, KL; Lai, KN; Lui, SF, 1994) |
| "Mediastinal recurrence was noted only in those who were treated with abdominal radiotherapy alone." | ( Baboo, HA; Dixit, S; Murthy, RR; Neema, JP; Singhal, S; Vyas, RK, 1994) |
| "The CAG regimen seems promising for the treatment of relapsed AML with its low toxicity contributing to a high quality of life for the patient." | ( Aoyagi, A; Arimura, H; Furusawa, S; Koike, T; Noguchi, M; Saito, K; Sakuma, H; Waga, K; Yamada, K; Yamato, H, 1995) |
| "Four patients were in untreated relapse, 7 had stable or progressive disease, 12 were in partial remission, and 11 were in complete remission after reinduction chemotherapy before proceeding to the preparative regimen." | ( Diener, K; Dimopoulos, M; Giralt, S; Hagemeister, F; Ippoliti, C; Khouri, I; Mehra, R; Nath, R; Przepiorka, D; Samuels, B, 1995) |
| "Preventive treatment of recurrence is mainly indicated in case of complex seizures using either prolonged daily monotherapy, preferentially sodium valproate, or intermittent administration of diazepam during febrile illnesses." | ( Bourrillon, A, 1995) |
| "Treatment of recurrence, which is one of the major complications of pericarditis, is often difficult." | ( Martines, C; Martines, M; Resta, M; Sforza, G; Targa, L; Vaglio, A, 1995) |
| "All nine eyes had recurrence of the membranes after treatment terminated and required a maintenance regimen of corticosteroid eyedrops." | ( Barad, JP; Carlson, DW; Parsons, MR, 1995) |
| "A significantly lower bleeding recurrence rate was found in Group A patients who presented with active bleeding at the first treatment session (Group A: 2 of 20, Group B: 8 of 18, p < 0." | ( Apostolidis, N; Benakis, P; Dimopoulos, C; Feretis, C; Kalliakmanis, B, 1995) |
| "Although the recurrence-free rate of the 46 peplomycin-treated patients was lower, the difference was not significant." | ( Fujita, K, 1994) |
| "The symptomatic recurrence rate (symptoms plus endoscopic and/or radiological confirmation of disease) in the treatment group was 31% (27 of 87) compared with 41% (31 of 76) in the control group (P = 0." | ( Andrews, DF; Blair, JE; Cangemi, JR; Carryer, PW; Cohen, Z; Cullen, JB; McLeod, RS; O'Rourke, K; Steinhart, AH; Wolff, BG, 1995) |
| "In those tolerating the treatment, the relapse rates in the high- and low-dose groups were 26." | ( Jorde, R; Størmer, J; Sundsfjord, J; Ytre-Arne, K, 1995) |
| "To determine the 12-month posttherapy recurrence (recrudescence) of Helicobacter pylori in patients with healed duodenal ulcer after apparent eradication of the organism with anti-H." | ( Beattie, S; Gilvarry, J; Hamilton, H; Keane, CT; O'Morain, CA; Sweeney, EC; Xia, HX, 1995) |
| "Headache recurrence (HR) may occur within 24 hours in approximately 40% of migraine attacks initially treated successfully with 6 mg subcutaneous (SC) sumatriptan." | ( Alderton, CJ; Cutler, NR; Davis, RL; Ferrari, MD; Paulsgrove, LA; Rapoport, AM; Visser, WH, 1995) |
| "The secondary objective was to compare recurrence rates in complete responders at six months in the two treatment groups." | ( Armstrong, DK; Dinsmore, WW; Maw, RD; Morrison, GD; Moss, T; Nathan, PM; Nayagam, A; Pattman, RS; Wade, A; Watson, PG, 1994) |
| "There is a significant recurrence rate whatever method of treatment is used, and there are many studies in the literature on the treatment of recurrence." | ( Koob, E; Steffens, K; Witthaut, J, 1994) |
| "Disease progression, which includes recurrence at the primary tumor site, is a major cause of treatment failure in patients with mediastinal presentations." | ( Kadin, M; Kersey, JH; King, D; Krailo, MD; Meadows, AT; Morse, M; Rosenstock, J; Steinherz, PG; Tubergen, DG, 1995) |
| "The ipsilateral recurrence rate of patients treated with TCP was 9 percent (6/66) and recurrence time ranged from 2 days to 9 months." | ( Alfageme, I; Beiztegui, A; Hernandez, J; Huertas, C; Moreno, L; Vargas, A, 1994) |
| "In animals receiving 4 weeks of treatment with TBF, relapse was not observed up to 8 weeks after the termination of treatment." | ( Kudoh, M; Uchida, K; Yamaguchi, H, 1994) |
| "There were no recurrences at discontinuation of the treatment." | ( Coustals, P; Dromer, C; Fournié, B; Le Guennec, P; Marc, V; Sixou, L, 1994) |
| "Twenty-three patients were treated in first relapse and 10 in second or subsequent relapse; 21 received mini-BEAM as their first salvage regimen." | ( Brandwein, JM; Colwill, R; Couture, F; Crump, M; Danish, R; Keating, A; Scott, JG; Stewart, AK; Sutcliffe, SB; Sutton, DM, 1995) |
| "Ten (91%) of these 11 patients with recurrence showed focal persistent enhancement after the initial treatment of toxoplasmosis abscess." | ( Benmelha, Z; Bouvet, E; Casalino, E; Laissy, JP; Lariven, S; Parlier, C; Servois, V; Sibert, A; Soyer, P; Vachon, F, 1994) |
| "High recurrence rates pose renewed potential sources of infection and a high cost of renewed treatment." | ( Elliott, AM; Halwiindi, B; Hayes, RJ; Luo, N; Machiels, L; Mwinga, AG; Nunn, PP; Pobee, JO; Steenbergen, G; Tembo, G, 1995) |
| "To detect DU recurrence, the gastroscopy was performed at 6, 12, 18, and 24 months after therapy." | ( Choi, JH; Jung, MH; Kim, NY; Lee, KH; Oh, HS; Wee, SH, 1994) |
| "Postpartum monitoring for recurrence of depressive symptoms was compared with postpartum monitoring plus postbirth treatment with either the medication that had been effective for the previous episode or nortriptyline." | ( Wheeler, SB; Wisner, KL, 1994) |
| "There were no recurrences in surgically treated patients at an average of 3." | ( Goh, P; Low, C; Ngoi, SS; Tekant, Y, 1995) |
| "Steroids are widely used in treating the relapse of multiple sclerosis." | ( Griffiths, TD; Newman, PK, 1994) |
| "We studied the recurrence rate of pterygium after administration of a single dosage of topical mitomycin C at the completion of pterygium surgery." | ( Frucht-Pery, J; Hemo, I; Ilsar, M, 1994) |
| "Among patients treated in first relapse, EFS was 14." | ( Amadori, S; Annino, L; Arcese, W; Camera, A; Di Montezemolo, LC; Giona, F; Ladogana, S; Liso, V; Meloni, G; Testi, AM, 1994) |
| "Higher posttreatment recurrence rates were noted with keloids forming at infected sites and in patients with a family history." | ( Anscher, M; Klumpar, DI; Murray, JC, 1994) |
| "The optimal treatment of relapsed or refractory non-Hodgkin's lymphoma is unknown." | ( Abdel-Warith, A; Berry, J; Ezzat, AA; Khalifa, F; Khan, B; Raja, MA, 1994) |
| "Over 80% of recurrences are infrequent and can be treated when they occur n 20% of ulcer patients have 3 recurrences/yr, ulcer complications, or such poor health that recurrence might prove fatal." | ( McCarthy, DM, 1993) |
| "A second recurrence of bleeding was noted in eight patients, requiring surgical treatment." | ( Barton, E; Paul-Martin, C; Römmele, UE; Strohm, WD, 1994) |
| "The ratio between patients with recurrence and total patients (recurrence ratio) was lower in the mianserin-treated group throughout the study, and the intergroup difference from the 3rd to the 18th month was significant." | ( Hazama, H; Kamase, H; Kishimoto, A; Kunimoto, N; Matsuzaki, F; Mizukawa, R; Tanaka, K, 1994) |
| "The cumulative proportion of recurrence at 6, 12 and 24 months was significantly lower in the mesalazine group than in untreated group (P = 0." | ( Andreoli, A; Assuero Lanfranchi, G; Caprilli, R; Capurso, L; Corrao, G; D'Albasio, G; Gioieni, A; Paladini, I; Pallone, F; Ponti, V, 1994) |
| "The primary recurrence rate during the first three years following primary therapy, was shown to depend on the kind of therapy with a clear advantage for BC therapy." | ( Goepel, E; Pahnke, VG, 1994) |
| "The aim of this study was to compare recurrence rates of reflux oesophagitis (after endoscopic healing with omeprazole) over a 12 month period of randomised, double blind, maintenance treatment with either daily omeprazole (20 mg every morning; n = 53), weekend omeprazole (20 mg on three consecutive days a week, n = 55) or daily ranitidine (150 mg twice daily, n = 51)." | ( Dent, J; Hetzel, DJ; Mackinnon, M; Narielvala, FM; Reed, W; Shearman, DJ; Solcia, E; Yeomans, ND, 1994) |
| "Freedom from recurrence did not correlate with the time from diagnosis, the number of previous treatments, the presence or absence of residual disease at the time of treatment, or during which specific remission the treatment was given (second v > second)." | ( Adams, K; Amess, JA; Arnott, SJ; Dorey, E; Johnson, PW; Matthews, J; Norton, AJ; Price, CG; Rohatiner, AZ; Whelan, JS, 1994) |
| "The 18% incidence of recurrence highlights the fact that cough often is the manifestation of a chronic or recurring process that requires chronic or episodic therapy." | ( Akers, S; Bartter, T; DuBois, J; Pratter, MR, 1993) |
| "The low morbidity and recurrence rates compare favorably with published series of alternative treatment options for spontaneous pneumothorax." | ( Donahue, DM; Mathisen, DJ; Viale, G; Wright, CD, 1993) |
| "Early recurrence of hemorrhage was noted in 3 patients with large tumors; two were successfully treated by a second embolization and one died immediately after the first embolization." | ( Goffette, P; Levesque, M; Pringot, J; Soyer, P; Van Beers, B; Zeitoun, G, 1993) |
| "A patient is described in whom a recurrence of vasculitis was observed in the kidney allograft six years after transplantation and one year after withdrawal of corticosteroid therapy." | ( Allegri, L; Banfi, G; Bignardi, L; Fogazzi, GB, 1993) |
| "Two developed recurrence of paratyphoid fever, 17 days and 4 months after therapy." | ( Jesudason, MV; John, J; Kaur, A; Keystone, JS; Kozarsky, PE; Kudva, GC; Lalitha, MK; Mathai, D; Pulimood, BM; Thomas, M, 1993) |
| "Bleeding recurrence was less frequent in the treated patients (Kaplan Meier analysis p < 0." | ( Armas, R; Jirón, MI; Soto, JR; Wolff, C, 1993) |
| "to study the ulcer recurrence rate of Helicobacter pylori-positive duodenal ulcers at 1 yr after eradication of the bacteria by triple therapy." | ( Cheng, AF; Chung, SC; Hosking, SW; Li, AK; Ling, TK; Sung, JJ; Yung, MY, 1994) |
| "The mean number of recurrences per 4-month treatment period was 1." | ( Alling, DW; Dumois, JA; Mannix, ML; Notkins, AL; Rooney, JF; Straus, SE; Wohlenberg, CR, 1993) |
| "Such intervention can stop further recurrences of keratitis that is poorly controlled by antiviral therapy." | ( Brik, D; Dunkel, E; Pavan-Langston, D, 1993) |
| "Although the five-year recurrence rates in primary HSK treated with ACV were significantly lower than those in patients treated with idoxuridine, the recurrence frequency before 1985 was equal to that after 1986." | ( Hatano, H; Ohno, S; Uchio, E, 1993) |
| "In the patients who relapsed, ulcer recurrence tended to occur early in those on placebo and cimetidine and to be evenly distributed over the year in those on free radical scavenging therapy." | ( Salim, AS, 1993) |
| "Stone-free rates, recurrences and complications of treatment were determined." | ( Banting, SW; Desmond, PV; Henderson, MA; Pritchard, CP; Salomon, KL; Vellar, D; Vellar, ID, 1993) |
| "pylori on the recurrence of duodenal ulcer, we treated 104 patients with H." | ( Brandstätter, G; Dragosics, B; Hentschel, E; Hirschl, AM; Nemec, H; Schütze, K; Taufer, M; Wurzer, H, 1993) |
| "In the event of a recurrence greater than grade 2 (pre-nodular threshold grade), they underwent a new course of treatment." | ( Lehucher-Ceyrac, D; Weber-Buisset, MJ, 1993) |
| "All three patients exhibited early recurrence of the NS and were treated 5-10 days after the onset of proteinuria." | ( Cochat, P; Colon, S; David, L; Glastre, C; Kassir, A; Martin, X; Parchoux, B; Tourniaire, B, 1993) |
| "After five recurrences of idiopathic pericarditis over a period of 8 months on steroidal anti-inflammatory therapy, a splenectomized patient aged 31 years benefited from treatment with colchicine." | ( Attali, P; Douchet, MP; Fincker, JL, 1993) |
| "To determine the long-term recurrence rate of endometriosis after treatment with gonadotropin-releasing hormone analogues (GnRH-a)." | ( Shaw, RW; Waller, KG, 1993) |
| "The cumulative recurrence rate for the fifth year after treatment ended was 53." | ( Shaw, RW; Waller, KG, 1993) |
| "After initial success a recurrence in the right arm was treated by intraarterial prostaglandin infusion." | ( Heun-Letsch, CA; Mörl, H, 1993) |
| "The incidence of recurrence could not be reduced by the administration of Vitamin D3 metabolites concurrently with a calcium infusion, although calcium and phosphorus levels were higher between 24 and 48 hours after calcium infusion alone." | ( Zepperitz, H, 1993) |
| "Duodenal ulcer recurrence and gastritis are reduced with successful Helicobacter pylori treatment." | ( Cutler, AF; Schubert, TT, 1993) |
| "The mean recurrence rate after three years of follow-up was 49% for all patients (60 of 122 patients), with no differences between treated and untreated patients (P = ." | ( Baarsma, GS; Boen-Tan, TN; Brinkman, CJ; Buitenhuis, HJ; de Jong, PT; Klaassen-Broekema, N; Meenken, C; Rothova, A; Schweitzer, CM; Timmerman, Z, 1993) |
| "The majority of the patients were recurrence free on an annual basis during suppressive therapy." | ( Batenhorst, RL; Boone, GS; Conant, MA; Eron, LJ; Goldberg, LH; Kaufman, R; Kurtz, TO, 1993) |
| "In the patients who relapsed, ulcer recurrence tended to occur early on placebo but to be evenly distributed over the year on active therapy." | ( Salim, AS, 1993) |
| "This recurrence rate is about the same as for external radiotherapy, but we prefer our method for practical reasons (cost, equipment, radiobiology, technique)." | ( Amar, A; Azaloux, H; Escarmant, P; Francois, H; G'Baguidi, R; Gosserez, O; Michel, M; Moris, A; Ratoanina, JL; Zimmermann, S, 1993) |
| "There was no recurrence of pneumothorax in the group treated with thoracotomy, but 8% recurrence in the tetracycline-treated group." | ( Halkier, E; Krasnik, M; Stimpel, H, 1993) |
| "There were seven recurrences in five patients, five of which responded to a second course of quadruple therapy." | ( Lam, S; Tessler, HH, 1993) |
| "Those without recurrence during this treatment were followed up for another 6 months." | ( Bonnevie, O; Bremmelgaard, A; Eriksen, J; Hansen, JM; Jensen, TG; Justesen, T; Rune, SJ; Scheibel, J; Thomsen, OO; Vilien, M, 1993) |
| "Factors affecting recurrence of dyspeptic symptoms included age, duration of symptoms prior to trial entry and mean symptom score at end of the treatment study, but not the symptom severity prior to treatment." | ( Hazelhoff, B; Heyse, PM; Rambaldo, R, 1993) |
| "The geometric mean microfilaremia (mf) recurrence percentage as compared to the pre-initial treatment mf level was 35%, 21%, 17% and 17% at 6, 12, 18 and 24 months, respectively." | ( Cartel, JL; Glaziou, P; Moulia-Pelat, JP; Nguyen, LN, 1995) |
| "There where no further recurrences of acute pericardial episodes during the 24 months of follow-up, and no side effects related to the treatment with colchicine were reported." | ( Barroso López, JL; Grande Ingelmo, JM; Hernández Osegueda, M; Kallmeyer Martín, C; López Bescós, L, 1995) |
| "The basis of recrudescence, the reappearance of malaria parasites after chemotherapy or after failure of immune suppressions of the parasites, was studied in cultures of Plasmodium falciparum." | ( Aikawa, M; Kanbara, H; Nakazawa, S, 1995) |
| "A total of 78 patients with second recurrence or progression of histologically verified breast cancer were treated with single-agent cyclophosphamide given at 2." | ( Hansen, F; Møller, P; Skovsgaard, T, 1996) |
| "To establish the long term recurrence rate in patients operated on for nodular goitre and to find out if oral treatment with thyroxine reduces this risk." | ( Järhult, J; Röjdmark, J, 1995) |
| "Patients with untreated relapse had a 92." | ( Bastion, Y; Berger, F; Brice, P; Chéron, N; Fermé, C; Gabarre, J; Lepage, E; Morel, P; Nédellec, G; Reman, O, 1995) |
| "pylori infection decreases recurrence rates and facilitates healing, antibiotic therapy is indicated for all H." | ( Soll, AH, 1996) |
| "Furthermore, the probability of stone recurrence was significantly higher in untreated patients as compared to treated patients." | ( Adler, G; Kratzer, W; Kuhn, K; Maier, C; Mason, R; Tudyka, J; Wechsler, JG, 1996) |
| "Only one recurrence of hidradenitis suppurativa has been observed; this occurred along the margin of the surgical scar in a previously treated area." | ( Finley, EM; Ratz, JL, 1996) |
| "The five-year actuarial rates of cancer recurrence at any site and of distant metastases in the radiotherapy-first group and the chemotherapy-first group were 38 percent and 31 percent (P = 0." | ( Come, SE; Gelman, RS; Harris, JR; Hayes, DF; Henderson, IC; Recht, A; Shulman, LN; Silver, B, 1996) |
| "We examined the recurrence rate of herpetic uveitis (HU) in 13 patients (group A) treated prophylactically with long-term systemic acyclovir (600-800 mg/day) and compared it with that of 7 patients with no prophylactic therapy (group B)." | ( Foster, CS; Neves, RA; Power, WJ; Rodriguez, A, 1995) |
| "Relief of head pain and recurrence of successfully treated headache." | ( Le Force, B; Margul, B; Ricalde, O; Saper, J; Winner, P, 1996) |
| "To compare surgical performance and recurrence rates in patients submitted to laparoscopy for endometrioma excision following GnRH agonist (GnRH-a) treatment versus no preoperative medical treatment." | ( Caruana, P; Mancuso, S; Marana, R; Muzii, L, 1996) |
| "Time to first treatment failure (relapse or non-attendance) was the primary outcome measure." | ( Fischer, F; Fleischhacker, WW; Lesch, OM; Nimmerrichter, A; Oberbauer, H; Platz, T; Potgieter, A; Walter, H; Whitworth, AB, 1996) |
| "Published long-term recurrence rates are higher after sclerotherapy than after surgery for the treatment of varicose veins involving greater saphenous tributaries associated with saphenofemoral incompetence (SFI)." | ( Kanter, A; Thibault, P, 1996) |
| "Prevention of recurrence is difficult, as the recurrence rate is high, treatment duration is potentially long, and residual thoracic pain during menstruation is sometimes seen." | ( Bruggisser, D; Hamacher, J; Mordasini, C, 1996) |
| "The median number of recurrences up to the observation of foveal-sparing retinitis was two (range one to eight), and five patients had active CMV retinitis despite treatment for at least two continuous months." | ( Ai, E; Luckie, AP, 1996) |
| "Cure of HP infection reduces the recurrence of peptic ulcer and of rebleeding from ulcer disease more effectively than does long-term maintenance therapy." | ( Cantero, J; Gómez-Cedenilla, A; Grávalos, RG; Pajares, JM; Santander, C, 1996) |
| "When atovaquone was used as monotherapy recrudescences occurred." | ( Lederman, J; Rosenbaum, GS; Tanowitz, HB; Weiss, LM; Wittner, M, 1996) |
| "Ulcer recurrence rates 24 weeks post-treatment were lower following treatment with ranitidine bismuth citrate plus clarithromycin (21%) compared with ranitidine bismuth citrate alone (86%; P < 0." | ( Ciociola, AA; McSorley, DJ; Peterson, WL; Sykes, DL; Webb, DD, 1996) |
| "Headache recurrence (HR) is the major limitation of sumatriptan in the acute treatment of migraine attacks." | ( de Vriend, RH; Ferrari, MD; Jaspers, NM; Visser, WH, 1996) |
| "We analysed the recurrences of 86 patients with monopolar and bipolar mood and schizoaffective disorders treated with lithium over a period of 8." | ( Berghöfer, A; Kossmann, B; Müller-Oerlinghausen, B, 1996) |
| "There were recurrences in both treated (13%, 7/54) and previously untreated historical patients (44%, 8/18)." | ( Boyer, KM; Holfels, E; Hopkins, J; Luciano, R; Mack, D; McLeod, R; Meier, P; Mets, MB; Patel, D; Remington, JS; Roizen, N; Stein, L; Stein, M; Swisher, CN; Withers, S, 1996) |
| "In order to evaluate the recurrence of calcium kidney stones, 520 patients (275 males and 245 females), aged 14-79 years, previously treated with lithotripsy were followed up for 23 months on average (median = 24 months; range = 12-48 months), and 101 relapses (10%/year) were recorded." | ( D'Angelo, AR; Di Silverio, F; Gallucci, M; Menotti, A; Seccareccia, F, 1996) |
| "The CAG regimen seems promising for the treatment of relapsed AML with its low toxicity contributing to a high quality of life for the patient." | ( Saito, K, 1996) |
| "During treatment, the number of recurrences per month decreased from 0." | ( Pavan-Langston, D; Simon, AL, 1996) |
| "The patient had a recurrence of the choroidal neovascular membrane eight months after the start of thalidomide therapy." | ( Gorin, MB; Ip, M, 1996) |
| "Of the six recurrences one patient was treated by direct repair and the remaining five by interposition of a prosthetic graft." | ( Becquemin, JP; Berrahal, D; Cervantes-Monteil, F; Le Chevillier, B; Melliere, D, 1996) |
| "Eighteen of them were untreated and 92 relapsed or became refractory to previous therapeutic modalities." | ( Błasinka-Morawiec, M; Ceglarek, B; Dmoszynska, A; Durzynski, T; Dwilewicz-Trojaczek, J; Grieb, P; Hansz, J; Hellmann, A; Kasznicki, M; Komarnicki, M; Konopka, L; Kopec, I; Kotlarek-Haus, S; Krykowski, E; Lewandowski, K; Maj, S; Mazur, G; Potemski, P; Płuzanska, A; Robak, T; Sikorska, A; Skotnicki, AB; Urasinski, I; Zaucha, JM; Zdziarska, B, 1996) |
| "Cumulative ulcer recurrence rate was significantly higher in rats initially treated with indomethacin than in controls." | ( Arakawa, T; Fukuda, T; Higuchi, K; Kobayashi, K; Takaishi, O; Tarnawski, A; Watanabe, T; Yamasaki, K, 1996) |
| "To determine the rate of recurrence of a second attack after a single unprovoked epileptic seizure by using 2 study groups of treated and untreated patients and, thus, to establish a treatment policy for these patients." | ( Eshel, Y; Gabbay, U; Gilad, R; Lampl, Y; Sarova-Pinhas, I, 1996) |
| "Both recurrences were treated with oral acyclovir and systemic steroids." | ( del Priore, LV; Gelb, LD; Sharp, J; Storch, GA; Zamora, RL, 1996) |
| "In eclampsia, recurrence of seizures was less common with magnesium sulphate therapy compared with phenytoin (odds ratio [OR] 0." | ( Arnott, N; Chien, PF; Khan, KS, 1996) |
| "The 1-, 2- and 3-year recurrence rate from the original main tumor was 0%, 20%, and 20%, respectively, in patients treated with percutaneous acetic acid injection alone and 12%, 24%, and 24% in patients treated with percutaneous acetic acid injection after transcatheter arterial embolization (P = NS)." | ( Fujiwara, K; Ito, S; Ohnishi, K; Yoshioka, H, 1996) |
| "Gallstone recurrence was promptly treated by a combination of ursodeoxycholic acid plus chenodeoxycholic acid (5 mg/kg per day each) for a period of 2 years, or less if complete redissolution was achieved." | ( Alvisi, V; Bland, JM; Boga, E; Facchinetti, D; Fracchia, M; Galatola, G; Heaton, KW; Jazrawi, RP; Lanzini, A; Northfield, TC; Pazzi, P; Petroni, ML; Podda, M; Zuin, M, 1996) |
| "Forty-five patients had gallstone recurrence; of these, 39 underwent one or more repeated courses of bile acid therapy (follow-up data available in 27)." | ( Alvisi, V; Bland, JM; Boga, E; Facchinetti, D; Fracchia, M; Galatola, G; Heaton, KW; Jazrawi, RP; Lanzini, A; Northfield, TC; Pazzi, P; Petroni, ML; Podda, M; Zuin, M, 1996) |
| "In addition, recurrence within the first 5 days of spray treatment was classified as 'early treatment failure'." | ( Grahn-Håkansson, E; Holm, SE; Lagergren, L; Roos, K, 1996) |
| "At ABMT, 17 patients were in untreated relapse and one was in third complete remission (CR)." | ( Bonanad, S; Carral, A; de la Rubia, J; Jarque, I; Larrea, L; López, F; Martín, G; Martínez, J; Picón, I; Sanz, GF; Sanz, MA; Sempere, A; Soler, MA, 1996) |
| "The lowest costs and recurrence rates were achieved by 3 regimens: standard triple therapy (a combination of bismuth subsalicylate, metronidazole, and tetracycline hydrochloride) for 14 days ($223, with 18% recurrence); a combination of clarithromycin, metronidazole, and a proton pump inhibitor for 7 days ($235, with 15% recurrence); and standard triple therapy with a proton pump inhibitor for 7 days ($236, with 14% recurrence)." | ( Freston, JW; Murphy, K; Taylor, JL; Zagari, M, 1997) |
| "To compare the efficacy, tolerance and recurrence rate of endometriosis after 5-year follow-up of treatment with Gestrinone and Buserelin, respectively." | ( Cortés-Prieto, J; Keller, J; Nieto, A; Serra, M; Tacuri, C, 1996) |
| "In one case, recurrence of the abscess occurred two months after resolution: a successful result was obtained by steroids and broad-spectrum antibiotic therapy alone." | ( Melatini, A; Sidoti, C; Skrap, M; Vassallo, A, 1996) |
| "The relative risk of recurrence in the group assigned to six months of therapy, as compared with the group assigned to therapy of indefinite duration, was 8." | ( Carlsson, A; Eklund, SG; Granqvist, S; Holmström, M; Lärfars, G; Leijd, B; Linder, O; Lindmarker, P; Loogna, E; Nicol, P; Nordlander, S; Schulman, S, 1997) |
| "The median time to first recurrence was 82 days in the placebo group, 114 days in those receiving famciclovir, 125 mg once daily, and more than 120 days in the other treatment groups." | ( Fowler, SL; Goade, D; Kraus, SJ; Levin, MJ; Loveless, MO; Mertz, GJ; Tyring, SK, 1997) |
| "Efforts are currently being made to treat patients that relapse and become resistant to ATRA." | ( Chomienne, C; Degos, L; Fenaux, P, 1997) |
| "Despite radiotherapy in six patients, recurrences continued to occur within a mean period of 2." | ( Koornneef, L; Mombaerts, I, 1997) |
| "Low-dose sulfonylurea therapy prevents recurrence of hyperglycemia in newly diagnosed obese African-American patients with a history of hyperglycemic crises." | ( Clark, WS; Steen, MT; Umpierrez, GE, 1997) |
| "Mesalamine treatment reduced relapse compared with placebo treatment, although conventional statistical significance was not achieved." | ( Bailey, RJ; Dallaire, C; Fedorak, RN; Lariviere, L; Martin, F; Poleski, M; Rossman, R; Saibil, F; Sutherland, LR, 1997) |
| "Four recurrences were successfully treated by further GTN ointment and one by sphincterotomy." | ( Lund, JN; Scholefield, JH, 1997) |
| "We defined relapse as a recurrence of symptoms of sufficient severity to warrant treatment with corticosteroids, following a remission without treatment lasting greater than 1 month." | ( Gottlieb, JE; Israel, HL; Patrick, H; Steiner, RM; Triolo, J, 1997) |
| "One patient had recurrence after discontinuation of this treatment; but promptly responded to resumption of therapy." | ( Hirayama, K; Kano, Y; Orihara, M; Shiohara, T, 1997) |
| "Any subsequent recurrence of migraine headache was treated with a randomised second injection of sumatriptan or placebo." | ( Cull, RE; Dunbar, A; Price, WH, 1997) |
| "Even if we reported a higher recurrence rate (82%) with sclerotherapy than that with laparoscopic treatment (5%) we consider the percutaneous drainage a valid approach because it is a safe, easy and at low cost procedure." | ( Bellinzoni, P; Bianchi, A; Bocciardi, A; Consonni, P; Guazzoni, G; Nava, L; Rigatti, P; Scattoni, V; Spaliviero, M, 1996) |
| "The greatest problem with combined treatment is relapse after drug discontinuance." | ( Bruce, TJ; Spiegel, DA, 1997) |
| "The time to recurrence of heartburn with Aflurax treatment was prolonged significantly; after 6 months the life table estimates were 48% of patients in remission on Aflurax versus 8% on placebo (P = 0." | ( Aalykke, C; Havelund, T; Rasmussen, L, 1997) |
| "Aflurax significantly delays recurrence of moderate or severe heartburn and erosive oesophagitis, when used as maintenance treatment." | ( Aalykke, C; Havelund, T; Rasmussen, L, 1997) |
| "Bleeding recurrence was assessed during a 1-month period after treatment." | ( Blanc, P; Bories, JM; David, XR; Desprez, D; García-Compeán, D; Larrey, D; Michel, H; Michel, J; Pageaux, GP, 1997) |
| "A prompt recurrence of nummuli in both eyes within 4 weeks forced us to resume CSA therapy." | ( Reinhard, T; Sundmacher, R, 1997) |
| "The other two approaches prevent more recurrences: waiting to initiate maintenance therapy until symptoms recur once requires an additional $73 for each recurrence prevented whereas maintenance PPI from the outset requires an additional $819 for each recurrence prevented." | ( Harris, RA; Kuppermann, M; Richter, JE, 1997) |
| "A Cox's regression analysis of time to recurrence of oesophagitis showed that four factors were associated with a higher relapse rate during placebo and active maintenance therapy: (a) pre-treatment severity of oesophagitis (P < 0." | ( Carlsson, R; Dent, J; Frison, L; Galmiche, JP; Lundell, L, 1997) |
| "Both patients had a recurrence on the peripheral aspect of scars from previous retinochoroiditis and were treated with pyrimethamine (50 mg/day) and sulfadiazine (4 g/day) for seven weeks." | ( Auer, C; Bernasconi, O; Herbort, CP, 1997) |
| "Frequent recurrences of EM may be abrogated by prophylactic treatment with acyclovir." | ( Morelli, JG; Weston, WL, 1997) |
| "pylori recurrences had occurred in the first year after therapy." | ( Abu-Mahfouz, MZ; Cutler, AF; Prasad, VM; Santogade, P, 1997) |
| "However, all placebo-treated subjects relapsed after sampling alcohol, whereas only three of six naltrexone-treated subjects met relapse criteria after alcohol exposure (P = 0." | ( Krois, S; Liberto, JG; Norbeck, J; O'Brien, J; Oslin, D, 1997) |
| "Only one case showed recurrence of symptoms, which was treated successfully in a second session." | ( Bakker, DJ; Borgmeijer-Hoelen, AM; Groot, RH; van den Akker, HP; van Merkesteyn, JP, 1997) |
| "The risk of recurrences was significantly lower in children receiving continuous phenobarbital therapy than placebo (odds ratio 0." | ( Rantala, H; Tarkka, R; Uhari, M, 1997) |
| "Observed rates of persistence or recurrence were consistent with reported rates of pharmacological treatment failure." | ( Black, CM; Coles, FB; Hillis, SD; Litchfield, B; Mojica, B; Schmitt, K; St Louis, ME, 1998) |
| "Estimates of the risk of HSV recurrence and cesarean delivery rates in acyclovir-treated and -untreated patients and frequency of neonatal acyclovir treatment were derived from literature reviews, prospective surveillance, and practices at our institution." | ( Alexander, J; Scott, LL, 1998) |
| "Two episodes of IPA recurrence were treated with antifungal therapy with good results." | ( Janczarski, M; Podsiadło, B; Wierzbicka, M, 1997) |
| "The median time to recurrence after primary treatment was 6 months." | ( Alvarez, R; Austin, JM; Barnes, MN; Kilgore, LC; Niwas, S; Partridge, EE; Robertson, MW; Roland, PY, 1998) |
| "The odds ratio for clinical recurrences during treatment was 0." | ( Brocklehurst, P; Carney, O; Cowan, F; Ellis, E; Helsen, K; Kinghorn, G; Mindel, A; Ross, E; Shen, R, 1998) |
| "Fistula recurrence invariably occurred within 12 months of successful therapy (median 46 days, range 9-335)." | ( Dudley, NE; Tam, PK; Willetts, IE, 1998) |
| "Wart recurrence was investigated during a 12-week treatment-free follow-up period." | ( Beutner, KR; Douglas, JM; Fox, TL; Hougham, AJ; Owens, ML; Schmitt, KA; Spruance, S; Trofatter, KF; Tyring, SK, 1998) |
| "Patients treated recurrence of moderate or severe headache with a second zolmitriptan dose in 32% of attacks which responded to the first dose within 2 hours." | ( , 1998) |
| "Headache recurrence was experienced by similar proportions of patients across treatment groups (35% to 48% after placebo; 26% to 39% after sumatriptan)." | ( Cunin, G; Pfaffenrath, V; Prendergast, S; Sjonell, G, 1998) |
| "In patients without maintenance treatment, relapse was markedly higher (50/78 group I, 529/742 group II), but group II still bled significantly less (20% group I vs." | ( Bardhan, KD; Nayyar, AK; Royston, C, 1998) |
| "Response rates, time to treatment failure, relapse data, and overall survival were comparable between the two arms." | ( Advani, SH; Dinshaw, KT; Joshi, SR; Mukhadan, M; Nair, NN; Nair, R; Parikh, PM; Ramakrishnan, G; Saikia, TK; Soman, CS, 1998) |
| "To analyze the recurrences of atrial fibrillation in patients treated with sotalol or quinidine." | ( de Paola, AA; Veloso, HH, 1998) |
| "The time to the first recurrence of seizures after initial treatment was longer for the patients receiving diazepam (P<0." | ( Bell, WE; Bergen, DC; Cloyd, JC; Conry, JA; Dreifuss, FE; Kuzniecky, RI; Lo, WD; Matsuo, F; Pellock, JM; Rosman, NP; Sharp, GB, 1998) |
| "Therefore, recurrence of hepatitis C after liver transplantation seems to be at least partially related to posttransplantation immunosuppressive therapy." | ( Cienfuegos, JA; Civeira, MP; de la Peña, A; García, N; Herrero, JI; Prieto, J; Quiroga, J; Sangro, B; Sola, I, 1998) |
| "In patients with frequent recurrences, continuous suppressive therapy significantly reduced relapses and colonization." | ( Dib, OP; Fothergill, AW; Hilsenbeck, SG; Kirkpatrick, WR; McAtee, RK; Patterson, TF; Redding, SW; Revankar, SG; Rinaldi, MG, 1998) |
| "The time to the recurrence of endometriosis-associated pain after danazol treatment was slightly longer than that after GnRH-a treatment." | ( Casper, RF; Dmowski, WP; Malinak, LR; Miller, JD; Moghissi, K; Rock, JA; Shaw, RW; Surrey, E; Thomas, EJ, 1998) |
| "To evaluate the recurrence rate after deep calf-vein thrombosis treated with 6 weeks of oral anticoagulation." | ( Astermark, J; Berntorp, E; Björgell, O; Lethagen, S; Lindén, E; Nilsson, P, 1998) |
| "We analyzed the incidence and recurrence rate of early and late primary VF in 9,720 patients with a first acute MI, treated with thrombolytics, enrolled in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 trial." | ( Cavalli, A; Negri, E; Santoro, L; Volpi, A, 1998) |
| "Four patients affected by glioblastoma recurrence were treated with a gene therapy-immunotherapy protocol consisting of intratumoral injections of culture cells producing a retroviral vector which expresses human interleukin-2 and the herpes simplex virus thymidine kinase genes." | ( Calvi, P; Casentini, L; Cavaggioni, A; Colombo, F; Franchin, E; Palù, G; Zanusso, M, 1997) |
| "Although no recurrence was seen 1 week after the therapy in either group, recurrence was seen in 14." | ( Ban, Y; Doi, T; Fujihiro, S; Hasegawa, Y; Ishihara, S; Ito, F; Ito, S; Ito, Y; Iwata, H; Kawada, Y; Koide, T; Minoshima, K; Nezasa, S; Sakai, S; Shinoda, I; Takeuchi, T; Taniguchi, M; Ueno, K; Uno, H; Yamaha, M, 1998) |
| "Clinical recurrence was seen in eight erythromycin-treated children (5." | ( Noack, R; Scholz, H, 1998) |
| "GABHS recurrences within 30 days after penicillin/amoxicillin treatment rose from 9% in 1975 to 1979 to 25." | ( Francis, AB; Gootnick, J; Green, JL; Hoeger, W; Marsocci, SM; Murphy, AM; Noriega, C; Pichichero, ME; Sorrento, A, 1998) |
| "Treatment-associated lesion recrudescence with delayed healing, which is suggestive of local toxicity, was observed in three patients treated with 5% cidofovir gel and one patient treated with 3% cidofovir gel." | ( Diaz-Mitoma, F; Hughes, A; Jaffe, HS; McGuire, B; Rudy, J; Sacks, SL; Safrin, S; Shafran, SD; Sibbald, RG; Trottier, S, 1998) |
| "The odds for pterygium recurrence following surgical treatment of primary pterygium are close to six and 25 times higher if no conjunctival autograft placement is performed or if no intra/postoperative mitomycin C is used, respectively." | ( Rocha, G; Sánchez-Thorin, JC; Yelin, JB, 1998) |
| "Because of the high risk of recurrence the antibiotic treatment was to be continued for two years." | ( Hofgärtner, F; Miljak, T; Schmeiser, T; Sigel, H, 1998) |
| "Cessation of therapy resulted in recurrence of hypercortisolemia in each case, showing the effectiveness of therapy." | ( Comi, RJ; Gorden, P, 1998) |
| "It indicated that parasite recrudescence rate may be effectively decreased by prolonging treatment courses." | ( Bian, WX; Fu, YX; Li, GQ, 1997) |
| "Due to the greater risk of recurrence the L-thyroxine administration should be complemented in areas of iodine deficiency with approximately 100-200 mg iodide." | ( Feldkamp, J; Scherbaum, WA, 1998) |
| "The time to recurrence of a major depressive episode for all 3 active treatments was significantly better than for placebo." | ( Cornes, C; Dew, MA; Frank, E; Houck, PR; Imber, SD; Kupfer, DJ; Mazumdar, S; Miller, MD; Perel, JM; Pollock, BG; Reynolds, CF; Stack, JA, 1999) |
| "Our results demonstrate that recurrence of VFs within the first year of cyclical etidronate therapy was related neither to a lack of histologic response to the treatment nor induction of an abnormality of mineralization." | ( Alexandre, C; Barou, O; Lafage-Proust, MH; Thomas, T; Vico, L, 1999) |
| "Survival, cause of death, response to treatment, relapse rate, and risk for late complications were analyzed in all patients and by age group." | ( Bacigalupo, A; Gratwohl, A; Henry-Amar, M; Hows, J; Ljungman, P; Locasciulli, A; Marin, P; Marsh, J; McCann, S; Passweg, J; Raghavachar, A; Schrezenmeier, H; Socié, G; Tichelli, A, 1999) |
| "The pneumothorax was successfully treated but soon relapsed." | ( Adachi, Y; Gabazza, EC; Hataji, O; Kobayashi, H; Kobayashi, T; Ohmoto, Y; Taguchi, O; Yasui, H; Yoshida, M, 1998) |
| "No difference in recurrence rate was observed between our two treatment groups." | ( Ahlstrand, C; Tiselius, HG, 1993) |
| "Two had recurrence after initial treatment, which was salvaged." | ( Chellam, VG; James, FV; Kusumakumary, P; Nair, MK; Ratheesan, K, 1999) |
| "To compare the recurrence rate following treatment of recurrent pterygia using one of two techniques-limbal conjunctival autograft transplantation versus low-dose intraoperative mitomycin C (0." | ( Mutlu, FM; Sobaci, G; Tatar, T; Yildirim, E, 1999) |
| "Both techniques showed similar recurrence rates in the treatment of recurrent pterygia." | ( Mutlu, FM; Sobaci, G; Tatar, T; Yildirim, E, 1999) |
| "After eradication, variceal recurrence was more frequent in patients treated by variceal ligation at 1 and 3 years (47% and 92% vs." | ( Crespo, J; de la Peña, J; Fábrega, E; Pons-Romero, F; Rivero, M; Sanchez, E, 1999) |
| "Significant recurrence of symptomatic fissures and a high incidence of headaches are limitations of the treatment." | ( Carapeti, EA; Chadwick, SJ; Kamm, MA; McDonald, PJ; Melville, D; Phillips, RK, 1999) |
| "To document and characterize the recurrence or persistence of coagulopathy among patients envenomed by pit vipers and treated with a Fab antivenom." | ( Boyer, LV; Clark, RF; Dart, RC; McNally, JT; Nordt, SP; Seifert, SA; Walter, FG; Williams, SR, 1999) |
| "To determine the effect on recurrences of herpetic keratitis, animals infected with McKrae strain herpes simplex virus type 1 that survived to day 32 after infection were randomized to treatment with latanoprost 0." | ( Kaufman, HE; Thompson, HW; Varnell, ED, 1999) |
| "In the recurrence study, treatment with latanoprost significantly increased the appearance of clinical recurrences in McKrae-infected eyes, compared with balanced saline solution treatment (P = ." | ( Kaufman, HE; Thompson, HW; Varnell, ED, 1999) |
| "As expected, the recurrence risk of CMF treated patients was lower than the corresponding risk of patients undergoing surgery only." | ( Bonadonna, G; Brambilla, C; Demicheli, R; Ferrari, L; Miceli, R; Moliterni, A; Valagussa, P; Zambetti, M, 1999) |
| "Two of these recurrences followed the withdrawal of oral acyclovir therapy after one year of therapy." | ( Akova, YA; Duman, S; Onat, M, 1999) |
| "However, the recurrence may develop after cessation of oral acyclovir therapy, especially in patients who underwent PK for corneal perforation due necrotizing HSK." | ( Akova, YA; Duman, S; Onat, M, 1999) |
| "For treating recurrences, two trials show that valacyclovir is as effective as acyclovir (200 mg five times a day) with a treatment period of 5 days." | ( , 1999) |
| "After treatment, all relapses remitted (third remission) in 3." | ( Frommer, JP; Suki, WN; Trimarchi, H, 1999) |
| "In the drug-untreated group, recurrence of stroke was repeated, deterioration and amelioration of neurological deficits (ND) were repeated, and histological examination and measurement of regional blood flow (rBF) using nonradioactive colored microspheres performed at the end of treatment revealed severe damages and significantly decreased rBF in brain and kidney, respectively." | ( Funato, H; Uemura, A; Watanabe, M, 1999) |
| "The median recurrence-free interval in the laser-treated group was 37." | ( Neumann, R; Schindl, A, 1999) |
| "All cases with recurrence resolved with continued administration of oxymetazoline." | ( Doo, G; Johnson, DS, 1999) |
| "One patient had a recurrence of DVT during the treatment with LMWH with extension of the existing thrombus." | ( Cruickshank, M; Goudie, D; Kovacs, MJ; Morrow, B; Savage, KJ; Schulz, V; Wells, PS, 1999) |
| "The therapy was repeated following recurrence of the lameness." | ( Meijer, MC; Rijkenhuizen, AB, 1999) |
| "To identify prognostic markers for recurrence and efficacy of treatment, we evaluated the outcome of 32 renal allografts in 29 pediatric patients with FSGS who underwent transplantation from 1987 to 1998 in the North Italy Transplant program." | ( Artero, M; Basile, G; Cardillo, M; Carraro, M; Dall'Amico, R; Ghiggeri, G; Ghio, L; Ginevri, F; Montini, G; Rivabella, L; Scalamogna, M; Zamorani, E; Zennaro, C, 1999) |
| "In an attempt to prevent postoperative recurrence of ossification, 100 mg of indomethacin was administered daily after surgery for 6 weeks." | ( Caterini, R; Farsetti, P; Formisano, R; Ippolito, E; Penta, F, 1999) |
| "Death and treatment failure (relapse or death, inverse of leukemia-free survival) were more frequent in the Bu/CY group (RR, 1." | ( Bolwell, B; Cahn, JY; Camitta, BM; Davies, SM; Gale, RP; Giralt, S; Heilmann, C; Henslee-Downey, PJ; Herzig, RH; Horowitz, MM; Hutchinson, R; Keating, A; Klein, JP; Lazarus, HM; Milone, GA; Neudorf, S; Perez, WS; Powles, RL; Prentice, HG; Ramsay, NK; Schiller, G; Socié, G; Vowels, M; Weisdorf, DJ; Wiley, J; Yeager, A, 2000) |
| "After 12 months recurrences were observed in 14 of 15 patients initially treated with steroids and in 7 of 15 subjects who were had received transdermal nicotine (P = 0." | ( Guslandi, M, 1999) |
| "Concomitantly, no predictor of recurrence of disease could be identified, irrespective of treatment modality." | ( Kmen, E; Raber, W; Vierhapper, H; Waldhäusl, W, 2000) |
| "Rates of recurrence during the first 40 weeks after lithium discontinuation were similar for pregnant (52%) and nonpregnant women (58%) but had been much lower for both in the year before treatment was discontinued (21%)." | ( Baldessarini, RJ; Cohen, LS; Murray, A; Nonacs, R; Tondo, L; Viguera, AC, 2000) |
| "The optimal treatment for relapsed ALL therefore remains uncertain." | ( Darbyshire, PJ; Eden, OB; Harrison, G; Lawson, SE; Oakhill, A; Richards, S; Stevens, R, 2000) |
| "In May 1997, a recurrence of the attacks required the readministration of verapamil, 360 mg per day." | ( Albano, O; Bassi, A; Causarano, V; Centonze, A; Centonze, V; Dalfino, L, 2000) |
| "The incidence of headache recurrence within 24 hours of treatment with naratriptan, 2." | ( O'Quinn, S; Pait, D; Sheftell, F; Watson, C; Winter, P, 2000) |
| "The median time to recurrence was longer for patients with moderate pain before treatment compared with patients with severe pain before treatment (14." | ( O'Quinn, S; Pait, D; Sheftell, F; Watson, C; Winter, P, 2000) |
| "The originality of our case is the recurrence of the disease on three occasions with the same bacterium isolated on each occasion, with disease remission after antibiotic therapy." | ( Azoulay-Petit, C; Combemale, P; Dupin, M; Faisant, M; Kanitakis, J, 2000) |
| "Because many patients experience recurrences once prophylaxis is discontinued, long-term therapy may be warranted." | ( Ringdahl, EN, 2000) |
| "However, after surgery she experienced recurrence of right pneumothorax, and was accordingly treated with danazol." | ( Aizawa, H; Hara, N; Inoue, H; Shibata, K; Sugio, K, 2000) |
| "To assess risk factors for gallstone recurrence following non-surgical treatment." | ( Alvisi, V; Bland, JM; Facchinetti, D; Ferraris, R; Fracchia, M; Heaton, KW; Jazrawi, RP; Lanzini, A; Northfield, TC; Pazzi, P; Petroni, ML; Podda, M; Zuin, M, 2000) |
| "Risk of PSA recurrence after 8 months of neoadjuvant therapy is low after 5 years of follow-up and remains proportional to the presence of adverse preoperative risk factors." | ( Bruchovsky, N; Gleave, ME; Goldenberg, SL; Jones, EC; La Bianca, SE; Sullivan, LD, 2000) |
| "Treatment options after recurrence remain poor." | ( Sheiner, PA, 2000) |
| "The high recurrence risk observed warrants testing of alternative treatment strategies such as intracranial angioplasty." | ( Albers, GW; Thijs, VN, 2000) |
| "With a probability of success of 90%, a recurrence rate of 5% to 15%, and few complications, catheter ablation emerges as the best treatment of recurrent, symptomatic flutter." | ( Aass, H; Kongsgaard, E, 2000) |
| "Four children were retreated for relapse and are now euthyroid and off treatment." | ( Desai, MP; Desai, U; Mokhashi, MH, 2000) |
| "A significant decrease in recurrences was observed only in patients treated with high-dose vancomycin (2 g/day) and S." | ( Borjal, D; Bowen, K; Brandmarker, S; Elmer, GW; Fekety, R; Garcia, RJ; Greenberg, RN; McFarland, LV; Mulligan, ME; Rubin, M; Surawicz, CM, 2000) |
| "We investigated the peptic ulcer recurrence rates during maintenance therapy with H2-receptor antagonists (H2RAs) following first-line therapy with a proton pump inhibitor (PPI)." | ( Asaka, M; Asaki, S; Ashida, K; Harasawa, S; Hoshihara, Y; Kajiyama, G; Kaneko, E; Kobayashi, K; Muto, Y; Nakamura, T; Nakazawa, S; Ogawa, N; Sakaki, N; Takemoto, T; Yao, T, 2000) |
| "Early recurrence was observed despite additional medical therapy with albendazole." | ( Akdemir, R; Basaran, Y; Dindar, I; Ermeydan, C; Kurtoglu, N, 2000) |
| "Two of them developed a recurrence, but further Gn-RHa therapy was followed by complete resolution of the cysts in one patient and we resume Gn-RHa therapy to the other patient." | ( Aoki, R; Banno, K; Iwata, T; Kubushiro, K; Nozawa, S; Tsukazaki, K; Yamashita, H, 2000) |
| "Treatment for malignant recurrences includes surgery, therapeutic embolization, chemotherapy, and the application of therapeutic doses of metaiodobenzylguanidine." | ( Duclos, JM; Gimenez-Roqueplo, AP; La Batide Alanore, A; Plouin, PF; Salenave, S, 2000) |
| "Severe form of hepatitis C recurrence should be treated early with the best currently available treatment which is a combination of IFN and ribavirin." | ( Balabaud, C; Bernard, PH; Bioulac-Sage, P; Le Bail, B; Neau-Cransac, M; Rullier, A; Trimoulet, P, 2000) |
| "As an outpatient without recurrence he has received oral administration of uracil plus tegafur." | ( Kawahara, M; Nashimoto, A; Yabusaki, H, 2001) |
| "In patients with recurrence, ursodeoxycholic acid (UDCA) treatment was effective." | ( Abe, A; Ebara, M; Saisho, H; Sugiura, N; Tsuchiya, Y; Tsumita, R, 2001) |
| "The preventive treatment of recurrences is not well codified." | ( Amoura, Z; Cacoub, P; Godeau, P; Piette, JC; Sbaï, A; Wechsler, B, 2000) |
| "Th rate of recurrence of pyoderma gangrenosum was 46% independently of treatment." | ( Azaiz, MI; Ben Osman-Dhahri, A; Cherif, F; El Euch, D; Haouet, S; Mokni, M; Riahi, I; Zitouna, MM, 2001) |
| "It was concluded that the recurrence of HP infection is low at the end of one year after successful eradication therapy in this urban East Asian population." | ( Fock, KM; Khor, CJ; Ng, A; Ng, TM; Sim, CS; Tan, AL; Teo, EK, 2000) |
| "Among 14 T4-treated patients, recurrence of hypothyroidism occurred in 7 patients after treatment was discontinued." | ( Azizi, F; Daftarian, N, 2001) |
| "Because very small aneurysm remnants or recurrences probably are not clinically important, MR angiography is an option for following up intracranial aneurysms treated with detachable coils and may partly replace DSA." | ( Boulin, A; Pierot, L, 2001) |
| "Local recurrence after medication or surgical treatment is common in these patients." | ( Elenitsas, R; Low, DW; Palevsky, HI; Xu, X, 2001) |
| "Thus, compared with the overall 30% recurrence risk, non-smoking patients with a negative TSHR-Ab (at the end of ATD) had a lower (18%) recurrence risk; smoking patients with negative TSHR-Ab (at the end of ATD) had a 57% recurrence risk; non-smoking patients with positive TSHR-Ab (at the end of ATD) had a high (86%) recurrence risk; the recurrence risk was 100% in those few patients who both smoked and maintained a positive TSHR-Ab at the end of ATD treatment." | ( Bex, M; de Nayer, P; Glinoer, D, 2001) |
| "Rapid initial responders showed lower recurrence risk with either combined or monotherapy, relative to placebo." | ( Begley, A; Dew, MA; Frank, E; Houck, PR; Kupfer, DJ; Mazumdar, S; Mulsant, B; Reynolds, CF, 2001) |
| "Given the elevated level of recurrence of mouth constriction (extraarticular ankylosis), a minimum of 2 years' follow-up after surgical treatment was considered mandatory." | ( Jaquinet, A; Montandon, D; Pittet, B, 2001) |
| "However, high recurrence rate and persistent cystinuria in our patients emphasize the inadequacy of our treatment schedule in the prevention of recurrent cystine calculi." | ( Atsu, N; Bakkaloglu, M; Sahin, A; Tekgul, S; Tekin, A, 2001) |
| "The 2 patients with recurrences are now successfully treated with a calcium channel blocker, an approach, to our knowledge, never before reported for adult-onset nesidioblastosis." | ( Costa, EA; Kaplan, EL; Koka, MR; Straus II, FH; Sugg, SL; Witteles, RM, 2001) |
| "The average time from treatment to recurrence in these 3 patients was 1." | ( Pogrel, MA; Schmidt, BL, 2001) |
| "To further decrease hepatitis B recurrence, 33 hepatitis B virus (HBV)-related cirrhotic patients were treated with lamivudine before liver transplantation and with lamivudine together with low-dose HBIG (46 500 IU the first month followed by 5,000 lU/monthly) after surgery." | ( Barbui, AM; Ciancio, A; David, E; Debernardi-Venon, W; Franchello, A; Gentilcore, E; Marzano, A; Negro, F; Piantino, P; Rizzetto, M; Salizzoni, M; Smedile, A, 2001) |
| "The incidence of recurrence after the discontinuation of treatment was 5." | ( Ageno, W; Agnelli, G; Bagatella, P; Bazzan, M; Bertoldi, A; Guazzaloca, G; Iorio, A; Moia, M; Prandoni, P; Santamaria, MG; Scannapieco, G; Tomasi, C, 2001) |
| "This would suggest that the lower recurrence rate observed for small thyroid cancers detected at screening was due to earlier diagnosis rather than more effective treatment." | ( Bucci, A; Gierlowski, T; Mihailescu, D; Ron, E; Schneider, AB; Shore-Freedman, E, 2001) |
| "1 year after drug therapy the recurrence of CDU is revealed in 16." | ( Fedorov, AV; Sazhin, VP, 2001) |
| "Seven treated subjects had a diagnosed recurrence of VTE." | ( Egermayer, P; Inder, A; Town, GI, 2001) |
| "Treatment of recurrence or persistence was again most commonly nystatin for both mother and infant, followed by oral nystatin for the infant and oral fluconazole for the mother or oral fluconazole for both." | ( Brent, NB, 2001) |
| "One patient had a recurrence of infection and was treated with resection arthroplasty." | ( Chang, JD; Cho, SH; Ha, YC; Kim, SY; Kim, YH; Koo, KH; Park, HB; Song, HR; Yang, JW, 2001) |
| "Time to the first recurrence, syncope or near syncope, was shorter for untreated vs treated patients: 5 +/- 2 vs." | ( Biffi, M; Boriani, G; Branzi, A; Bronzetti, G; Frabetti, L; Picchio, FM, 2001) |
| "In order to decrease endometriosis recurrence after surgical therapy, it has been proposed to use a post-surgical oestrogen-lowering medical treatment." | ( Bianchi, S; Busacca, M; Calia, C; Candiani, M; De Marinis, S; Somigliana, E; Vignali, M, 2001) |
| "In contrast only 18% developed HBV recurrence under perioperative lamivudine treatment." | ( Bechstein, WO; Berg, T; Müller, AR; Naumann, U; Neuhaus, P; Neuhaus, R; Rayes, N; Seehofer, D; Steinmüller, T; Tullius, SG, 2001) |
| "Factors predictive of recurrence are, according to another study, dependence on oxygen therapy, prolonged corticosteroid therapy, smoking, and/or heart disease." | ( Gaillat, J, 2001) |
| "Variables predicting the recurrence of new affective disorder episodes as well as premature discontinuation of treatment were identified." | ( Brodersen, A; Hansen, PE; Jepsen, K; Licht, RW; Rasmussen, NA; Vestergaard, P, 2001) |
| "Intracoronary radiation therapy reduces recurrence of in-stent restenosis." | ( Dangas, G; Desai, KJ; Fahy, M; Lansky, AJ; Leon, MB; Mehran, R; Mintz, GS; Stone, GW; Waksman, R; Wu, H, 2002) |
| "Finally thrombo-embolic recurrences also benefit from a long treatment." | ( Baudouy, M; Benhamou, M; Ferrari, E; Schiano, N, 2001) |
| "In the previously untreated group, the relapse rate at 3 years after CR was 26." | ( Han, X; Hu, L; Li, X; Liu, P; Qiu, F; Wang, S; Xiao, Y; Yang, H; Zhang, P; Zhou, J, 2000) |
| "These results support that MP treatment of relapses induces immediate post-treatment and short-term effects on the immune system that could partly account for the clinical and radiological improvement observed in MS patients." | ( Barberà, N; Barrau, MA; Brieva, L; Espejo, C; Martínez-Cáceres, EM; Montalban, X, 2002) |
| "During and after treatment of relapses in patients with MS, the MSFC appears to be more sensitive in detecting changes in function than the EDSS." | ( Malin, JP; Ossege, LM; Patzold, T; Schwengelbeck, M; Sindern, E, 2002) |
| "But in view of the high recurrence rate, there is a need for further improvement of the treatment of ingrowing toenails." | ( Geelkerken, RH; Gerritsma-Bleeker, CL; Hermans, J; Klaase, JM; van Det, RJ, 2002) |
| "When a recurrence did occur, however, significantly less alcohol was consumed than before the treatment." | ( Fuchs, WJ; Riebenfeld, D, 2002) |
| "To determine the risk of recurrence of breast cancer associated with the use of hormone replacement therapy (HRT) in the management of menopausal symptoms in women previously treated for breast cancer who were taking concurrent tamoxifen or who were estrogen receptor-positive." | ( Dew, JE; Eden, JA; Wren, BG, 2002) |
| "Endoscopic therapy reduces the recurrence of bleeding from actively bleeding peptic ulcers and those with visible vessels." | ( Bleau, BL; Bracy, WP; Fleischer, DE; Gostout, CJ; Harford, WV; Keate, RF; Shaw, MJ; Sherman, KE, 2002) |
| "On the other hand, recurrence of uveitis and ocular complications were found significantly lower in the patients treated with regimen 1, as compared with that in patients treated with regimen 2 (23." | ( Du, H; Hu, T; Liu, Q; Min, H; Zhang, M, 2002) |
| "Thirty had no recurrences in the treated area, but in 12 cases de novo suppurating lesions, separated from the initial surgical site by >5 cm, developed." | ( Emtestam, L; Lapins, J; Sartorius, K, 2002) |
| "In 9/26 patients (35%) with confirmed recurrences, the PET findings significantly altered the treatment choice by detecting either clinically or radiologically unsuspected distant metastases." | ( Belhocine, T; De Barsy, C; Hustinx, R; Willems-Foidart, J, 2002) |
| "If immediate recurrences of AF occurred 2 more times, the alternative study drug was administered, and cardioversion was repeated." | ( Chugh, A; Greenstein, R; Hassan, S; Knight, BP; Lai, SW; Morady, F; Oral, H; Ozaydin, M; Pelosi, F; Scharf, C; Strickberger, SA; Tada, H, 2002) |
| "No differences in time to first recurrence or overall survival were observed between treatment groups." | ( Erikstein, B; Fjösne, HE; Jacobsen, AB; Kvinnsland, S; Skovlund, E; Söreide, JA; Varhaug, JE, 2002) |
| "Patients with six or more recurrences of herpes genitalis per year applied study cream (imiquimod or placebo) to lesions one, two, or three times per week for 3 weeks for each recurrence during a 16-week treatment period." | ( Conant, M; Schacker, TW; Smith, M; Stanczak, T; Thoming, C; Wang, Z, 2002) |
| "At 24 weeks, the recurrence rate of excised keloids treated with postoperative imiquimod 5% cream was lower than recurrence rates previously reported in the literature." | ( Berman, B; Kaufman, J, 2002) |
| "The active stage and the recurrences were treated by oral and periocular cortico steroids; and two patients were supplemented with oral azathioprine." | ( Rawoof, A; Sahu, DK; Sujatha, B, 2002) |
| "Prophylactic treatment of the recurrences by oral antiviral drugs represents a promising new concept for herpetic keratitis." | ( Colin, J, 2002) |
| "To determine the frequency of TB recurrence among MDR (multidrug-resistant) patients who achieved treatment 'success' on standard short-course chemotherapy." | ( Danilova, ID; Espinal, M; Grzemska, M; Migliori, GB; Punga, VV; Raviglione, MC, 2002) |
| "The frequency of TB recurrence among MDR-TB patients declared 'cured' after short-course chemotherapy is high." | ( Danilova, ID; Espinal, M; Grzemska, M; Migliori, GB; Punga, VV; Raviglione, MC, 2002) |
| "After the blinding was removed, recurrence of the fissure was observed in 3 of 52 patients in the nifedipine group within 1 year of treatment, and 2 of these patients healed with an additional course of topical nifedipine and lidocaine ointment." | ( Antropoli, C; Antropoli, M; Attena, F; Balzano, A; Bove, A; De Stefano, G; Molino, D; Perrotti, P, 2002) |
| "To determine the risk of seizure recurrence after a first seizure due to neurocysticercosis (NC) and to evaluate risk factors for seizure recurrence, including the influence of antihelminthic treatment." | ( Carpio, A; Hauser, WA, 2002) |
| "About 65% of cases had recurrences at varying intervals during treatment." | ( Choudhury, V; Popli, VK; Saxena, A; Talukdar, B, 2002) |
| "Ninety-six patients had no recurrence after 6 months of follow-up; 249 patients were finally included in the intent-to-treat (ITT) population." | ( Chosidow, O; Drouault, Y; Garraffo, R; Veyssier, P, 2003) |
| "Without this additional therapy, the recurrence rate of strictures might have been much higher." | ( Isotalo, T; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T, 2002) |
| "The frequency of headache recurrence (within 24 hours) for patients initially responding by 2 hours was lower in patients treated with droperidol than placebo, but differences failed to reach significance." | ( Alam, AS; Mendizabal, JE; Rothrock, JF; Silberstein, SD; Young, WB, 2003) |
| "The risk of recurrence during the first 24 weeks was reduced by 78% with suppressive therapy (P < 0." | ( Marina, RB; Roberts, JN; Romanowski, B, 2003) |
| "To understand the causes of recrudescence, we retrospectively studied a cohort of 104 malaria patients treated with artesunate monotherapy, 32 of whom recrudesced." | ( Emery, K; Ittarat, W; Looareesuwan, S; Low, J; Meshnick, SR; Pickard, AL; Rattanasinganchan, P; Udomsangpetch, R; Wilairatana, P, 2003) |
| "Treatment of recurrence of renal disease on graft remains controversial." | ( Badid, C; Fouque, D; Harzallah, K; Laville, M; Lefrancois, N; Touraine, JL, 2003) |
| "In patients with recurrence, CsA was administered IV, at an initial dose of 3 mg/kg per day, which was afterward adapted to maintain whole-blood levels between 250 and 350 ng/mL." | ( Gagnadoux, MF; Niaudet, P; Salomon, R, 2003) |
| "However, after excluding recurrences within 21 days of treatment, risk of recurrence was similar in both groups." | ( Conway, TS; Golombek, A; Hagenlocker, E; Kaneene, JB; Kruger, JM; Perry, RL; Stuhler, J, 2003) |
| "Palmoplantar warts are often hard to treat." | ( Wollina, U, 2003) |
| "Fifteen patients with previous AF recurrence (without antiarrhythmic drugs) after CV (CV1) were selected for amiodarone therapy and repeat CV (CVamio)." | ( Armstrong, KL; Fitzpatrick, AP; Fynn, SP; Garratt, CJ; Hobbs, WJ; Todd, DM, 2003) |
| "There are indications that the risk of recurrence after treatment with vitamin K antagonists decreases relative to the time since the first event." | ( Büller, HR; Hutten, BA; Prins, MH; van Dongen, CJ; Vink, R, 2003) |
| "Rates of recurrence were not different between patients maintained on cyclosporine therapy (16%) compared with those maintained on tacrolimus therapy (18%; P = 1." | ( Cohen, SM; Hart, J; Levitsky, J; Te, HS, 2003) |
| "There were no signs of recurrence 3 months after cessation of the treatment." | ( Barenholz, Y; Cagnano, E; Frankenburg, S; Vardy, D; Zvulunov, A, 2003) |
| "We reviewed 47 prospective studies of recurrence of pulmonary tuberculosis (TB) after cure to assess the influence of human immunodeficiency virus (HIV) infection and rifampin treatment." | ( Dye, C; Korenromp, EL; Nunn, P; Scano, F; Williams, BG, 2003) |
| "However, a biological and clinical recurrence occurred when therapy was discontinued." | ( Boeckler, P; Grange, F; Grosshans, E; Guillaume, JC; Krzisch, S, 2003) |
| "Eyes with recurrence less than 2 mm were treated with subconjunctival 5-fluorouracil injections." | ( Akarsu, C; Ergin, A; Taner, P, 2003) |
| "Twenty [20] of these patients had local recurrence in the prostate and eleven [11] patients had seminal vesicle invasion which was not diagnosed nor treated with the initial brachytherapy." | ( Bondy, H; Gil-Montero, G; Hendricks, F; Katz, S; Khawand, N; Koutrouvelis, P; Lailas, N; Sehn, J, 2003) |
| "One-year retreatment of relapsers with the combination of IFN+ribavirin led to 61% of virological SR and to a significant improvement of histological activity." | ( Boucher, EJ; Brissot, P; Canva, V; Colimon, R; Deugnier, Y; Guyader, D; Jacquelinet, C; Jacquelinet, S; Turlin, B, 2003) |
| "Frequency of attack recurrences was twice as large in the patients with IGE (mainly after the end of treatment) than in those with CFE, where they occurred during the reduction period and up to 3 months after the end of treatment." | ( Marszał, E; Szwed-Białozyt, B, 2003) |
| "Of seven cases observed after 25-mg treatment, five relapsed." | ( BURGESS, RW; YOUNG, MD, 1959) |
| "No patient had a recurrence after treatment of the husband." | ( MONROE, SE, 1963) |
| "falciparum recrudescences that had occurred after primary treatment with mefloquine-artesunate." | ( Binh, TQ; De Vries, PJ; Giao, PT; Hung, LQ; Kager, PA; Nam, NV, 2003) |
| "The post-treatment relapse patterns and efficacy of lamivudine re-treatment for relapsed patients have not been clarified." | ( Bang, SJ; Joo, KR; Kim, DH; Park, JH; Park, NH; Shin, JW, 2003) |
| "Predictive factors for post-retreatment relapse were age and the duration of additional lamivudine therapy after response." | ( Bang, SJ; Joo, KR; Kim, DH; Park, JH; Park, NH; Shin, JW, 2003) |
| "Clinical outcomes and recurrence rates did not differ significantly with treatment." | ( Baldwin, CD; Chonmaitree, T; Freeman, DH; Heikkinen, T; McCormick, DP; Saeed, K; Uchida, T, 2003) |
| "In the follow-up period of 8 weeks, recurrence of lesions was noted in 10% of patients treated with calcipotriol compared with 16." | ( Kaur, I; Kumar, B; Sharma, V, 2003) |
| "Maintenance treatment to prevent recurrences is recommended for chronic forms of major depressive disorder (MDD), but few studies have examined maintenance efficacy of antidepressants with chronic MDD." | ( Arnow, B; Banks, P; Borian, FE; Dunner, DL; Gelenberg, AJ; Hirschfeld, RM; Howland, R; Keitner, GI; Keller, MB; Klein, DN; Kocsis, JH; Kornstein, SG; Manber, R; Markowitz, JC; Miller, I; Munsaka, M; Rothbaum, B; Rush, AJ; Russell, JM; Thase, ME; Trivedi, MH; Zajecka, J, 2003) |
| "To characterize posttreatment recurrence of Helicobacter pylori in Peru, 192 adults with H." | ( Bautista, CT; Berg, DE; Dailide, G; Gilman, RH; Katz, U; Meza, R; Monath, TP; Ogura, M; Razuri, M; Roth, DE; Soto, G; Taylor, DN; Velapatiño, B, 2003) |
| "Anhedonia is often the cause for recurrence in heroine addiction, therefore, an appropriate treatment is an important aspect in recurrence prevention and remission stabilization." | ( Grinenko, AIa; Krupitskiĭ, EM; Zvartau, EE, 2003) |
| "Clinical recurrence of AOM after completion of therapy occurred in 31 patients." | ( Dagan, R; Echols, RM; Greenberg, D; Hamed, KA; Jacobs, MR; Ledeine, JM; Leiberman, A; Leibovitz, E; Pierce, PF; Piglansky, L; Press, J; Raiz, S, 2003) |
| "The likelihood of recurrence was not correlated with pretreatment cystic volume." | ( Chu, CH; Chuang, MJ; Lam, HC; Lee, JK; Lu, CC; Wang, MC, 2003) |
| "The Kaplan-Meier estimated rate of recurrence at five years was higher among patients with macroprolactinomas and those with microprolactinomas who had small remnant tumors visible on MRI at the time of treatment withdrawal than among patients whose MRI scans showed no evidence of tumor at the time of withdrawal (patients with macroprolactinomas, 78 percent vs." | ( Cappabianca, P; Colao, A; Di Sarno, A; Di Somma, C; Lombardi, G; Pivonello, R, 2003) |
| "In 14 out of the 20 pts (70 %) the recurrence occurred during chemotherapy or within 6 months after the end of the chemotherapy." | ( Chatzigeorgiou, K; Chatzigeorgiou, N; Chrysafis, G; Dimasis, A; Economou, S; Lyratzopoulos, N; Manolas, K; Minopoulos, G; Setzis, K; Zafiriou, G, 2003) |
| "The post-treatment relapse rate was 37% at two years in patients with serum HBV DNA levels of <200 copies/ml but 73% in those with > or =10(3) copies/ml." | ( Chung, YH; Kim, H; Lee, HC; Lee, YS; Lim, YS; Ryu, SH; Shin, JW; Suh, DJ, 2003) |
| "falciparum malaria was found where recrudescence occurred, despite standard oral treatment with chloroquine, sulfadoxine/pyrimethamine, and quinine sequentially." | ( Dev, V; Dua, VK; Gupta, NC; Phookan, S; Sharma, VP; Subbarao, SK, 2003) |
| "Thus, in addition to recurrence of symptoms of the illness, discontinuation of treatment can be associated with clinical signs and symptoms related to these changes." | ( Adler, L; Allen, AJ; Brown, WJ; Heiligenstein, J; Kelsey, D; Michelson, D; Milton, D; Ruff, D; Spencer, T; Wernicke, JF; West, SA, 2004) |
| "Post-OLT HCV recurrence can be safely treated with PEG-IFN and RIB." | ( Balan, V; De Petris, G; Douglas, DD; Hansen, K; Khatib, A; Moss, A; Mulligan, D; Ortiz, J; Rakela, J; Rodriguez-Luna, H; Sharma, P; Vargas, HE; Williams, JW, 2004) |
| "Treatment for posttransplant recurrence of hepatitis C with interferon-based therapy is difficult but results in loss of detectable virus in up to 30% of patients." | ( Abdelmalek, MF; Crawford, JM; Davis, GL; Firpi, RJ; Hemming, AW; Liu, C; Nelson, DR; Reed, AI; Soldevila-Pico, C, 2004) |
| "As the recurrence rate of active lichen sclerosus in prepubertal girls treated with topical corticosteroids is high, and the majority of prepubertal girls with lichen sclerosus continue to have disease after menarche, a treatment regimen that does not rely on corticosteroids may be beneficial." | ( Christopher, K; Goldstein, AT; Marinoff, SC, 2004) |
| "The cumulative recurrence rate in the GBF group with steroid tapering treatment was significantly lower compared with the value in the control group." | ( Andoh, A; Araki, Y; Bamba, T; Fujiyama, Y; Fukuda, M; Hanai, H; Kanauchi, O; Kojima, A; Mitsuyama, K; Sata, M; Takayuki, I; Takeuchi, K; Toyonaga, A, 2004) |
| "In the third graft, recurrence of disease could be prevented by immediate allopurinol treatment." | ( Eller, P; Laufer, J; Lhotta, K; Mark, W; Rosenkranz, AR; Theurl, I, 2004) |
| "Indications for the procedure included recurrence of bleeding after sclerotherapy (28 patients with cirrhosis, one patient without), refractory ascites or hydrothorax (21 patients with cirrhosis, one patient without), and Budd-Chiari syndrome (two patients)." | ( Bezzi, M; Fanelli, F; Marcelli, G; Passariello, R; Pepino, D; Riggio, O; Rossi, M; Rossi, P; Salvatori, FM, 2004) |
| "The cost of treating relapsed patients could offset the reduced drug acquisition cost associated with switching." | ( Barbeau, M; Layton, S, 2004) |
| "In the second treatment year, relapse rates under continued neuroleptic treatment are compared with those under stepwise drug withdrawal substituting instead prodrome-based early intervention (intermittent treatment)." | ( Bottlender, R; Buchkremer, G; Gaebel, W; Klingberg, S; Möller, HJ; Ohmann, C; Riesbeck, M; Von Wilmsdorff, M; Wölwer, W, 2004) |
| "We aimed to assess healing and recurrence rates after treatment with compression with or without surgery in people with leg ulceration." | ( Barwell, JR; Davies, CE; Deacon, J; Earnshaw, JJ; Harvey, K; Heather, BP; Minor, J; Mitchell, DC; Poskitt, KR; Sassano, A; Taylor, M; Usher, J; Wakely, C; Whyman, MR, 2004) |
| "For prevention of stroke recurrence, warfarin was administrated in 32 patients, antiplatelet therapy was given in 21 patients, and combination of warfarin and antiplatelet therapy was chosen in 10 patients." | ( Kajimoto, K; Nagano, K; Nagatsuka, K; Naritomi, H; Oe, H; Otsubo, R; Yasaka, M, 2004) |
| "One year later, the patient had a new recurrence and was treated with mycophenolate mofetil , improving his clinical situation." | ( Bueno, B; Espejo, B; González, E; Gutiérrez, E; Martínez, A; Torres, A; Valentín, M, 2004) |
| "She had three recurrences and her facial plaque, which was resistant to several conventional treatments, was eventually excised and then grafted in 1996." | ( Misago, N; Narisawa, Y; Shinogi, T, 2004) |
| "Early recurrence or disease refractory to therapy often results in a fatal outcome." | ( Hörl, W; Kleinert, J; Köstler, W; Lorenz, M; Soleiman, A; Sunder-Plassmann, G, 2004) |
| "Intensive PEG-ASNase therapy in the treatment of relapsed acute lymphoblastic leukemia reliably results in high-level serum PEG-ASNase activity, and asparagine depletion in serum and CSF is usually achieved." | ( Avramis, VI; Felgenhauer, JL; Hawkins, DS; Holcenberg, JS; Panosyan, EH; Park, JR; Thomson, BG, 2004) |
| "The risk of recurrence is low if thrombosis was provoked by a major reversible risk factor such as surgery; 3 months of treatment is usually adequate for such patients." | ( Kearon, C, 2004) |
| "Using genotyping results, recurrence was defined as relapse if pretreatment and subsequent nasal isolates were clonally identical; if the isolates were different, it was considered recolonization." | ( Ariza, J; Ayats, J; Domínguez, MA; Fernández-Sabe, N; Gudiol, F; Martinez-Castelao, A; Peña, C; Pujol, M, 2004) |
| "The patient presented with recurrence of Thygeson's SPK in the left eye 10 months after the LASIK procedure and no recurrence on the right eye, which was treated with PRK." | ( Chalita, MR; Krueger, RR; Netto, MV, 2004) |
| "Time to first treatment failure (relapse or non-attendance) was the primary outcome measure." | ( Niederhofer, H; Staffen, W, 2003) |
| "Without treatment the recurrence rate ranges between 50 and 100 %." | ( Gschwend, JE; Hautmann, RE; Rinnab, L; Straub, M, 2004) |
| "The patient experienced repeated recurrences shortly after stopping treatment." | ( Baylson, FA; Nyirjesy, P; Weitz, MV, 2004) |
| "Patients with 'persistence' or 'recurrence' of chyluria were treated with second course of RPIS using same sclerosant." | ( Bhandari, M; Goel, S; Gogoi, S; Kapoor, R; Kumar, A; Mandhani, A; Srivastava, A, 2004) |
| "Failure of treatment plus relapse was seen in 22 (15." | ( Ahmadi, SA; Gangi, SM; Roushan, MR, 2004) |
| "Owing to recurrence after conventional surgery and the tumor size, a novel treatment method using ablative Er:YAG laser combined with topical 5-fluorouracil was performed." | ( Elsner, P; Fuchs, S; Thiele, JJ; Ziemer, M, 2004) |
| "Six months after the treatment, no recurrence was observed." | ( Elsner, P; Fuchs, S; Thiele, JJ; Ziemer, M, 2004) |
| "We attempted to ascertain whether the recurrence rate decreased in patients with hydatid disease infestation of the bone and skeletal muscle who were treated with current surgical techniques and antihelminthic chemotherapy, and whether the outcomes for bone infestation were different when compared with outcomes for muscular infestation." | ( Arazi, M; Erikoglu, M; Memik, R; Odev, K; Ozdemir, M, 2005) |
| "The post-treatment recurrence rate of H." | ( Maaroos, HI; Oona, M; Rägo, T, 2004) |
| "The risk factors for recurrence of endometriosis include a history of endometriosis surgery, bilateral endometrioma, left endometrioma, tenderness nodules at cul-de-sac, post-operative administration of clomiphene, post-operative r-AFS scores,whereas the protective factors include the post-operative gravidity, post-operative adjuvant therapy and age at surgery." | ( Ding, XM; Lang, JH; Leng, JH; Li, HJ; Liu, ZF; Sun, DW; Wang, HL; Zhu, L, 2005) |
| "To characterize prevention of posttreatment relapse, amphotericin B was used to kill approximately 90-95% of Leishmania donovani in livers of mice deficient in mechanisms of acquired antileishmanial resistance." | ( Murray, HW, 2005) |
| "Seven of 9 recurrences (78%) occurred in 5 years or less, with 2 (22%) occurring more than 5 years after initial treatment." | ( Burton, CC; Morgan, TA; Qian, F, 2005) |
| "However, recurrence rates are high after cessation of treatment." | ( von Weizsäcker, F, 2005) |
| "There are, however, suggestions that treatment of relapses gives a response rate similar to that of first-time treatment." | ( de Rave, S; Schalm, SW; Vrolijk, JM, 2005) |
| "Discrete hazards of recurrence and recurrence risk reductions for treated patients relative to controls were analyzed for all patients enrolled in two separate randomized clinical trials [study 1 (386 women): no further treatment versus 12 cycles of CMF; study 2 (459 women): six versus 12 cycles of CMF] and a historical group (396 women: surgery alone) of axillary node-positive patients undergoing mastectomy." | ( Bonadonna, G; Demicheli, R; Hrushesky, WJ; Miceli, R; Moliterni, A; Retsky, MW; Valagussa, P; Zambetti, M, 2005) |
| "The dynamics of both post-treatment recurrence risk and CMF effectiveness are similar for both pre- and postmenopausal women, suggesting that post-resection mechanisms by which chemotherapy prevents metastases are similar, but of different magnitude in pre- and postmenopausal women." | ( Bonadonna, G; Demicheli, R; Hrushesky, WJ; Miceli, R; Moliterni, A; Retsky, MW; Valagussa, P; Zambetti, M, 2005) |
| "The total effective rate and recurrence rate of the treated group were superior to those of the control group significantly (P < 0." | ( Chen, G; Ding, SQ; Ha, NL; Ye, H; Yu, SP, 2005) |
| "In conclusion, lamivudine re-treatment in relapsed patients after initial lamivudine therapy had a higher response rate and shorter duration to HBeAg seroconversion than during the initial therapy." | ( Bang, SJ; Jeong, ID; Joo, KR; Kim, DH; Park, JH; Park, NH; Shin, JW, 2005) |
| "Patients with recurrence were re-treated." | ( Karacorlu, M; Karacorlu, SA; Ozdemir, H, 2005) |
| "Treatment for post-transplant recurrence results in sustained virological response (SVR) in up to 30% of cases." | ( Adham, M; Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Mabrut, JY; Pradat, P; Radenne, S; Souquet, JC; Trepo, C; Zoulim, F, 2005) |
| "The HCV recurrence rate was similar in both groups, although significantly lower HCV RNA loads were obtained with Thymoglobulin pretreatment." | ( Cautero, N; Cucchetti, A; Dazzi, A; De Ruvo, N; Del Gaudio, M; Di Benedetto, F; Di Francesco, F; Lauro, A; Masetti, M; Molteni, G; Pinna, AD; Ramacciato, G; Ravaioli, M; Risaliti, A, 2005) |
| "We report recrudescence of imported Plasmodium falciparum malaria following quinine treatment in the context of concurrent phenytoin use." | ( Criddle, J; Fabre, C; Klein, JL; Nolder, D, 2005) |
| "It is known that recurrence is very rare after successful steroid treatment." | ( Choi, WB; Kim, MH; Lee, SK; Lee, SS; Pyun, DK; Seo, DW; Yun, JP, 2005) |
| "The effect of treatment on recurrence has not been determined." | ( Guy, JE; Lowell, JA; Peters, MG; Qian, P, 2005) |
| "Fourteen patients with early recurrence were treated with a protracted high-dose prednisone or IV methylprednisolone, oral cyclophosphamide, high-dose oral or IV cyclosporine, and plasma exchanges." | ( André, JL; Cochat, P; Deschênes, G; Guyot, C; Loirat, C; Nathanson, S; Nivet, H, 2005) |
| "To review the recurrence rates of keloids after surgical excision followed by radiotherapy, and to answer the question whether after normalization of the dose, a dose-effect relationship could be derived." | ( Kal, HB; Veen, RE, 2005) |
| "Rituximab treatment in relapsed or refractory HCL results in a CR of 13% to 53%, but its use in HCL-v has not been reported in the literature to our knowledge." | ( Januszewicz, H; Quach, H; Westerman, D, 2005) |
| "At the time of the initial disease recurrence, 13 patients were readministered TMZ." | ( Abrey, LE; Demopoulos, A; Franceschi, E; Lassman, AB; Nolan, C; Omuro, AM, 2005) |
| "Nevertheless, multiple recurrences may occur, which are difficult to treat." | ( Bac, DJ; Dingemans-Dumas, AM; Visser, WE, 2005) |
| "Because of the high risk of fatal recurrence of the fungal infection, neither long-term maintenance chemotherapy nor allogeneic hematopoietic stem cell transplant (HSCT) was considered appropriate." | ( Barfield, RC; Behm, FG; Burnette, K; Eldridge, P; Hale, GA; Handgretinger, R; Knapp, K, 2007) |
| "New agents are needed to reduce the recurrence rate after frontline chemotherapy." | ( Cabanillas, F; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; O'Brien, S; Rodriguez, MA; Sarris, AH; Thomas, DA, 2006) |
| "Following HCV recurrence at 5 years, the patient underwent 4 cycles of antiviral therapy over a 4-year period, using various protocols." | ( Bruno, M; Coccoli, P; Cordone, G; Parrilli, G, 2005) |
| "The rate of appendicitis recurrence after conservative treatment was 25." | ( Chau, GY; Chiu, JH; Lai, HW; Loong, CC; Lui, WY; Wu, CW, 2006) |
| "Once treated, relapses are rare." | ( Kapoor, S; Sharma, A, 2006) |
| "Although these infections can easily be treated, the relapse rate is high." | ( Rusch, K; Rusch, V; Schwiertz, A; Taras, D, 2006) |
| "In addition, those patients with high recurrence rates or not presenting pain free at 2 h and/or sustained pain free at 24 h may also respond better to combination therapy suited to their individual profile, which must include nonsteroidal anti-inflammatory agents plus a triptan or a gastrokinetic drug." | ( Bigal, ME; Krymchantowski, AV, 2006) |
| "Both patients had no recurrence during a period of 2-year follow up with continuous clozapine therapy." | ( Huang, TL; Hung, YY; Yang, PS, 2006) |
| "We wished to determine recurrences of bacterial vaginosis (BV) after treatment over the course of 12 months and to establish factors associated with recurrence." | ( Bradshaw, CS; Fairley, CK; Garland, SM; Hocking, J; Horvath, LB; Kuzevska, I; Morris, MB; Morton, AN; Moss, LM, 2006) |
| "start of treatment for relapse." | ( Balestrieri, M; Detke, MJ; Fava, M; Perahia, D; Raskin, J; Wang, F, 2006) |
| "The probability free of symptoms recurrence was analyzed according to sex, age, number of syncope episodes previously to the treatment, clinical history time, treatment time, drug free from treatment time and TT result." | ( Bastos, S; Darrieux, F; Hachul, DT; Ludovice, AC; Scanavacca, M; Sosa, E, 2006) |
| "Male urethral stricture is prone to recurrence, ranging from 40% to 80% according to the length of stricture no matter what treatment is introduced." | ( Chen, KK; Huang, WJ; Lin, YH, 2006) |
| "The number of recurrences and need for new sessions of extracorporeal lithotripsy in patients with hypercalciuria treated with thiazides is significantly smaller than in Group A (p=0." | ( Arrabal-Martín, M; Arrabal-Polo, MA; Fernández-Rodríguez, A; García-Ruiz, MJ; Pichardo-Pichardo, S; Zuluaga-Gómez, A, 2006) |
| "Assessment of risk factors for ulcer recurrence in chronic leg ulcer patients treated by varicose vein surgery." | ( Magnusson, MB; Nelzén, O; Volkmann, R, 2006) |
| "Side effects and recurrences while on AZA therapy can occur, requiring either replacement of the drug or addition of another immunosuppressive agent." | ( Burnier, MN; Deschênes, J; Ozdal, PC; Vianna, RN, 2006) |
| "Overall, the recurrence rate was 19%; 4% of patients had to undergo retreatment." | ( Ghalamkarpour, F; Nasiri, S, 2006) |
| "Because of the high local recurrence rate associated with surgical resection alone, patients with diffuse intraarticular pigmented villonodular synovitis were treated with surgical resection followed by colloidal chromic P32 synoviorthesis." | ( Ball, JD; Boles, CA; Cline, MT; Ward, WG, 2007) |
| "One had a recurrence and was treated by internal carotid artery (ICA) occlusion." | ( Chang, CY; Chang, FC; Luo, CB; Teng, MM, 2006) |
| "There were no obvious signs of recurrence 5 months after chemotherapy." | ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "During long-term treatment relapses were more frequent in the monotherapy group (47 vs 15%, P<0." | ( Alexopoulos, E; Leontsini, M; Memmos, D; Papagianni, A; Tsamelashvili, M, 2006) |
| "The 5-year incidence of local recurrence was lower with chemoradiotherapy (8." | ( Bedenne, L; Bonnetain, F; Bouché, O; Buecher, B; Chapet, O; Closon-Dejardin, MT; Conroy, T; Ducreux, M; Francois, E; Gérard, JP; Leduc, B; Mackiewicz, R; Maurel, J; Seitz, JF; Untereiner, M, 2006) |
| "Symptomatic remission and recurrence rates were noted following six months local therapy." | ( Ayhan, A; Guven, S; Guvendag Guven, ES; Kucukali, T; Sakinci, M, 2006) |
| "Pregnant women who had recurrence of parasitaemia following 7 days supervised quinine treatment were treated with AL." | ( Ashley, EA; La, Y; Lindegardh, N; McGready, R; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2006) |
| "Inflammatory recurrence after discontinuation of efalizumab therapy is a manageable event, with a number of therapies and approaches available to physicians, including short courses of cyclosporin or methotrexate." | ( Papp, KA; Rosoph, L; Toth, D, 2006) |
| "The clinical effect and recurrence rate were observed, and levels of IL-6 and TNF-alpha in blood and urine were determined before treatment and at the 4th, 8th, 12th week after treatment." | ( Dang, XQ; Hu, GH; Wang, JH, 2006) |
| "Furthermore, the recurrence rate of the treatment group was lower than that of the control group showed by a 18-month follow-up (P < 0." | ( Dang, XQ; Hu, GH; Wang, JH, 2006) |
| "Survival and recurrence of liver failure events after therapy were main outcomes." | ( Accadia, L; Andriulli, A; Annicchiarico, BE; Bombardieri, G; Caruso, N; Iacobellis, A; Leandro, G; Perri, F; Siciliano, M, 2007) |
| "Although the overall recurrence rates for small and large aneurysms in HEAL were no lower than published rates for aneurysms treated with platinum coils, patients treated in HEAL had a reduced recurrence rate when greater than 75% of the coil length used to treat an aneurysm was HES and when the final coil was HES." | ( Cloft, HJ, 2007) |
| "The association between treatment relapse and hRFC levels was validated in a separate study population of 14 cases and 12 controls from an earlier case-control study (P = 0." | ( Devidas, M; Ge, Y; Haska, CL; LaFiura, K; Linda, SB; Liu, M; Matherly, LH; Taub, JW; Thomas, R, 2007) |
| "Thyroid hormone therapy reduced recurrences in this irradiated cohort." | ( Collins, BJ; Schneider, AB; Subbiah, S, 2007) |
| "After treatment there were 23 non-fatal recurrences in the three month group and 16 in the six month group." | ( Bentley, DP; Campbell, IA; Prescott, RJ; Routledge, PA; Shetty, HG; Williamson, IJ, 2007) |
| "Treatment of recurrence is often difficult and the guidelines issued by scientific societies remain vague." | ( Martin y Porras, M; Piérard, L; Waleffe, A, 2007) |
| "One of 27 treated patients relapsed after 6 months of observation." | ( Edstein, MD; Kitchener, S; Nasveld, P, 2007) |
| "Due to recurrence of the arrhythmia and a desire to continue chemotherapy, an automatic cardioverter-defibrillator was implanted with excellent effect." | ( Bednarkiewicz, Z; Ciesielczyk, M; Krzeminska-Pakula, M; Religa, W; Rudzinski, T, 2007) |
| "No patients had recurrence of optic neuropathy while receiving immunosuppressive drug therapy." | ( Dunn, JP; Jabs, DA; Kedhar, SR; Thorne, JE; Wittenberg, S, 2007) |
| "To investigate recurrences of erysipelas during prophylactic antibiotic treatment and to delineate the reasons for such failure." | ( Koster, JB; Kullberg, BJ; van der Meer, JW, 2007) |
| "Risk factors for amblyopia recurrence are insufficiently studied, but therapy weaning has recently been suggested as a method for reducing the risk of recurrence." | ( Baumann, M; Nilsson, J; Sjöstrand, J, 2007) |
| "The majority of recurrences occurred within the first 6 months after primary treatment." | ( Baumann, M; Nilsson, J; Sjöstrand, J, 2007) |
| "HCV-RNA at the end of treatment or at relapse was <10(5) IU/mL in the five subjects who cleared the virus and <10(4) IU/mL in four of them." | ( Annicchiarico, BE; Avolio, AW; Bombardieri, G; Grillo, RL; Siciliano, M, 2007) |
| "The ratio and HOXB13 alone predicted recurrence-free survival after endocrine treatment, with a benefit of prolonged treatment in estrogen receptor-positive patients correlated to a low ratio (recurrence rate ratio: RR = 0." | ( Brommesson, S; Fernö, M; Gruvberger-Saal, S; Jerevall, PL; Malmström, P; Nordenskjöld, B; Söderkvist, P; Stål, O; Strand, C; Wingren, S, 2008) |
| "Once recurrence is diagnosed patients should be treated with an increased dosage of steroid in addition to standard immunosuppressives." | ( Strecker, T; Wiest, GH; Zimmermann, I, 2007) |
| "The authors evaluated the recurrence rate of therapy-resistant keloids treated with excision followed by radiotherapy (1200 Gy in three or four fractions)." | ( Kreulen, M; Oldenburger, F; van de Kar, AL; van Zuijlen, PPM, 2007) |
| "This high recurrence rate suggests that radiotherapy might be less efficacious than suggested by other studies." | ( Kreulen, M; Oldenburger, F; van de Kar, AL; van Zuijlen, PPM, 2007) |
| "She was diagnosed with a recurrence of HSV epithelial keratitis and was treated with oral acyclovir 400 mg, 5 times a day, with good resolution of HSV signs and symptoms." | ( Mian, SI; Saxe, SJ; Shtein, RM; Stahl, RM, 2007) |
| "Early therapy after HCV recurrence, tailoring treatment duration to the individual decline in HCV-RNA and the management of side effects are key factors for improved efficacy." | ( Goldmann, G; Kalff, JC; Oldenburg, J; Rockstroh, JK; Sauerbruch, T; Speidel, N; Spengler, U; Vogel, M; Voigt, E; Wojcik, K, 2007) |
| "Knowledge of the hyper-tHcy recurrence time after folate therapy discontinuation may help in optimizing folate supplementation pulses." | ( Belcastro, V; Caccamo, D; Gaetano, G; Ientile, R; Italiano, D; Oteri, G; Pisani, F; Pisani, LR; Striano, P; Striano, S, 2007) |
| "Therapies for treating hepatitis C recurrence have limited applicability and tolerability, and they have a low SVR." | ( Arjal, RR; Burton, JR; Rosen, HR; Villamil, F, 2007) |
| "The efficacy of re-dosing to treat a recurrence/relapse was very high without differences between the drugs (pain-free: 60% with Indoprocaf and 50% with sumatriptan in the total attacks)." | ( Cerbo, R; Del Bene, E; Ferrari, A; Genco, S; Grazioli, I; Martelletti, P; Nappi, G; Pinessi, L; Sandrini, G; Sarchielli, P; Tamburro, P; Uslenghi, C; Zanchin, G, 2007) |
| "We report on the use of bortezomib to treat patients with relapsed/refractory multiple myeloma in routine clinical practice." | ( Calderoni, A; Cornu, P; Freimann, H; Olie, R, 2007) |
| "The mean +/- SE number of recurrences per 120 days of follow-up (primary endpoint) was lower with suppressive therapy (0." | ( Gilbert, SC, 2007) |
| "Current treatments for relapsed/refractory leukemias are unable to achieve extended remissions in most patients even with multiagent chemotherapy." | ( Jeha, S; Meyers, PA; Steinherz, LJ; Steinherz, PG, 2007) |
| "16 patients with hepatitis C recurrence and 1 with de novo HCV infection with a mean age of 54 y (range 43-66 y), 71% males, were treated." | ( Gjertsen, H; Hörnfeldt, E; Weiland, O, 2008) |
| "After surgical treatment, recurrence is rapid and severe." | ( Chung, ES; Cristol, SM; Kim, EK; Kim, SW; Kim, TI; Moon, JW, 2007) |
| "At the time of recurrence, four patients were on maintenance dose (5-10 mg/day) of oral corticosteroid while the remaining three were off treatment." | ( Gupta, A; Gupta, V; Sachdev, N; Singh, R, 2008) |
| "An early HCV recurrence can be expected in case of an older donor, with a marginal or fatty liver graft transplanted with a higher transfusion need and having an acute rejection treated with steroid bolus in the postoperative period." | ( Doros, A; Fazakas, J; Fehér, J; Fehérvári, I; Gálffy, Z; Gerlei, Z; Görög, D; Járay, J; Lengyel, G; Lotz, G; Máthé, Z; Nagy, P; Nemes, B; Németh, A; Pár, A; Sárváry, E; Schaff, Z; Schuller, J; Telegdy, L, 2007) |
| "In developing countries the recurrence rate of Helicobacter pylori after successful eradication therapy is as high as 42%, while in developed countries it is estimated to be less than 3%." | ( Achiel, K; Hazazi, R; Lederfein, T; Niv, Y; Waked, A, 2008) |
| "Four recurrences/nonsatisfactory results out of nine treated keloids were observed after treatments with 1 x 4 Gy + 2 x 3 Gy." | ( Kal, HB; Veen, RE, 2007) |
| "The frequent recurrence of pulmonary lesions was suspected to be due to immunological impairment associated with Behçet's disease, and the pulmonary lesions and inflammatory reaction tests showed improvement after colchicine was administered." | ( Miyamoto, T; Miyara, T; Nakajima, H; Nakajima, S; Sawaguchi, H; Tohda, Y; Tsuji, F, 2007) |
| "Treatment of post-transplantation recurrence of hepatitis B virus (HBV) infection despite prophylaxis with hepatitis B immunoglobulin (HBIG) and lamivudine combination therapy is not easy." | ( Akyildiz, M; Aydin, U; Karasu, Z; Kilic, M; Ozacar, T; Zeytunlu, M, 2007) |
| "Treatment of recurrence consisted of AD 10 mg once a day and lamivudine 300 mg/daily and HBIG was discontinued in those patients." | ( Akyildiz, M; Aydin, U; Karasu, Z; Kilic, M; Ozacar, T; Zeytunlu, M, 2007) |
| "Patients with recurrence were retreated." | ( Karacorlu, M; Karacorlu, SA; Ozdemir, H; Senturk, F, 2007) |
| "Surgical myectomy may still result in recurrence in eight patients (24 percent), which will necessitate further treatment with botulinum toxin injections." | ( Chen, CK; Tang, YB, 2007) |
| "Isolated anterior segment recurrence in VKH disease may occur concomitantly with subclinical choroidal inflammation and requires systemic therapy." | ( Bacsal, K; Chee, SP; Wen, DS, 2008) |
| "However, nine had recurrences within eight months of stopping treatment and required further courses of ganciclovir." | ( Bacsal, K; Chee, SP; Cheng, CL; Jap, A; Se-Thoe, SY; Tan, BH, 2008) |
| "Risk of relapse and recurrence was based on a recent randomised clinical trial assessing the efficacy and tolerability of maintenance treatment with venlafaxine over 2 years." | ( Ekman, M; Jönsson, B; Khandker, R; Ovanfors, A; Sobocki, P, 2008) |
| "To differentiate new infections from recrudescence, we genotyped pre- and post-treatment parasitaemia." | ( Annerberg, A; de Radiguès, X; Guthmann, JP; Imwong, M; Lesage, A; Lindegardh, N; Min Lwin, M; Nosten, F; Pittet, A; Zaw, T, 2008) |
| "Despite advances in treatment relapses are still frequent, and systemic disease remains associated with an adverse prognosis." | ( Angermann, CE; Bröcker, EB; Ertl, G; Hoyer, C; Kneitz, C; Störk, S, 2008) |
| "In contrast the cancer recurrence rate of the 15 matched untreated controls was 20% (3 of 15) and adenomas evolved in 4 of those patients (27%)." | ( Edler, L; Groh, B; Hoensch, H; Kirch, W, 2008) |
| "Disease recurrence has been and remains the leading cause of treatment failure in patients with high-risk leukemia." | ( Auberger, J; Clausen, J; Erdel, M; Gastl, G; Gunsilius, E; Nachbaur, D; Petzer, A; Willenbacher, W, 2008) |
| "The 11 recurrences were classified as 3 probable reinfections (27%), 2 probable infections from a new sexual partner (18%), and 6 probable treatment failures (55%); 2 of the 6 patients who experienced probable treatment failure had isolates with mild resistance to metronidazole." | ( Clark, RA; Curtin, E; Kissinger, P; Leichliter, JS; Martin, DH; Schmidt, N; Secor, WE, 2008) |
| "The atrial fibrillation (AF) recurrence rate after pulmonary vein isolation (PVI) has been relatively high and in some unsuccessful PVI cases, antiarrhythmic drugs that were ineffective before PVI may become effective (hybrid therapy)." | ( Hirai, M; Inden, Y; Murakami, Y; Murohara, T; Okada, T; Toyama, J; Tsuboi, N; Yamada, T; Yoshida, N; Yoshida, Y, 2008) |
| "We document the recurrence of a CSMD in a patient subsequent to the instillation of topical ocular hypotensive medications and its resolution on discontinuation of therapy." | ( Besada, E; Frauens, BJ; Shechtman, D, 2008) |
| "Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4." | ( Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S, 2008) |
| "This case suggests that recurrence of HCV infection in a sustained responder may be probable after immunosuppressive therapy." | ( Fragopanagou, E; Giannakoulas, NC; Lampropoulou-Karatza, Ch; Mimidis, K; Pallasopoulou, M; Thomopoulos, K; Tsamandas, AC, 2008) |
| "In spite of a diagnosis of having a recurrence of LAM based on radiologic findings and deteriorating pulmonary function, her clinical symptoms, which included dyspnea and chylothorax, were significantly improved after treatment with sirolimus." | ( Aoe, M; Date, H; Nakao, A; Okazaki, M; Oto, T; Sano, Y; Seyama, K; Sugimoto, R; Toyooka, S; Yamane, M, 2008) |
| "A suspected recurrence was successfully treated with topical ciprofloxacin and at final follow up 15 months later there was no evidence of infection." | ( Booth, F; Gottlieb, T; Janarthanan, P; Karim, R; McCarthy, S; Merani, R; Orekondy, S, 2008) |
| "To evaluate whether the initial recurrence after PEA of benign hepatic, renal, and splenic cysts is true recurrence, and to decide whether additional treatment is needed." | ( Hahn, HJ; Hahn, HM; Hahn, ST; Han, SY; Lee, HJ; Lee, SH; Park, SH; Yun, EH, 2008) |
| "GBT positivity recurrence rate was high after antibiotic treatment." | ( Cammarota, G; Cesario, V; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Lauritano, EC; Lupascu, A; Novi, M; Scarpellini, E; Serricchio, M; Sottili, S; Vitale, G, 2008) |
| "We present a case of successful treatment of relapsed lymphomatoid granulomatosis with bexarotene, a novel retinoid agent." | ( Berg, SE; Chong, EA; Downs, LH; Schuster, SJ; Torigian, DA; Tsai, DE; Wasik, MA, 2008) |
| "Eligibility criteria were recurrence or a second primary tumor in a previously irradiated area, no major sequelae resulting from the first radiotherapy, good general condition, no distant metastasis, and salvage surgery with macroscopic complete resection." | ( Bardet, E; Benhamou, E; Bensadoun, RJ; Bourhis, J; Castaing, M; de Raucourt, D; Dolivet, G; Ferron, C; Géry, B; Grégoire, V; Hamoir, M; Janot, F; Julieron, M, 2008) |
| "The lack of reported recurrences may lead to less cautious administration of antithrombotic therapy." | ( Fonville, S; Ramos, LM; Rinkel, GJ; van der Worp, HB, 2009) |
| "Psychotherapy is still the mainstay of treatment; however, relapse rates are high." | ( Elkashef, A; Hanson, G; Tiihonen, J; Vocci, F; White, J; Wickes, W, 2008) |
| "Risks and benefits of treating a relapse must be considered." | ( Thrower, BW, 2009) |
| "Genotyping confirmed that recrudescence after malaria treatment occurred in 7 (21%) out of 33 pregnant women with consecutive episodes during the same pregnancy (time range between recrudescent episodes: 14 to 187 days)." | ( Alonso, PL; Aponte, JJ; Bardají, A; Cisteró, P; Mandomando, I; Mayor, A; Menéndez, C; Puyol, L; Sanz, S; Serra-Casas, E; Sigauque, B, 2009) |
| "In the latter, 4/115 women reported recurrence of pain in the treatment group compared with 0/57 patients in the no-treatment arm." | ( Al Kadri, H; Al-Fozan, HM; Hajeer, A; Hassan, S, 2009) |
| "The number of recurrences of anterior uveitis per patient per year before treatment with latanoprost was 0." | ( Chalkidou, S; Georgopoulos, G; Halkiadakis, I; Kostakou, A; Markomichelakis, NN; Papakonstantinou, D, 2009) |
| "To assess time to next recurrence and development of antiviral resistance in patients with recurrent genital herpes treated with either single-day famciclovir (1 g twice-daily) or 3-day valacyclovir (500 mg twice-daily)." | ( Abudalu, M; Bodsworth, N; Fife, K; Hamed, K; Koltun, W; Prichard, M; Tyring, S, 2009) |
| "The median time to next recurrence from treatment initiation was 33." | ( Abudalu, M; Bodsworth, N; Fife, K; Hamed, K; Koltun, W; Prichard, M; Tyring, S, 2009) |
| "Six patients (2%) had recurrence of hypercortisolism, all of whom were treated successfully with reoperation." | ( DeVroom, HL; Jagannathan, J; Nieman, LK; Oldfield, EH; Smith, R; Stratakis, CA; Vortmeyer, AO, 2009) |
| "Two of them had recurrence of the amyloidosis, which cleared with subsequent treatment." | ( Fraunfelder, FW, 2008) |
| "Since recurrence of toxicity may necessitate administration of additional doses of lipid emulsion, a sufficient quantity of lipid emulsion should be available when regional anesthesia is performed." | ( Coetzee, AR; Levin, AI; Marwick, PC, 2009) |
| "However, the high rate of AF recurrence and substantial drug-related adverse effects, including sudden death, raised caution about using bepridil to treat persistent AF." | ( Aizawa, Y; Atarashi, H; Fujiki, A; Inoue, H; Ito, M; Katoh, T; Kobayashi, Y; Koretsune, Y; Kumagai, K; Niwano, S; Ogawa, S; Okazaki, O; Okumura, K; Origasa, H; Saku, K; Sato, T; Tanabe, T; Yamashita, T, 2009) |
| "For keloid recurrence after radiotherapy following keloid removal, with either teletherapy or brachytherapy, the recurrence rate after having delivered a BED greater than 30 Gy is less than 10%." | ( Jürgenliemk-Schulz, IM; Kal, HB; Veen, RE, 2009) |
| "Retreatment of the recurrence of SD with pimecrolimus as monotherapy is an effective and safe approach in the management of the disease." | ( Durmazlar, PK; Eren, C; Eskioglu, F; Oktay, B; Tatlican, S, 2010) |
| "We sought to identify risk factors for recurrence of Staphylococcus aureus bacteraemia (SAB) by auditing compliance with guidelines on its treatment in our hospital." | ( Bejon, P; Bowler, IC; Walker, TM, 2009) |
| "We found the recurrence rate after SAB was low despite poor compliance with guidelines on treatment duration." | ( Bejon, P; Bowler, IC; Walker, TM, 2009) |
| "Lesion recurrence rates at 12 months after two treatments were similar [19% (3 of 16) with 1 h vs." | ( Braathen, LR; Fritsch, C; Frølich, KW; Gardlo, K; Morken, T; Paredes, BE; Ros, AM; Saksela, O; Solér, AM; Warloe, T, 2009) |
| "Two patients had posttreatment recurrence of conjunctival amyloidosis and received 2 rounds of cryotherapy per affected eye (per patient)." | ( Fraunfelder, FW, 2009) |
| "Because of the risk of recurrence, she received postoperative systemic adjunctive chemotherapy using CMF, but this had to be withdrawn because of liver toxicity." | ( Morohashi, H; Morohashi, S; Odagiri, H; Saito, C, 2009) |
| "We describe an infant who had recurrence of Kawasaki disease and responded to therapy with Intravenous Immune globulin (IVIG) and highlight the need for recognition of this vasculitis, which is being increasingly recognised in the Indian subcontinent." | ( Balasubramanian, S; Ganesh, R, 2009) |
| "The risk of recurrence of endometriosis during hormone replacement therapy seems marginal if combined preparations or tibolone are used and oestrogen-only treatments are avoided." | ( Abbiati, A; Barbara, G; Fedele, L; Somigliana, E; Vercellini, P; Viganò, P, 2009) |
| "For our analysis of recurrence, we excluded six of the 40 patients who were lost to followup or had less than 18 months followup; five patients treated with resection also were excluded." | ( Cummings, JE; Heck, RK; Smith, RA, 2010) |
| "The primary outcome was endoscopic recurrence, while the secondary outcome was symptomatic recurrence (defined as symptoms attributable to Crohn's disease and severe enough to warrant treatment, plus endoscopic disease recurrence)." | ( McKenzie, M; McLeod, RS; Parkes, R; Ross, S; Wolff, BG, 2009) |
| "In addition, on the day of recurrence of parasitaemia the levels of chloroquine-desethylchloroquine (CQ-DCQ) were above the minimum effective concentration (>or=100 etag/ml) in all the three cases, showing that treatment failure could not be attributed to low level of drug in the patients blood." | ( Bacha, K; Birhanu, T; Ketema, T; Petros, B, 2009) |
| "Ten SLK recipients were treated for HCV recurrence with pegylated interferon+ribavirin: two had sustained virologic response, five stopped due to side effects, and three had no response." | ( Ahya, SN; Baker, T; Levitsky, J; Norvell, JP; Van Wagner, LB; Wang, E, 2009) |
| "Rates of recurrence were lower for patients receiving betamethasone therapy." | ( Dulabon, L; Martin-Alguacil, N; Mayoglou, L; Pfaff, D; Schober, J, 2009) |
| "Upon recurrence of an episode, a 5-day therapy phase started during which the gel was to be applied eight times daily." | ( Busch, R; Faergemann, J; Graubaum, HJ; Gruenwald, J, 2009) |
| "Tamoxifen reduces recurrence risk among women treated for estrogen receptor-positive breast cancer." | ( Ahern, TP; Cronin-Fenton, DP; Lash, TL; Pedersen, L; Sørensen, HT, 2009) |
| "The suppression of tumor recurrence after liver transplantation and a significant prolongation of survival were observed in the FTY720-treated rats, in comparison with FTY720-untreated rats." | ( Asahara, T; Itamoto, T; Kobayashi, T; Kuroda, S; Miyata, Y; Ogawa, T; Ohdan, H; Tanimoto, Y; Tashiro, H; Ushitora, Y, 2009) |
| "Because of its lower recurrence rate, dermofasciectomy is increasingly being performed to treat recurrences." | ( van Rijssen, AL; Werker, PM, 2009) |
| "This regimen offers a postrecurrence treatment alternative for patients, especially those who have received anthracycline-containing chemotherapy." | ( Crews, KR; Inaba, H; Pounds, S; Pui, CH; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Stewart, CF; Yang, S, 2010) |
| "Mode of treatment, microbial organisms, recurrence, associated FIA and association with IBD were recorded." | ( Abel, RM; Agarwal, T; Broadhurst, J; Niyogi, A, 2010) |
| "15 months after initial treatment the first relapse of Hodgkin lymphoma was histologically confirmed and involvement of lymph nodes was identical with initial staging." | ( Konífrová, E; Móciková, H; Stríteský, J, 2009) |
| "To identify risk factors for recurrence and efficacy of treatment, we reviewed the outcome of 23 grafts in 16 children with FSGS who had undergone transplantation between 1985 and 2007 at La Paz Children's Hospital." | ( Carrion, AP; Fuentes, GM; Garcia-Pose, A; Hijosa, MM; Melgar, AA; Meseguer, CG; Torres, MN, 2010) |
| "Successful hemostasis, recurrence rates, rebleeding rates, survival rates, complications and prognostic factors after the treatment were retrospectively reviewed." | ( Hikichi, T; Imamura, H; Irisawa, A; Kasukawa, R; Kuwana, T; Obara, K; Ohira, H; Oyama, H; Saito, A; Sakamoto, H; Sato, A; Sato, M; Shibukawa, G; Shishido, H; Takagi, T; Takahashi, Y; Takiguchi, F; Wakatsuki, T; Yamamoto, G, 2009) |
| "The cumulative recurrence rates at 1, 3 and 5 years after the treatment were 7." | ( Hikichi, T; Imamura, H; Irisawa, A; Kasukawa, R; Kuwana, T; Obara, K; Ohira, H; Oyama, H; Saito, A; Sakamoto, H; Sato, A; Sato, M; Shibukawa, G; Shishido, H; Takagi, T; Takahashi, Y; Takiguchi, F; Wakatsuki, T; Yamamoto, G, 2009) |
| "The 21-gene recurrence score assay is prognostic for women with node-negative, oestrogen-receptor-positive breast cancer treated with tamoxifen." | ( Albain, KS; Allred, DC; Baehner, FL; Barlow, WE; Bugarini, R; Davidson, NE; Gralow, JR; Hayes, DF; Hortobagyi, GN; Hudis, C; Ingle, JN; Livingston, RB; Osborne, CK; Perez, EA; Pritchard, KI; Ravdin, P; Shak, S; Shepherd, L; Sledge, GW; Winer, EP; Yeh, IT; Yoshizawa, C, 2010) |
| "A low recurrence score identifies women who might not benefit from anthracycline-based chemotherapy, despite positive nodes." | ( Albain, KS; Allred, DC; Baehner, FL; Barlow, WE; Bugarini, R; Davidson, NE; Gralow, JR; Hayes, DF; Hortobagyi, GN; Hudis, C; Ingle, JN; Livingston, RB; Osborne, CK; Perez, EA; Pritchard, KI; Ravdin, P; Shak, S; Shepherd, L; Sledge, GW; Winer, EP; Yeh, IT; Yoshizawa, C, 2010) |
| "Neither recurrences nor side effects were observed during therapy and follow-up in this study." | ( Aebersold, DM; Greiner, RH; Pajic, B; Pajic-Eggspuehler, B; Vastardis, I, 2009) |
| "The median number of syncopal recurrences was lower in the first year of non-pharmacological treatment compared with the last year before treatment (median 0 vs." | ( Go-Schön, IK; Harms, MP; Lenders, JW; Luitse, JS; Reitsma, JB; Romme, JJ; Ruiter, JH; van Dijk, N; Wieling, W, 2010) |
| "In patients with frequent recurrences of VVS, non-pharmacological treatment has a beneficial effect on both syncopal recurrence and QoL, but nearly half of these patients still experience episodes of syncope." | ( Go-Schön, IK; Harms, MP; Lenders, JW; Luitse, JS; Reitsma, JB; Romme, JJ; Ruiter, JH; van Dijk, N; Wieling, W, 2010) |
| "The relationship between post-treatment relapse and longer pretreatment periods of abstinence is counterintuitive, yet not without precedence in the literature." | ( Anthenelli, RM; Arteaga, C; Heffner, JL; Lee, TC, 2010) |
| "When recurrence rates by EPBD/EST were compared among the four treatment groups, they were lower with EPBD than with EST in all groups." | ( Hirai, T; Hiramatsu, T; Kojima, Y; Kuwahara, T; Miyata, A; Nakagawa, H; Ohhara, Y; Ohyama, I; Okada, A, 2010) |
| "Cancer recurrence after radical surgery might happen even in the case of patients with localized prostate carcinoma treated by radical prostatectomy." | ( Cindric, M; Cipak, A; Custovic, Z; Jurkovic, I; Sonicki, Z; Uchida, K; Zarkovic, K; Zarkovic, N, 2010) |
| "The present study aimed to estimate recurrence rate and treatment response in GERD patients treated with proton pump inhibitor." | ( Choi, TH; Hwang, JH; Hwang, TJ; Jeong, SH; Jeong, YJ; Jung, HC; Kim, JW; Kim, N; Lee, BH; Lee, DH; Lee, SH; Nah, JC; Park, YS; Song, IS, 2010) |
| "Subsequent symptomatic recurrence on the cessation of therapy in each improved patients was checked by telephone survey or outpatient interview." | ( Choi, TH; Hwang, JH; Hwang, TJ; Jeong, SH; Jeong, YJ; Jung, HC; Kim, JW; Kim, N; Lee, BH; Lee, DH; Lee, SH; Nah, JC; Park, YS; Song, IS, 2010) |
| "Recurrence rate, recurrence time, and rate of symptom improvement were not significantly different between NERD group treated with half dose and ERD group treated with full dose lansoprazole." | ( Choi, TH; Hwang, JH; Hwang, TJ; Jeong, SH; Jeong, YJ; Jung, HC; Kim, JW; Kim, N; Lee, BH; Lee, DH; Lee, SH; Nah, JC; Park, YS; Song, IS, 2010) |
| "We evaluated the clinical response, recurrence and adverse events of photodynamic therapy for in situ extramammary Paget's disease in 14 male and 3 female Chinese patients with 21 lesions." | ( Gao, T; Hu, X; Jiao, B; Li, C; Li, Q; Liao, W; Long, HA; Lv, Y; Qi, X; Qiao, H; Wang, L; Wang, S, 2010) |
| "At a mean follow-up of 44 months, the recurrence rate in patients treated with BCG was 28." | ( Bini, V; Costantini, E; Del Zingaro, M; Giannantoni, A; Lazzeri, M; Mearini, L; Porena, M, 2010) |
| "After tumour resection an early recurrence made a re-resection necessary, followed by radiotherapy." | ( Goertz, O; Hauser, J; Kuhnen, C; Steinau, HU, 2010) |
| "The clinical implications and treatment of relapse are discussed." | ( Seet, CS; Tan, JH; Yeh, BI, 2010) |
| "We examined the recurrence of gastric mucosal lesions in rats after a single treatment with compound 48/80 (C48/80), a mast cell degranulator." | ( Inui, K; Kobayashi, T; Nakazawa, S; Ohta, Y; Yoshino, J, 2009) |
| "There was a recurrence of enuresis in both groups during the 4 weeks after treatment was discontinued (10% increase in group A and 8% increase in group B)." | ( Abedin Zadeh, M; Kholaseh Zadeh, G; Moslemi, MK, 2011) |
| "The moderate-to-high recurrence rate following discontinuation of medical treatment indicates the need for a longer term study involving more cases." | ( Abedin Zadeh, M; Kholaseh Zadeh, G; Moslemi, MK, 2011) |
| "Adult glioblastoma patients at any recurrence after standard temozolomide chemoradiotherapy received sorafenib (400 mg twice daily) and continuous daily temozolomide (50 mg/m²/day)." | ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011) |
| "Time to recurrence showed no significant treatment effect (ITT analysis, p=0." | ( Bliddal, H; Bødtker, S; Egund, N; Eriksen, C; Frimer-Larsen, H; Hørslev-Petersen, K; Jørgensen, A; Pedersen, NW; Pfeiffer-Jensen, M; Simonsen, O; Snerum, LØ; Stengaard-Pedersen, K, 2010) |
| "The high risk of recurrence following surgical resection provides the rationale for adjuvant therapy." | ( Del Chiaro, M; Funel, N; Giaccone, G; Giovannetti, E; Hwang, JH; Kang, GH; Kim, MA; Kim, SW; Kim, YT; Leon, LG; Park, JK; Peters, GJ; Steinberg, SM; Voortman, J, 2010) |
| "Migraine recurrence was defined as any migrainous headache that occurred within 24 h post treatment, only when pain free at 2 h was achieved." | ( Charmoussi, S; Doitsini, S; Georgiadis, G; Kodounis, A; Mitsikostas, DD; Thomas, A; Vikelis, M; Xifaras, M; Zaglis, D, 2010) |
| "The treatment of recurrence is still controversial, and most reports related to use of plasma exchange have been uncontrolled trials with relatively small groups of patients and conflicting results." | ( Canaud, G; Legendre, C; Mamzer, MF; Martinez, F; Niaudet, P; Noël, LH, 2010) |
| "Treatment of patients by predictors of recurrence and personalization of management based on genotypes/phenotypes will be the focus of future study." | ( Regueiro, M; Swoger, JM, 2010) |
| "However, the effect on stone recurrence of citrate treatment in these patients has never been studied." | ( Abaterusso, C; Bernich, P; Fabris, A; Gambaro, G; Lupo, A; Marchionna, N; Nouvenne, A, 2010) |
| "The risk of recurrence with hormone therapy is probably increased in women with residual disease after surgery." | ( Brincat, M; Erel, T; Gambacciani, M; Lambrinoudaki, I; Moen, MH; Rees, M; Rozenberg, S; Schenck-Gustafsson, K; Tremollieres, F; Vujovic, S, 2010) |
| "Time to persistent arrhythmia recurrence was compared between first and multiple DCCV, and the effect of age, gender, presence of heart disease, left atrial size, fractional shortening, arrhythmia duration, anti-arrhythmic drug therapy (AAD) and other concomitant cardiac medication was evaluated using the Kaplan-Meier method and Cox's Proportional-hazards model." | ( Arya, A; Boodhoo, L; Bordoli, G; Cheek, E; Large, J; Lloyd, GW; Mitchell, A; Patel, NR; Pugh, P; Silberbauer, JS; Sulke, AN; Taggu, W; Vrahimides, J, 2010) |
| "A case is presented with fourth recurrence of keloids after surgical treatment of lop ears with final satisfactory outcome after combined therapy that included surgical excision, skin flap transposition and radiotherapy." | ( Ahmetasević, SG; Barisić, J; Grah, J; Gverić, T; Huljev, D; Ivkosić, A; Trajbar, D; Zdilar, B, 2010) |
| "Despite a variety of treatment options, recurrence is the norm." | ( Caccialanza, M; Piccinno, R; Recalcati, S, 2011) |
| "However, the rate of recurrence over 6 months was significantly lower in the EGF-treated groups than in the control group (p < 0." | ( Hong, JP; Kim, YH; Lee, SW; Ryu, SH, 2010) |
| "All patients experienced symptom recurrences after oral metronidazole therapy (250 mg 3 times daily for either 14 or 28 days) and after oral vancomycin therapy (125 mg 4 times daily for 14 days)." | ( Gaddis, A; Kaiser, TE; Kemmer, N; Neff, G; Zacharias, V, 2010) |
| "Since abdominal CT revealed peritoneal recurrence with massive ascites, we conducted chemotherapy using gemcitabine (GEM) in September 2008." | ( Fujiwara, M; Inoue, K; Ito, N; Kubo, N; Maruyama, A; Nakayama, A; Ogiwara, H; Rokuhara, T; Shirozaki, T; Takasu, K; Takeuchi, N; Tsujimoto, K, 2010) |
| "Steroids were effective in all treated patients." | ( Couvelard, A; Hammel, P; Hentic, O; Le Baleur, Y; Lévy, P; Maire, F; Rebours, V; Ruszniewski, P; Sauvanet, A; Voitot, H; Vullierme, MP, 2011) |
| "However, recurrences are possible after early treatment interruption." | ( Ayari, S; Carrabin, L; Couloigner, V; Cox, A; Denoyelle, F; Fayoux, P; Froehlich, P; Garabédian, EN; Leboulanger, N; Lescanne, E; Marianowski, R; Marie, JP; Mom, T; Mondain, M; Nicollas, R; Roger, G; Teissier, N; Triglia, JM; Van Den Abbeele, T, 2010) |
| "No difference in 10-years breast recurrence-free, disease-free, metastasis-free, and overall survival rates was observed in the 2 treatment sequence groups." | ( Arcangeli, G; Giannarelli, D; Giordano, C; Pinnarò, P; Rambone, R; Strigari, L, 2011) |
| "Although recrudescence in some cannot be ruled out, our cohort had a shorter median time to RP compared with other artemether-lumefantrine treatment studies." | ( Heppner, DG; Ogutu, B; Olsen, CH; Polhemus, ME; Schnabel, D; Waitumbi, JN; Walsh, DS; Woodring, JV, 2010) |
| "The early detection of the site of recurrence could lead to a prompt instauration of the most appropriate treatment, i." | ( Allegri, V; Ambrosini, V; Boschi, S; Castellucci, P; Fanti, S; Fuccio, C; Martorana, G; Marzola, MC; Montini, GC; Nanni, C; Rubello, D; Santi, I; Schiavina, R, 2011) |
| "Treatment success without recurrence was achieved in 32 of 34 eyes (94." | ( Park, KH; Shin, JY; Woo, SJ; Yu, HG, 2011) |
| "In case of a confirmed recurrence/appearance of new colorectal cancer, patients can be treated with surgery or any subsequent line of chemotherapy and will be followed for survival until the end of study follow up period as well." | ( Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE, 2010) |
| "Of 250 cases started on Category II retreatment, 209 were relapse cases; of these, 18 were INH-resistant RMP-susceptible, 18 were INH+RMP-resistant and nine were culture-negative." | ( Maharjan, B; Shrestha, B; Yoshiyama, T, 2010) |
| "Despite treatment, there were six recurrences of BRONJ, four of them with additional sinusitis maxillaris." | ( Hollstein, S; Hölzle, F; Kriwalsky, MS; Kunkel, M; Maurer, P; Rashad, A; Sandulescu, T; Stricker, I, 2011) |
| "MET-PET enables early diagnosis of recurrence of brain tumor in the follow-up after the radiation therapy." | ( Hattori, N; Katoh, N; Kubo, N; Kuge, Y; Nishijima, K; Okamoto, S; Sawamura, Y; Shiga, T; Takei, T; Tamaki, N, 2011) |
| "Few controlled trials have studied the treatment of relapse in adults with minimal change disease." | ( Shigidi, MM, 2011) |
| "Allo-HCT in heavily pretreated relapsed Hodgkin lymphoma is feasible, tolerable, and can induce durable clinical remissions." | ( Chen, R; Delioukina, M; Forman, S; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Rosenthal, J; Shen, J; Smith, E, 2011) |
| "At the first recurrence, 81% (13 patients) of exudative retinal detachments (ERD) were associated with an initial immunomodulatory treatment conducted ≤6 months (3." | ( Bodaghi, B; Cohen, D; Errera, MH; Fardeau, C; Gaudric, A; LeHoang, P; Navarro, A; Westcott, M, 2011) |
| "Although the risk of recurrence varies among patients with a first unprovoked proximal DVT or PE, and a number of factors can identify patients with a lower risk of recurrence, the safety of routinely stopping anticoagulant therapy based on the presence of these factors needs to be established in prospective studies before this is done in clinical practice." | ( Kearon, C, 2011) |
| "Subsequent recurrence of type 1 hepatorenal syndrome may require long-term treatment with terlipressin and albumin." | ( Angeli, P; Boccagni, P; Boscato, N; Cavallin, M; Cillo, U; Fasolato, S; Gatta, A; Morando, F; Piano, S; Zanus, G, 2011) |
| "Ofatumumab has shown efficacy in the treatment for relapsed or refractory CLL." | ( Castillo, JJ; Reagan, JL, 2011) |
| "Post-surgical recurrences were anterior and responded to topical treatment, except for an episode of intermediate uveitis that required a periocular injection of triamcinolone." | ( Arruabarrena, C; Contreras, I; Figueroa, MS; García-Pérez, JL; Gil-Cazorla, R; Noval, S; Sales, M, 2010) |
| "Also, in the short term, the rate of recurrence was comparable to other reported patients who were diagnosed and treated in a month." | ( Çolakoğlu, Ş; Demıroğlu, YZ; Erken, E; Özelsancak, R; Solmaz, S; Turunç, T; Zümrütdal, A, 2010) |
| "The diagnosis of recurrence led to a treatment modification in 123 patients (54%)." | ( Alberini, JL; Bellet, D; Brain, E; Champion, L; Edeline, V; Giraudet, AL; Le Stanc, E; Madar, O; Pecking, A; Wartski, M, 2011) |
| "As the goal for the treatment for relapsed myeloma should be disease control while maintaining quality of life, lower doses of melphalan might be preferable." | ( Andersson, PO; Blimark, C; Brune, M; Hjorth, M; Holmberg, E; Mellqvist, UH; Rödjer, S; Veskovski, L; Westin, J, 2011) |
| "To decrease the recurrence of venous ulcers, we recommend ablation of the incompetent superficial veins in addition to compression therapy (GRADE 1A)." | ( Comerota, AJ; Dalsing, MC; Eklof, BG; Gillespie, DL; Gloviczki, ML; Gloviczki, P; Lohr, JM; McLafferty, RB; Meissner, MH; Murad, MH; Padberg, FT; Pappas, PJ; Passman, MA; Raffetto, JD; Vasquez, MA; Wakefield, TW, 2011) |
| "Distant recurrences were reduced by 5-FU-based adjuvant treatment in dMMR stage III tumors, and a subset analysis suggested that any treatment benefit was restricted to suspected germline vs sporadic tumors." | ( Allegra, C; Foster, NR; Gallinger, S; Kim, GP; Labianca, R; Marsoni, S; Monges, G; Moore, MJ; Sargent, DJ; Sinicrope, FA; Thibodeau, SN; Yothers, G, 2011) |
| "Regarding recurrence, case 1 recurred 4 months after surgery and again 14 months after discontinuing prednisone; case 2 relapsed 16 months after receiving high-dose methylprednisolone pulse therapy; and case 3 recurred during the period of prednisone dose reduction." | ( Ba, JM; Dou, JT; Du, J; Gu, WJ; Guo, QH; Lu, JM; Lu, ZH; Mu, YM; Wang, XL; Yang, GQ, 2011) |
| "The time to first dysphagia recurrence was significantly different between each combination treatment group and the control group (overall test: P=0." | ( Butruk, E; Fijuth, J; Kraszewska, E; Polkowski, M; Regula, J; Rupinski, M; Wronska, E; Zagorowicz, E, 2011) |
| "No patients showed recurrence in the combination treatment group." | ( Hou, G; Ji, H; Xue, Y, 2011) |
| "Rapid recurrence of a new cluster headache attack following oxygen treatment was named the 'rebound effect' by Kudrow (1981)." | ( Geerlings, RP; Haane, DY; Koehler, PJ, 2011) |
| "Early and correct diagnosis of tumor recurrence and its differentiation from therapy-related changes is crucial for prompt and adequate management of glioma patients." | ( Bal, C; Julka, PK; Kumar, R; Malhotra, A; Santra, A; Sharma, P, 2011) |
| "Rapid recurrence after stopping treatment however suggests that anti-inflammatory effects may predominate." | ( Boer, J; Ingvarsson, G; Jemec, GB; Szepietowski, JC; Yazdanyar, S, 2011) |
| "Therefore, treatment of relapsed or refractory patients is complex and there is no uniformly accepted approach available." | ( Bokemeyer, C; Honecker, F; Koychev, D; Oechsle, K, 2011) |
| "In 2010, we treated his sixth relapse with a single dose of rituximab." | ( Amemiya, N; Itabashi, M; Kojima, C; Nitta, K; Nokiba, H; Takei, T, 2011) |
| "Based on the recurrence rates, we suggest transvaginal aspiration together with tetracycline sclerotherapy rather than only simple transvaginal aspiration in the management of non-neoplastic ovarian cysts." | ( Buyukbayrak, EE; Kars, B; Karsidag, AY; Pirimoglu, M; Turan, C; Unal, O, 2012) |
| "Fourteen patients who developed recurrence after stopping EGFR-TKI were retreated, with a median time to progression of 10 months and radiographic response seen in 8 of 11 patients with evaluable disease (73%)." | ( Arcila, ME; Azzoli, CG; Janjigian, YY; Kass, SL; Kris, MG; Ladanyi, M; Miller, VA; Oxnard, GR; Pao, W; Riely, GJ; Sima, CS, 2011) |
| "The primary endpoint was the recurrence of acute cholangitis within 3 days after the withdrawal of antibiotic therapy." | ( Harada, S; Hirano, K; Isayama, H; Kawabe, T; Kawakubo, K; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Ota, Y; Sasahira, N; Sasaki, T; Tada, M; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y, 2011) |
| "Fluid recurrence was determined clinically and generally re-treated." | ( Holmäng, S; Jahnson, S; Sandblom, D, 2011) |
| "A 65-year-old male experiencing the recurrence of a solitary sigmoid cancer liver tumor was treated with bevacizumab (Bev)/XELOX chemotherapy, because he had refused surgical resection." | ( Hamasu, S; Konishi, S; Manaka, D; Nishitai, R; Sakamoto, K; Uehara, M, 2011) |
| "The respective pre-treatment relapse rates (3." | ( Bagga, A; Gulati, A; Hari, P; Sinha, A, 2012) |
| "The 2 most important determinants for recurrence were minute spillage of the hydatid cyst and inadequate treatment owing to missing cysts or incomplete pericystectomy." | ( Anthimidis, G; Fachantidis, E; Kapoutzis, K; Karamanlis, E; Kosmidis, C; Prousalidis, J, 2012) |
| "The main risk is recurrence, and thus the current usual practice is to combine surgery, immediately followed by hormone therapy focusing on GnRH analogues." | ( Deswarte, S; Hagneré, P; Leleu, O, 2011) |
| "To determine the recurrence rate, in postmenopausal patients managed with hormonal therapy (HT) compared with patients without HT treated in El Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes." | ( Arteaga-Gómez, AC; Castellanos-Barroso, G; Colin-Valenzuela, A; García-Vargas, J; Márquez-Acosta, G; Reyes-Muñoz, E, 2011) |
| "There was only one patient with recurrence for which no hormonal therapy was administered." | ( Arteaga-Gómez, AC; Castellanos-Barroso, G; Colin-Valenzuela, A; García-Vargas, J; Márquez-Acosta, G; Reyes-Muñoz, E, 2011) |
| "Even with proper immunosuppressive treatment, SLE can relapse." | ( Arellanes-Garcia, L; Cornejo-Ballesteros, H; Hernandez-Da Mota, SE; Melgoza-del-Angel, C; Recillas-Gispert, C; Sanchez-Gonzalez, R; Teran-Estrada, L, 2011) |
| "Prevention of relapse or recurrence is a primary treatment objective in the management of the disorder." | ( Degenhardt, EK; Gatz, JL; Jacob, J; Tohen, M, 2012) |
| "The frequency of late recurrences following treatment completion has not been well-studied." | ( Deriemer, K; Flood, JM; Pascopella, L; Watt, JP, 2011) |
| "Outcomes included initial cure, recurrence, and treatment harms." | ( Bliss, D; Butler, M; Drekonja, DM; Filice, GA; MacDonald, R; Rector, TS; Wilt, TJ, 2011) |
| "Moreover, there was no recurrence of CHB when therapy was suspended, as confirmed by a 29 month and an eight month follow-up, respectively." | ( Cerutti, A; Chiandetti, L; De Silvestro, G; Gervasi, MT; Milanesi, O; Pengo, V; Punzi, L; Ruffatti, A, 2012) |
| "Possible recurrence of NMB was assessed by neuromuscular monitoring, performed with acceleromyography, and was continued until ∼90 minutes after the start of diclofenac or flucloxacillin administration." | ( Clerck, Ed; Grobara, P; Heuvel, MW; Jadoul, JL; Kam, PJ; Peeters, PA; Ramael, S; Zwiers, A, 2012) |
| "Because of the impact of HCV recurrence on graft and patient survival, several treatment strategies have been evaluated." | ( Roche, B; Samuel, D, 2012) |
| "To date, data about a possible recurrence of disease activity after discontinuation of fingolimod treatment are scarce." | ( Gerdes, LA; Havla, JB; Hohlfeld, R; Kümpfel, T; Meinl, I; Pellkofer, HL, 2012) |
| "It is necessary to establish the recurrence cut-off scores for each of the scales according to the treatment used." | ( Ferreira, LM; Furtado, F; Hochman, B, 2012) |
| "Data regarding treatment failure and recurrence following metronidazole and vancomycin treatment were extracted and analysed." | ( Falagas, ME; Patouni, K; Polyzos, KA; Rafailidis, PI; Samonis, G; Vardakas, KZ, 2012) |
| "Despite aggressive surgical treatment, recurrence was observed after every intervention." | ( Bruna, J; Mestak, J; Mestak, O; Pokorna, K; Sukop, A, 2012) |
| "Despite initial recovery after steroid treatment, she relapsed twice." | ( Angioi, K; Le Corre, A; Maalouf, T; Robin, A, 2012) |
| "All late recurrences of CDI occurred in the setting of antimicrobial therapy for treatment of infections unrelated to C." | ( Aroniadis, OC; Brandt, LJ; Kanatzar, A; Kelly, C; Mellow, M; Park, T; Rohlke, F; Stollman, N; Surawicz, C, 2012) |
| "Given the low recurrence rate and excellent outcomes in suitable patients, kidney transplantation remains the optimal form of renal replacement therapy for ESRD due to ANCA-associated vasculitis." | ( Amos, L; Lau, D; Mulley, W; Simpson, I; Summers, S, 2012) |
| "After diagnosis of the recurrence, the patient was treated with long-term vinorelbine (VNR)biweekly and zoledronate (ZOL) monthly, and a response was obtained." | ( Furukawa, K; Hosaka, M; Ishida, J; Matsushima, Y; Saito, M, 2012) |
| "A patient with postoperative recurrence of lung cancer associated with multiple bone metastases responded to combination chemotherapy with VNR and ZOL." | ( Furukawa, K; Hosaka, M; Ishida, J; Matsushima, Y; Saito, M, 2012) |
| "The AF recurrence rate was significantly lower in the telmisartan-treated patients than in the amlodipine-treated patients in both group 1 (12 vs 39, P < 0." | ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A, 2012) |
| "Eleven had recurrence after one to three failed surgeries, and the others had no prior treatment." | ( Sun, GB; Sun, N; Tang, HH; Wen, W; Zheng, HL; Zhu, QB, 2012) |
| "Previous studies have shown that retreatment of relapsed/refractory multiple myeloma (MM) with a second course of bortezomib therapy could be effective in heavily pre-treated patients." | ( Olie, RA; Taverna, C; Trojan, A; Voegeli, J; von Rohr, A, 2012) |
| "After first recurrence the patient was treated with 2 weeks of oral nitazoxanide." | ( Cheema, FH; Kanwal, S; Korsten, MA; Luthra, M; Majeed, UM; Rafiullah, F; Sohail, MR, 2011) |
| "PET-CT was performed for suspected recurrence or for post-therapy surveillance." | ( Bal, C; Kumar, R; Malhotra, A; Reddy, RM; Sharma, A; Sharma, P; Singh, H; Suman, SK; Thulkar, S, 2012) |
| "Here, we report a case with recurrence of rectal cancer who received FOLFIRI with bevacizumab chemotherapy under haemodialysis, and obtained good tumor control." | ( Endo, T; Hasegawa, H; Hoshino, G; Hoshino, H; Hoshino, Y; Ishii, Y; Kitagawa, Y; Matsunaga, A; Ochiai, H; Seo, Y; Shigeta, K, 2012) |
| "Our aim was to compare the recurrence rates of OM in patients treated with daptomycin or vancomycin." | ( Finnegan, PM; Linneman, TW; McDonald, JR; Moenster, RP, 2012) |
| "The primary outcome was recurrence of infection within 6 months after the discontinuation of therapy." | ( Finnegan, PM; Linneman, TW; McDonald, JR; Moenster, RP, 2012) |
| "Standard-of-care (SOC) treatment for relapse offers less satisfactory treatment response than in nontransplanted patients." | ( Ackefors, M; Gjertsen, H; Weiland, O; Wernerson, A, 2012) |
| "Current guidelines recommend the first recurrence to be treated with the same agent used for the initial episode." | ( Kim, SW, 2012) |
| "We describe our experience with treatment of relapses and maintenance of remission using steroid-sparing immunomodulators (IMs) and induction of remission using rituximab (RTX)." | ( Chari, ST; Clain, JE; Gleeson, FC; Hart, PA; Klebig, RR; Levy, MJ; Pearson, RK; Petersen, BT; Smyrk, TC; Sugumar, A; Takahashi, N; Topazian, MD; Vege, SS; Witzig, TE, 2013) |
| "Half the recurrences occurred in the first year since completing treatment." | ( Crampin, AC; French, N; Glynn, JR; Houben, RM; Mboma, S; Mpunga, J; Mwaungulu, L; Mwaungulu, NJ; Mwenibabu, M; Mzemba, T, 2012) |
| "There was no difference in SVT recurrence in infants treated with digoxin versus propranolol." | ( Anderson, CC; Bar-Cohen, Y; Batra, AS; Blaufox, AD; Etheridge, SP; Fournier, A; Gibbs, KA; Kanter, RJ; Mackie, AS; McCrindle, BW; Potts, JE; Reed, JH; Ro, PS; Ross, BA; Sanatani, S; Saul, JP; Singh, HR; Stephenson, EA; Tisma-Dupanovic, S; Wong, KK, 2012) |
| "Patients with HCC recurrence after OLT were treated with sorafenib (400 mg twice daily)." | ( Boccagni, P; Burra, P; Cillo, U; D'Amico, F; Kertusha, X; Lodo, E; Lombardi, G; Pastorelli, D; Ramirez Morales, R; Senzolo, M; Vitale, A; Zanus, G, 2012) |
| "Whenever there was a recurrence of retinal-retinal anastomosis (RRA) or retinal-choroidal anastomosis (RCA) and marked leakage from subretinal neovascularization, the triple therapy was reapplied." | ( Fujiwara, A; Nitta, E; Shiraga, F; Shiragami, C; Shirakata, Y; Yamashita, A, 2012) |
| "Response to treatment and relapse during the first and second post-treatment years were evaluated." | ( Cakir, GA; Erdogan, FG; Gurler, A, 2013) |
| "There exist some treatments for relapsed AML; however, almost all treatments are associated with a high level of regimen-related toxicities (RRTs)." | ( Ando, S; Hashino, S; Higashiyama, A; Imamura, M; Kahata, K; Okada, K; Onozawa, M; Takahata, M; Tanaka, J, 2012) |
| "Problem of treatment is the high recurrence of papilloma growth after surgical removal; therefore adjuvant therapy schemes have been established." | ( Friedrich, G; Graupp, M; Gugatschka, M; Hammer, G; Kiesler, K; Reckenzaun, E, 2013) |
| "In the subgroup of prior treatment "relapsers," telaprevir had greater relative efficacy than boceprevir (odds ratio [OR], 2." | ( Barry, M; Bergin, C; Kieran, J; Norris, S; O'Leary, A; Schmitz, S; Walsh, C, 2013) |
| "Post-treatment virologic relapse, biochemical breakthrough, hepatitis flare, and retreatment results were retrospectively analyzed." | ( Chung, YH; Jin, YJ; Kim, KM; Lee, HC; Lee, YS; Shim, JH; Suh, DJ; Yoo, DJ, 2012) |
| "Post-treatment virologic relapse and biochemical breakthrough incidence were low in patients who achieved undetectable viral titer at lamivudine cessation." | ( Chung, YH; Jin, YJ; Kim, KM; Lee, HC; Lee, YS; Shim, JH; Suh, DJ; Yoo, DJ, 2012) |
| "Real-world costs during treatment of relapsed/refractory multiple myeloma vary greatly." | ( Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Tan, SS; Uyl-de Groot, CA, 2013) |
| "Two patients developed disease recurrence at 7 months and 24 months, respectively, after negative interim and posttreatment imaging." | ( Hartridge-Lambert, SK; Lim, RC; Maragulia, JC; Portlock, CS; Schöder, H, 2013) |
| "Because of a low risk of disease recurrence, posttreatment radiologic surveillance appears to be unnecessary in patients with early-stage, nonbulky (CD20 negative) cHL who achieve a PET-detected CR with the ABVD combination alone." | ( Hartridge-Lambert, SK; Lim, RC; Maragulia, JC; Portlock, CS; Schöder, H, 2013) |
| "No data exist about bendamustine retreatment after relapse, concerning efficacy and toxicity in this patient population." | ( Feiten, S; Friesenhahn, V; Heymanns, J; Kleboth, K; Köppler, H; Thomalla, J; van Roye, C; Weide, R, 2013) |
| "On May 2007, peritoneal recurrences were recognized on CT scan, and treatment with 400 mg daily of imatinib mesylate was started." | ( Ikehara, T; Inoue, T; Kanehara, I; Nishiguchi, Y; Sakashita, K; Shimizu, S; Teraoka, H; Toyokawa, T; Yamamoto, A; Yamashita, Y, 2012) |
| "The absence of recurrence was confirmed for 6 months after treatment." | ( Fujii, T; Fujiwara, M; Jinno, S; Kobayashi, D; Kodera, Y; Nomoto, S; Ohashi, N; Shimokata, T; Takeda, S; Tanaka, C; Yamada, S, 2012) |
| "Bacterial vaginosis (BV) recurrence posttreatment is common." | ( Bradshaw, CS; De Guingand, D; Fairley, CK; Garland, SM; Hocking, JS; Law, M; Morton, AN; Pirotta, M; Vodstrcil, LA, 2013) |
| "Cumulative 6-month BV recurrence was 28% (95% confidence interval [CI], 24%-33%) and not associated with treatment." | ( Bradshaw, CS; De Guingand, D; Fairley, CK; Garland, SM; Hocking, JS; Law, M; Morton, AN; Pirotta, M; Vodstrcil, LA, 2013) |
| "Risk of BV recurrence was increased with the same pre-/posttreatment sexual partner and inconsistent condom use, and halved with use of estrogen-containing contraceptives." | ( Bradshaw, CS; De Guingand, D; Fairley, CK; Garland, SM; Hocking, JS; Law, M; Morton, AN; Pirotta, M; Vodstrcil, LA, 2013) |
| "The slightly lower recurrence rates after BF-200 ALA treatment compared with MAL treatment enhanced the better treatment outcome due to the significantly superior efficacy." | ( Berking, C; Borrosch, F; Brüning, H; Deichmann, M; Dirschka, T; Dominicus, R; Foguet, M; Gröne, D; Hahn, S; Hofbauer, G; Hönigsmann, H; Hübinger, F; Jenne, L; Karl, L; Klövekorn, W; Krähn-Senftleben, G; Lehmann, P; Lübbert, H; Mensing, H; Moers-Carpi, M; Oster-Schmidt, C; Pabst, G; Radny, P; Reich, K; Reinhold, U; Schmitz, B; Sebastian, M; Simon, M; Szeimies, RM; Tanner, M; Voss, D; Wernicke-Panten, K; Wolf, P, 2013) |
| "We report a rare case of late recurrence after curative resection in a patient treated for early gastric cancer." | ( Amano, R; Hirakawa, K; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Noda, E; Ohira, M; Sakurai, K; Sawada, T; Tanaka, H, 2012) |
| "In order to treat this second recurrence, we administered imatinib and sunitinib sequentially." | ( Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Minato, H; Morioka, E; Nakano, Y; Nakata, S; Noguchi, M; Ohnishi, T; Ohno, Y; Omote, K; Takamura, H; Tomita, Y; Ueda, N, 2012) |
| "Post-treatment recurrence was observed in six cases." | ( Inoue, K; Mizuguchi, S; Morita, R; Nishiyama, N; Oka, H; Tsukioka, T, 2013) |
| "He is free of recurrence now without adjuvant chemotherapy four years after repeat hepatectomy." | ( Bando, E; Goto, H; Kawamura, T; Makuuchi, R; Miki, Y; Sugisawa, N; Tanizawa, Y; Terashima, M; Tokunaga, M; Uesaka, K; Yamakawa, Y, 2013) |
| "Our high recurrence and regrowth rates emphasize that our treatment schedule is inadequate to prevent recurrent cystine calculi." | ( Argun, B; Caliskan, S; Canpolat, N; Citgez, S; Dogan, C; Erozenci, A; Onal, B; Onder, AU; Sever, L; Tasdemir, M, 2013) |
| "Patients with HBV recurrence were divided into four groups according to their treatment: group L (lamivudine-based therapy n = 21) and group N [new nucleos(t)ide analogue (NA)-based therapy, n = 38]." | ( Han, SS; Hong, G; Kong, SY; Lee, KB; Lee, KW; Park, KU; Park, SJ; Suh, KS; Yi, NJ, 2013) |
| "The time from start of initial treatment to first relapse was significantly shorter (2." | ( Hataya, H; Honda, M; Iijima, K; Ishikura, K; Nakanishi, K; Nakazato, H; Sasaki, S; Yoshikawa, N, 2013) |
| "Parasite fingerprints of pretreatment and relapse bone marrow isolates within 8 patients were similar, suggesting that clinical relapses were not due to reinfection with a new strain." | ( Beijnen, JH; Bhattarai, NR; Boelaert, M; Das, ML; Decuypere, S; Dhakal, SS; Dorlo, TP; Dujardin, JC; Karki, P; Ostyn, B; Rai, K; Rijal, S; Singh, R; Uranw, S; Vanaerschot, M, 2013) |
| "No patient experienced HBV recurrence through 72 weeks of the study while he or she was receiving the randomized treatment." | ( Bzowej, N; Dinh, P; Flaherty, J; Martin, P; Poordad, F; Pungpapong, S; Rossi, S; Schiano, T; Spivey, J; Subramanian, GM; Teperman, LW, 2013) |
| "In patients with biochemical recurrence, it also guides to an optimal treatment approach after initial treatment." | ( Beheshti, M; Haim, S; Kunit, T; Langsteger, W; Loidl, W; Nader, M; Steinmair, M; Waldenberger, P; Zakavi, R, 2013) |
| "We encountered a case of recrudescence of prostate cancer positive for CEA with a low serum PSA level and report the effect of docetaxel therapy for atypical prostatic carcinoma." | ( Arima, R; Fujita, M; Goto, T; Saiki, S; Uchida, K, 2013) |
| "Histological recurrence of HCV (fibrosis stage ≥ F1 according to the METAVIR score), BPAR resistant to 2 sets of steroid pulse therapy, hepatocellular carcinoma (HCC) recurrence, retransplantation, and patient death were defined as events, and the primary endpoint was event-free survival." | ( Asonuma, K; Inomata, Y; Isaji, S; Kaido, T; Kiuchi, T; Kubo, S; Matsubara, Y; Sakabayashi, S; Sakurai, H; Takada, Y; Teramukai, S; Tsumura, H; Uemoto, S, 2013) |
| "Clofarabine could be a promising new treatment for relapsed/refractory acute lymphoblastic leukemia." | ( Cheng, YF; Liu, GL; Lu, AD; Suo, P; Wang, B; Wu, J; Zhang, LP; Zuo, YX, 2013) |
| "Further, the relapse and recurrence rates within 3 months after respective treatments were also measured." | ( Gao, D; Jiang, CG; Yi, ML; Yue, FG; Zhang, T, 2013) |
| "After local pelvic recurrence, she underwent radiation therapy(50 Gy in total), and then chemotherapy(XELOX+bevacizumab)was started." | ( Arisawa, Y; Chiba, N; Hashimoto, M; Ishii, M; Ishikawa, S; Nakamura, T; Shimada, A, 2013) |
| "After three courses of treatment, local recurrence had almost disappeared and CEA level was normalized." | ( Kadoya, N; Munemoto, M; Murata, S; Saito, H; Yoshimoto, K, 2013) |
| "20 percent of the patients have recurrence after metronidazole or vancomycin treatment, and each recurrence increases the chance of a further one." | ( Baji, P; Banai, J; Brodszky, V; Gulácsi, L; Kertész, A; Kopcsóné Németh, I; Ludwig, E; Péntek, M; Prinz, G; Reményi, P; Strbák, B; Zsoldiné Urbán, E, 2013) |
| "To determine the cumulative recurrence rates of endometriosis-associated pain after long-term intramuscular depot medroxyprogesterone acetate (DMPA) therapy." | ( Cheewadhanaraks, S, 2013) |
| "The cumulative recurrence rates of pain after DMPA treatment were 18%, 28%, 41%, 46%, and 50% at months 12, 24, 36, 48, and 60, respectively." | ( Cheewadhanaraks, S, 2013) |
| "Opiate abuse recurrence during antiviral therapy happened in 6." | ( Fabri, M; Kiralj, K; Mikić, SS; Preveden, T; Ruzić, M; Vukadinov, T, 2013) |
| "Even after complete surgery, recurrence is frequent and adjuvant mitotane treatment improves outcome, but uncertainty exists as to whether all patients benefit from this therapy." | ( Allolio, B; Fassnacht, M; Kroiss, M, 2013) |
| "This recurrence was effectively prevented by combination treatment with a CD3 antibody leading to the restoration of self-tolerance." | ( Bach, JF; Chatenoud, L; Clozel, M; Kuhn, C; Piali, L; Sauvaget, V; Steiner, B; Valette, F; You, S, 2013) |
| "Among patients who were treated for RPLN relapse, the 2-year DSS and DFS rates from the relapse day were 12." | ( Ho, TY; Lee, LY; Liao, CT; Lin, CY; Tseng, JR; Wang, HM; Yen, TC, 2013) |
| "Stone activity, defined as either stone recurrence or stone-related events, and predictors of activity were evaluated after combined surgical and medical treatment." | ( Ferrandino, MN; Hanna, J; Iqbal, MW; Kuntz, N; Lipkin, ME; Neisius, A; Preminger, GM; Youssef, RF, 2016) |
| "The timing, recurrence, and resolution of edema and stasis dermatitis with respect to the administration and termination of levofloxacin suggest that the leg edema and stasis dermatitis occurred secondary to levofloxacin administration." | ( Cohen, PR; Hyman, DA, 2013) |
| "We report a case of postoperative recurrence of thymic carcinoma that was effectively treated with combination chemotherapy of nedaplatin(NDP)and docetaxel(DOC)." | ( Hanaoka, J; Hayama, M; Inoue, H; Kanai, O; Kataoka, Y; Kitamura, T; Kobayashi, T; Mio, T; Motoishi, M; Okamoto, K; Okamura, M; Oshio, M; Sawai, S; Tanaka, H, 2013) |
| "Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE." | ( Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S, 2014) |
| "Onyx was associated with a higher recurrence rate, suggesting it is less suitable as an embolization material for SDAVF treatment." | ( Clark, S; Kandasamy, J; Lee, M; Nahser, H; Pigott, T; Powell, G, 2013) |
| "Under the diagnosis of local recurrence, the patient received chemotherapy consisting of adriamycin and cyclophosphamide( AC) and docetaxel." | ( Aoyagi, H; Hasegawa, K; Kaneko, J; Maejima, S; Matsui, T; Yoshida, T, 2013) |
| "Microbiologic recurrences during therapy occurred in 14% of patients: 73% with reinfection MAC isolates, 27% with true relapse isolates (P = ." | ( Brown-Elliott, BA; Griffith, DE; Killingley, J; McNulty, S; Philley, JV; Shepherd, S; Wallace, RJ; Wilson, RW; York, DS, 2014) |
| "Microbiologic recurrences during or after therapy are common and most often due to reinfection MAC genotypes." | ( Brown-Elliott, BA; Griffith, DE; Killingley, J; McNulty, S; Philley, JV; Shepherd, S; Wallace, RJ; Wilson, RW; York, DS, 2014) |
| "Angiographic aneurysm recurrence is widely used as a surrogate for treatment failure, but studies documenting the correlation of angiographic recurrence with clinical failure are limited." | ( Barnwell, SL; Bonafe, A; Carroll, K; Chaloupka, JC; Dowd, CF; Fox, AJ; Gholkar, A; Imm, SJ; Johnston, SC; Massó Romero, J; McDougall, CG; Tampieri, D; Turk, AS; Vazquez Suarez, JC; Wakhloo, AK, 2014) |
| "Here, we describe treatment of a relapsed APL in a child with limited treatment of ATO and ATRA and review the literature." | ( Ansari, M; Bourquin, JP; Gumy-Pause, F; Huezo-Diaz, P; Judas, C; Mattiello, V; Rock, N, 2014) |
| "Data show high frequent headache recurrence, typical side effects of opioids, increased risk of chronification, and development of addiction in primary headache patients treated with opioids." | ( Gaul, C; Totzeck, A, 2014) |
| "One study documented less eclampsia recurrence associated with community administration of a MgSO4 loading dose before referral to a care facility versus treatment in a care facility (RR 0." | ( de Silva, D; Firoz, T; Gordon, R; Magee, LA; Payne, B; Sawchuck, D; Tu, D; Vidler, M; von Dadelszen, P, 2014) |
| "We reported the successful treatment of relapsed 6q24-related TNDM with a DPP4 inhibitor." | ( Fujii, M; Fujimaru, R; Hashimoto, Y; Hatake, K; Hosokawa, Y; Kawakita, R; Nakajima, H; Tamagawa, N; Yorifuji, T, 2014) |
| "The prediction model for recurrence may be useful for treatment decision." | ( Collins, SH; D'Agostino, RB; Gorbach, S; Kean, Y; Pencina, KM, 2014) |
| "Moderate endoscopic postsurgical recurrence while on thiopurines may even revert with no additional therapy in some patients." | ( Bernal, I; Boix, J; Cabré, E; Domènech, E; Lorenzo-Zúñiga, V; Mañosa, M; Marín, L; Moreno, V; Zabana, Y, 2014) |
| "With the similar BP control, the AF recurrences rate was significantly lower in the telmisartan-treated patients than in the other antihypertensive drugs-treated patients (HR 0." | ( Pan, G; Zhao, J; Zhou, X, 2014) |
| "After 2 years of follow-up, recurrences of nonoperatively treated right lower quadrant abdominal pain are less than 14% and may be safely and effectively treated with further antibiotics." | ( Ansaloni, L; Biscardi, A; Catena, F; Coccolini, F; Di Saverio, S; Giorgini, E; Pisano, M; Sartelli, M; Sibilio, A; Smerieri, N; Tugnoli, G; Villani, S, 2014) |
| "For the possibility of recurrence, close monitoring of patients is very important in the critical course after adequate treatment." | ( Acar, A; Erdem, H; Görenek, L; Karaahmetoğlu, G; Öncül, O; Turhan, V; Ülçay, A, 2014) |
| "We evaluated whether there was CPA recurrence within 1 year after treatment cessation and investigated risk factors for relapse." | ( Ando, T; Kawashima, M; Koyama, K; Matsui, H; Nagai, H; Ohshima, N; Ohta, K; Sato, R; Suzuki, J; Takeda, K, 2014) |
| "There is no evidence for preventing TTC recurrence by drug therapy." | ( Brunetti, ND; Di Biase, M; Ferraretti, A; Ieva, R; Musaico, F; Santoro, F; Tarantino, N; Triggiani, G, 2014) |
| "Due to the high rate of recurrence following surgery, conservative treatment is recommended to treat PICs." | ( Ichida, K; Motoyama, S; Murakoshi, H; Okada, J; Yasuda, R; Yokoyama, N; Yoshida, S, 2014) |
| "In post-transplant patients with HCV recurrence who are not eligible for standard antiviral treatment, IV SIL can be considered as an alternative, but further investigations are necessary to establish treatment protocols." | ( Bander, D; Jurczyk, K; Karpińska, E; Lachtara, M; Laurans, Ł; Socha, Ł; Wawrzynowicz-Syczewska, M, 2014) |
| "74% of the S-PC group completed the treatment without relapses and remained abstinent three months after the completion of the treatment, understanding abstinence as being continuous (with no relapses allowed and co-oximetry below 1 ppm) from the day of stopping." | ( Abella, F; Alves, R; Cuadrado, J; Mateo, J; Solsona, F; Vilaplana, J, 2014) |
| "Following recurrence, the median number of chemotherapy regimens was 3(range, 0-5)." | ( Egawa, C; Hamanaka, M; Hashimoto, N; Kato, T; Kawashima, H; Kusama, H; Matsushita, K; Mukai, Y; Nakahira, S; Okishiro, M; Sakisaka, H; Suzuki, R; Takatsuka, Y; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H, 2014) |
| "Parasite recrudescence after treatment was defined using a model that incorporated each erythrocytic stage of the P." | ( Batty, KT; Gibbons, PL; Kirkpatrick, CM; Moore, BR; Patel, K, 2014) |
| "After periods of improvement and recurrence of antimuscarinic effects, a continuous infusion of physostigmine was administered at 2 mg/h and continued for almost 8 h to maintain attenuation of symptoms." | ( Acquisto, NM; Gorodetsky, RM; Phillips, MA; Wiegand, TJ, 2014) |
| "Risk factors for multiple treatment and recurrence of anal condyloma were examined." | ( Goldstone, SE; Silvera, RJ; Smith, CK; Swedish, KA, 2014) |
| "Sixteen patients had recrudescence of IH off-treatment, with propranolol discontinued at a median age of 14 months (interquartile range 10-15 months)." | ( Castelo-Soccio, L; Chu, DH; Gelfand, JM; Perman, MJ; Shaddy, RE; Shah, KN; Treat, JR; Wan, J; Yan, AC, 2014) |
| "Drug resistance and recurrence are the major obstacles to bladder cancer chemotherapy." | ( Hu, H; Lei, T; Meng, Q; Zhang, M, 2015) |
| "The Patients Prone to Recurrence after Endovascular Treatment (PRET) trial was designed to assess whether hydrogel coils were superior to platinum coils in these high-risk patients." | ( Barnwell, SL; Bracard, S; Chagnon, M; Desal, H; Evans, AJ; Fiorella, D; Guilbert, F; Hoh, BL; Klink, R; Mocco, J; Raymond, J; Roy, D; Turk, AS; Turner, RD; Weill, A, 2014) |
| "The ability of MBL-HCV1 to prevent HCV recurrence after liver transplantation was investigated in a phase 2 randomized clinical trial evaluating six MBL-HCV1-treated subjects and five placebo-treated subjects." | ( Ambrosino, DM; Babcock, GJ; Iyer, S; Molrine, DC; Pierce, BG; Rowley, K; Smith, HL; Wang, Y; Weng, Z; Zamore, PD, 2014) |
| "We investigated the time and site of recurrence, response to re-induction therapy, and performance of hematopoietic stem cell transplantation (HSCT) in relapsed cases, and performed a multivariate analysis to identify prognostic factors." | ( Adachi, S; Hamamoto, K; Hanada, R; Hayashi, Y; Horibe, K; Imaizumi, M; Kobayashi, R; Kudo, K; Miyamura, T; Morimoto, A; Moritake, H; Nakayama, H; Shimada, A; Tabuchi, K; Taga, T; Tawa, A; Tomizawa, D; Tsuchida, M; Tsukimoto, I; Yabe, H, 2014) |
| "All patients received standard steroid treatment for the relapse at screening and stopped taking immunosuppressive agents by 169 days after randomisation." | ( Aya, K; Iijima, K; Ishikura, K; Ito, S; Kaito, H; Kamei, K; Miura, K; Mori, R; Nakamura, H; Nakanishi, K; Nozu, K; Ohashi, Y; Ohtomo, Y; Sako, M; Takahashi, S; Tanaka, R; Tuchida, N, 2014) |
| "Identifying molecular markers for tumor recurrence is critical in successfully selecting patients with colon cancer who are more likely to benefit from adjuvant chemotherapy." | ( Andrada, E; Aparicio, J; Burgos, E; Calatrava, A; Cejas, P; Custodio, A; Díaz-López, E; Feliu, J; Gallego-Plazas, J; Madero, R; Maurel, J; Moreno-Rubio, J; Ramos, D; Rodríguez-Salas, N; Sánchez, A; Yaya, R, 2014) |
| "Patients with suspected recurrence of prostate cancer undergoing [18F]fluoromethyl choline ([18F]FCH) PET/CT were retrospectively evaluated to investigate the influence of hormonal therapy (HT) in [18F]FCH uptake." | ( Aristei, C; Bellavita, R; Buresta, T; Ferretti, F; Fravolini, ML; Mearini, L; Palumbo, B; Palumbo, I; Pelliccia, G; Radicchia, V; Scialpi, M; Sivolella, S, 2016) |
| "Patients with multiple recurrences of ISR seem to have the same prospects of acute and mid-term success for endovascular treatment as those with first presentation of ISR." | ( Engelbertz, C; Gebauer, K; Lüders, F; Malyar, NM; Meyborg, M; Reinecke, H, 2015) |
| "Last, we show that the recurrence rate of an adverse pregnancy outcome persisted at 30% despite treatment intervention." | ( Botta, A; Bucourt, M; Carbillon, L; Chollet-Martin, S; Chudzinski, A; Cornelis, F; Costedoat-Chalumeau, N; De Carolis, S; Emmanuelli, V; Fain, O; Hachulla, E; Masseau, A; Mekinian, A; Montestruc, F; Nicaise, P; Revaux, A; Subtil, D; Theulin, A, 2015) |
| "Lenalidomide was approved for the treatment of relapsed and refractory multiple myeloma (rrMM) based on MM009 and MM010 clinical trials." | ( Coelho, I; Costa, C; Esteves, S; João, C; Lucio, P, 2015) |
| "To decrease the recurrence rate after intralesional curettage for aneurysmal bone cysts, different adjuvant treatments have been recommended." | ( Marfori, ML; Rubio, DA; Serrano, MV; Wang, EH, 2014) |
| "The cumulative hazard of recurrence over 72 h was reduced by frovatriptan compared to rizatriptan-treated patients (log-rank test, P=0." | ( Egan, CG; Mogavero, S; Savi, L, 2014) |
| "Rabeprazole prevents the recurrence of peptic ulcers with no evidence of a major dose-response effect in subjects on low-dose aspirin therapy." | ( Arakawa, T; Fujimoto, K; Fujishiro, M; Higuchi, K; Iwakiri, R; Kato, M; Kinoshita, Y; Nakagawa, H; Ogawa, H; Okada, Y; Sanomura, M; Sugisaki, N; Takeuchi, T; Watanabe, T; Yamauchi, M, 2014) |
| "This study aimed to assess off-treatment virologic relapse rates and to characterize the outcomes of subsequent re-treatment in CHB patients who have discontinued oral NA following complete virologic suppression." | ( Hwang, JH; Jang, ES; Jeong, SH; Kim, JW; Kim, N; Lee, DH; Lee, SS; Min, BY; Park, YS; Seong, MH; Shin, CM; Sohn, HR; Song, JC, 2014) |
| "Patients with multiple resistant recurrences were not represented in any published or on-going trials, and it is these patients that are in the most need for treatment." | ( Alabed, S; Burls, A; Cabello, JB; Irving, GJ; Qintar, M, 2014) |
| "Posttreatment follow-up for the recurrence of head and neck squamous cell carcinoma (HNSCC) is a diagnostic challenge." | ( Abgral, R; Keromnes, N; Le Roux, PY; Marianowski, R; Palard, X; Potard, G; Robin, P; Rousset, J; Salaun, PY; Valette, G, 2015) |
| "These are commonly used in the treatment of relapsed/refractory (R/R) multiple myeloma (MM), but there is no universally accepted standard treatment." | ( Vij, R, 2011) |
| "In case of recurrence within 6 months after the second treatment course, patients were treated again with a 28-day course followed by weekly applications for 2 months." | ( Loening-Baucke, V; Swidsinski, A; Swidsinski, S; Verstraelen, H, 2015) |
| "Scar quality and possible scar recurrence were assessed before treatment and post treatment (6 and 12 months) with objective devices determining scar color, scar elasticity, scar volume, and patient's skin type." | ( Bulstra, AE; Niessen, FB; van Leeuwen, MC; van Leeuwen, PA, 2014) |
| "At 6-month posttreatment follow-up, recurrence of cleared lesions (no clinically visible lesions in treatment area) occurred in 39." | ( Dirschka, T; Dominicus, R; Karl, L; Rodríguez, R; Simon, JC; Willers, C, 2015) |
| "High-dose fish oil does not reduce AF recurrence in patients with a history of AF not receiving conventional AA therapy." | ( Brophy, JM; Jones, P; Kopecky, S; Lambert, J; Nattel, S; Nigam, A; Nozza, A; O'Hara, G; Ramprasath, VR; Roy, D; Talajic, M; Tardif, JC, 2014) |
| "The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established." | ( Cella, D; Drullinsky, PR; Elstrom, R; Gerecitano, JF; Hamilton, AM; Hamlin, PA; Lia Palomba, M; Matasar, MJ; Noy, A; Straus, DJ; Wegner, B; Wortman, K; Zelenetz, AD, 2015) |
| "While some of the factors determining recurrence depend on the patient and their treatment, differences in the Mycobacterium tuberculosis genome appear to have a role in both relapse and reinfection." | ( Banda, L; Chiwaya, A; Clark, TG; Coll, F; Crampin, AC; Glynn, JR; Guerra-Assunção, JA; Harris, D; Houben, RM; Khan, P; Mallard, K; McNerney, R; Mzembe, T; Parkhill, J; Pereira, RP, 2015) |
| "Stroke recurrence in the territory of the treated artery was reported." | ( Aguilar-Pérez, M; Arnold, G; Bäzner, H; Fischer, S; Henkes, H; Kurre, W; Schmid, E, 2015) |
| "In case of treatment failure or recurrence, moxifloxacin-based triple therapy (MA) or bismuth-based quadruple therapy (QUAD) was randomly given." | ( Choi, YJ; Kim, JM; Kim, N; Kwon, YH; Lee, DH; Lee, JY; Lee, S; Nam, RH; Park, YS; Shin, CM; Suh, JH; Yoon, H; Yoon, K, 2015) |
| "Eighty-six patients had recurrence at least once during consecutive lines of treatments." | ( Choi, YJ; Kim, JM; Kim, N; Kwon, YH; Lee, DH; Lee, JY; Lee, S; Nam, RH; Park, YS; Shin, CM; Suh, JH; Yoon, H; Yoon, K, 2015) |
| "Newer approaches are needed for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL)." | ( Borthakur, G; Brandt, M; Cortes, J; Daver, N; Estrov, Z; Garcia-Manero, G; Jabbour, E; Jain, P; Kadia, TM; Kantarjian, HM; O'Brien, S; Pemmaraju, N; Pierce, S; Ravandi, F; Thomas, DA; Wang, X, 2015) |
| "There were no differences between treatment groups in relapses at 6, 12, or 18 months." | ( Brunetta, P; Ding, L; Fervenza, FC; Fessler, BJ; Geetha, D; Hoffman, GS; Ikle, D; Jepson, B; Kallenberg, CG; Langford, CA; Merkel, PA; Seo, P; Specks, U; Spiera, R; St Clair, EW; Stone, JH; Tchao, NK, 2015) |
| "Seven of the patients had a recurrence of descending palatine neuralgia after they received treatment of maxillary neuralgia with neurotomy and avulsion of the infraorbital nerve; two patients were diagnosed with descending palatine neuralgia of the maxillary division in our department." | ( Chen, S; Guo, J; Huang, D; Rong, Q; Zhu, S, 2015) |
| "The primary end point was AF/AFL recurrence in patients previously treated with another AAD that was discontinued for whatever reason prior to randomization." | ( Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D, 2014) |
| "These results suggest that the recurrence of NSAID-induced small bowel injury was not frequent in the presence of conservative treatment." | ( Chang, DK; Cheon, JH; Choi, MG; Chun, HJ; Jang, BI; Jeen, YT; Jeon, SR; Jeon, SW; Kim, JH; Kim, JO; Kim, JS; Lee, KJ; Lim, YJ; Moon, JS; Park, CH; Shim, KN; Song, EM; Song, HJ; Ye, BD, 2015) |
| "Steroid was given as the treatment after relapse in most of the patients and the total remission rate at the end of follow-up was 96." | ( Chang, XJ; He, YX; Hu, LH; Jin, G; Jin, ZD; Li, ZS; Liao, Z; Shao, CW; Xin, L; Zhang, QH; Zheng, JM; Zhu, XF; Zou, DW; Zuo, CJ, 2014) |
| "Assess treatment patterns and recurrence among patients hospitalized for VTE." | ( Frean, M; Friedman, M; Jacqueline Kwong, W; Menzin, J; Preblick, R, 2014) |
| "Although the recurrence rate after stopping MTX was 70%, these patients responded well to re-treatment with MTX." | ( Abril, A; Berianu, F; Cohen, MD; Ginsburg, WW, 2015) |
| "The cumulative rate of post-treatment HBV relapse at 5 years was 57." | ( Changchien, CS; Chen, CH; Hsu, MC; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH; Yao, CC, 2015) |
| "Treatment according to clinical risk of recurrence, with early colonoscopy and treatment step-up for recurrence, is better than conventional drug therapy alone for prevention of postoperative Crohn's disease recurrence." | ( Andrews, JM; Bampton, PA; Bell, SJ; Brown, SJ; Connell, WR; De Cruz, P; Debinski, H; Desmond, PV; Elliott, PR; Florin, TH; Gearry, RB; Gibson, PR; Gorelik, A; Hamilton, AL; Johnston, MJ; Kamm, MA; Krejany, EO; Kronborg, I; Lawrance, IC; Leong, RW; Liew, D; Macrae, FA; Prideaux, L; Radford-Smith, G; Ritchie, KJ; Selby, W; Sparrow, M; Woods, R, 2015) |
| "Added to that is treatment for 74 recurrences ($1." | ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015) |
| "The reduction in inpatient utilization, recurrences, and major bleeding resulting from a 25% shift from standard therapy to rivaroxaban following acute VTE would conserve ∼$860,475 for every 1 million commercial health plan enrollees." | ( Bookhart, B; Mody, SH; Ogden, K; Patel, AA, 2015) |
| "However, given recurrence after interval disease-controlled period, long-term follow-up should be required to detect recurrence in patients with any residual lesion after treatment." | ( Byun, H; Jeon, P; Kim, B; Kim, D; Kim, H; Kim, K; Kim, S; Kim, Y, 2015) |
| "In the present article, when and how to treat relapsed MM is discussed." | ( Bladé, J; Fernández de Larrea, C; Rosiñol, L, 2015) |
| "To analyse the rate of clinical recurrences in Brazilian patients with Vogt-Koyanagi-Harada (VKH) disease after early high-dose corticosteroid treatment." | ( Costa, RA; da Silva, FT; Hirata, CE; Kalil, J; Marin, ML; Rodrigues, H; Sakata, VM; Yamamoto, JH, 2015) |
| "In addition, secondary recurrence without optimal first-line therapy is ~50%." | ( Coons, JC; Rao, SK; Schwier, NC, 2015) |
| "Eight patients had symptomatic recurrence of lesions 3-12 weeks after treatment and underwent reoperation." | ( Ahmed, FU; Garg, A; Gupta, A; Mahapatra, AK; Naik, V; Sarkar, C; Sharma, B, 2015) |
| "The patient declined surgery for recurrence so radiotherapy was planned." | ( Akita, H; Fujino, S; Fujiwara, Y; Fukata, T; Gotoh, K; Kishi, K; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2014) |
| "The patient died from recurrence of gastric cancer 69 months after completion of the initial chemotherapy and 2 months after the stent insertion." | ( Ishiyama, S; Iwasaki, Y; Maeda, Y; Natsume, S; Oohinata, R; Takahashi, K; Yajima, K; Yuu, K, 2014) |
| "Response to treatment and relapse is similar regardless of infusion number." | ( Bunch, DO; Falk, RJ; Hogan, SL; Hu, Y; Katsanos, SL; Kidd, JM; Kotzen, ES; McGregor, JG; Nachman, PH; Negrete-Lopez, R; Poulton, CJ, 2015) |
| "For patients with locoregional recurrence(s), image fusion was performed between radiotherapy planning CT and follow-up CT(s)." | ( Boterberg, T; Ceelen, W; Pattyn, P; Thoen, H; Van Daele, E, 2015) |
| "In-field recurrence is associated with widespread tumor dissemination and poor pathological response to neoadjuvant treatment." | ( Boterberg, T; Ceelen, W; Pattyn, P; Thoen, H; Van Daele, E, 2015) |
| "The median duration from initiation of treatment to relapse was 14." | ( Advani, RH; Hiniker, SM; Hoppe, RT; Khodadoust, MS; Kozak, MM; Pollom, EL; Quon, A; Xu, G, 2015) |
| "Secondary endpoints are anatomic recurrence rate, symptomatic recurrence rate, quality of life, surgical site infection, time to wound closure, symptoms related to treatment, pain, usage of pain medication and total treatment time." | ( Davids, PH; Furnée, EJ; Pronk, A; Smakman, N, 2015) |
| "For reducing the rate of recurrence, 3 treatments were ranked as follows: radioiodine therapy, therapy with antithyroid drugs and surgery." | ( Li, J; Li, Y; Qin, L; Ren, Z; Wang, JQ; Zhang, RG, 2015) |
| "Five patients had recurrences and were treated as outpatients without antibiotics." | ( Andreasson, K; Chabok, A; Isacson, D; Nikberg, M; Smedh, K; Thorisson, A, 2015) |
| "However, HBV recurrence still occurs with these treatments." | ( Bai, JH; Chen, G; Gan, XM; Hu, ZQ; Li, L; Liu, H; Liu, QY; Ma, LJ; Wang, DD; Wang, F; Zhao, YP, 2015) |
| "However, there were five recurrences in 52 patients treated with the European protocol." | ( Bai, JH; Chen, G; Gan, XM; Hu, ZQ; Li, L; Liu, H; Liu, QY; Ma, LJ; Wang, DD; Wang, F; Zhao, YP, 2015) |
| "In the present retrospective study, the recurrence rate of KOTs treated by E&C with application of CS is significantly lower than that of MC." | ( Braun, TM; Dashow, JE; Edwards, SP; Helman, JI; McHugh, JB; Ward, BB, 2015) |
| "No difference in 60-day VRE-BSI recurrence was observed between treatment groups." | ( Britt, NS; Patel, N; Potter, EM; Steed, ME, 2015) |
| "After treatment, the relapse rate and the required dose of oral corticosteroid were decreased in most cases, showing a significant steroid-sparing effect." | ( Chung, YR; Lee, ES; Lee, K; Park, JY; Song, JH, 2015) |
| "The rate of recurrence of subacute thyroiditis (SAT) during prednisolone (PSL) therapy is approximately 10 to 20%." | ( Arao, T; Kurozumi, A; Narisawa, M; Okada, Y; Tanaka, Y; Torimoto, K; Yamamoto, S, 2015) |
| "Events of keloid recurrence were associated with anatomic areas and treatment modalities." | ( Chang, CH; Park, TH, 2015) |
| "More failures and recurrence with metronidazole have led to treatment algorithms suggesting its use for mild infections and switching to vancomycin if there is no clinical improvement." | ( Marra, F; Ng, K, 2015) |
| "No patient had VTE recurrence, and no patient had a major or clinically relevant bleeding event while on therapy (none of the 106, 0%, 95% confidence interval [CI] = 0% to 3." | ( Beam, DM; Kahler, ZP; Kline, JA, 2015) |
| "The pooled total recurrence rate was 19% (95%CI, 15-24%); 17% (95%CI, 14-22%) in the HES-treated subgroup." | ( Beuth, W; Di Leo, G; Nowaczewska, M; Pałys, A; Sardanelli, F; Serafin, Z, 2015) |
| "The first recurrence can be treated with the same therapeutic agent and, for subsequent recurrences, vancomycin in a tapered and/or pulsed regimen is recommended." | ( Doron, S; Gorbach, S; Mizusawa, M, 2015) |
| "There was 1 recurrence in a periphyseal lesion in a 2-year-old boy treated with curettage, burring, and adjuvant chemotherapy." | ( Crowe, MM; Houdek, MT; Kakar, S; Moran, SL, 2015) |
| "The mainstay of therapy for recurrences is aspirin or NSAIDs, with the adjunct of colchicine." | ( Brucato, A; Gaita, F; Imazio, M; Lazaros, G, 2016) |
| "In patients allocated to 14 weeks treatment a relapse was observed in 11% of TMA undetectable patients and 26% of TMA positive (p = 0." | ( Bjøro, K; Dalgard, O; Marcellin, P; Martinot-Peignoux, M; Ring-Larsen, H; Verbaan, H, 2015) |
| "Although recurrences of neonatal HSV infection with CNS disease after suppressive therapy are uncommon, both clinical and virological assessments at the end of the suppressive therapy may be required." | ( Hara, S; Ito, Y; Kato, K; Kawada, J, 2015) |
| "Post-OLT patients with a proven recurrence of HCV were treated with SOF and ribavirin (RBV) for 24 weeks (n=10)." | ( Beckebaum, S; Bester, C; Heinzow, H; Hüsing, A; Kabar, I; Schmidt, HH; Seifert, LL; Stahl, M; Vorona, E, 2015) |
| "Patients with histological recurrence were treated with pegylated interferon in escalating dose regimen for 48 weeks and weight-based ribavirin." | ( Bhangui, P; Choudhary, NS; Gautam, D; Goja, S; Lipi, L; Menon, PB; Ramachandra, SK; Rastogi, A; Saigal, S; Saraf, N; Soin, AS, 2015) |
| "There has been no finding of recurrence or metastasis after chemotherapy." | ( Fukuda, H; Iida, S; Iizuka, J; Ikeda, T; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Toda, N, 2015) |
| "Two patients experienced a recurrence of hypercortisolism, and one was treated with mitotane, whereas the other underwent a second adrenal surgery 9 years after initial UA." | ( Benoit, M; Caron, P; Chabre, O; Chaffanjon, P; Debillon, E; Lambert, B; Massoutier, M; Salenave, S; Tabarin, A; Velayoudom-Cephise, FL; Wagner, T; Young, J, 2015) |
| "A high HR-HPV load is a risk factor for recurrence, but is not related to treatment response." | ( Hong, JH; Kim, YS; Koo, YJ; Lee, JK; Min, KJ, 2016) |
| "Potential risk factors for recurrence-age, menopausal status, symptoms, cyst diameter, laterality, aspirated volume, simple US-guided aspiration or alcohol sclerotherapy, and complications-were analyzed by logistic regression." | ( Carreras, R; Castellarnau, M; Cayuela, E; García-Tejedor, A; Ponce, J, 2016) |
| "Based on the lower recurrence rate, ethanol sclerotherapy was more efficacious than simple aspiration in the management of simple adnexal cysts measuring <10 cm." | ( Carreras, R; Castellarnau, M; Cayuela, E; García-Tejedor, A; Ponce, J, 2016) |
| "The cumulative recurrence rate of bleeding was significantly higher in the sclerotherapy+ group (14." | ( Chen, J; Chen, SY; Gao, H; Li, B; Lian, JJ; Luo, TC; Ma, LL; Tseng, YJ; Wang, J; Zeng, XQ, 2016) |
| "Early recurrence (ER) of atrial tachyarrhythmias during the first 3 months (blanking period) after atrial fibrillation ablation can be highly symptomatic, often requiring emergency treatment." | ( Choi, KJ; Han, S; Kim, J; Kim, KH; Kim, SH; Kim, YH; Kim, YR; Lee, S; Nam, GB, 2015) |
| "Despite occasional late recurrences, antibiotic-only treatment of early appendicitis in children is feasible, safe, cost-effective and is experienced more favorably by patients and parents." | ( Hartwich, J; Kurkchubasche, AG; Luks, FI; Muratore, CS; Tracy, TF; Watson-Smith, D; Wills, HE, 2016) |
| "No retreatments or recurrences were seen." | ( Amans, MR; Cooke, DL; Dowd, CF; Halbach, VV; Hetts, SW; Higashida, RT; Nicholson, AD; Settecase, F, 2016) |
| "However, an unusual recurrence of the disease in a Ghanaian male after standard treatment was observed and is herein reported." | ( Quashie, NB; Tsegah, E, 2015) |
| "Two Plasmodium vivax recurrences in a Peruvian sailor with weight above the 60 kg (cap for primaquine dosage) highlight the importance of adequate radical cure weight dosage for patient treatment and control efforts, particularly within the military." | ( Cavalcanti, S; Gonzalez, S; Lescano, AG; McFarland, AP; Mercado, A; Sanchez, JF; Ventocilla, JA, 2015) |
| "vivax recurrences in the 12 months following therapy were classified as relapses." | ( Baird, JK; Basri, H; Chand, K; Djoko, D; Duparc, S; Ekasari, T; Ekawati, LL; Elyazar, I; Nelwan, EJ; Noviyanti, R; Setiabudy, R; Subekti, D; Sudoyo, H; Sutanto, I; Taylor, WR; Tjahjono, B, 2015) |
| "Risks of recurrence and bleeding are highest during the first weeks of anticoagulant therapy for venous thromboembolism (VTE)." | ( Agnelli, G; Buller, HR; Cohen, AT; Gallus, AS; Ramacciotti, E; Raskob, GE; Sanders, P; Thompson, JR; Weitz, JI, 2016) |
| "The adverse reactions and recurrence of constipation after treatment were analyzed." | ( Chang, Q; Deng, Q; Meng, S; Pan, Y; Wang, L, 2015) |
| "The early recurrence of neurological symptoms (NR) after urgent aggressive best medical therapy (BMT) in symptomatic carotid stenosis is not well documented." | ( Ellemann, K; Gottschalksen, B; Owen-Falkenberg, A; Shahidi, S, 2016) |
| "Despite that 12 patients had recurrence in the steroid non-treated group." | ( Badem, H; Cakmak, M; Cimentepe, E; Kaynar, M; Kosem, B; Ozyuvali, E; Yıldırım, ME, 2016) |
| "He is doing well without recurrence for 4 year and 6 months, without any adjuvant chemotherapy." | ( Asai, K; Baba, M; Hiratsuka, M; Katsuyama, S; Murata, M; Saso, K; Sawami, H; Takahashi, H; Takayama, O; Tanaka, N; Yagi, T; Yamada, M; Yamamoto, M, 2015) |
| "The patient was treated for his relapsed CLL with good effect, and has had no further episodes of angioedema and an improvement in the level of his C1 esterase protein level and function." | ( Ange, N; Pidcock, M; Rabbolini, DJ; Randall, KL, 2016) |
| "Although the recurrence rate was found to be higher in the patient group treated once with crystallized phenol application, the success rate following multiple applications of crystallized phenol was found to be 94." | ( Alparslan Yumun, HN; Bayhan, Z; Duzgun, SA; Mestan, M; Ucar, BI; Zeren, S, 2016) |
| "Only 1 patient had a local recurrence 1 year after the treatment." | ( Guan, H; Jiang, H; Liu, A; Liu, C; Qian, Y; Shi, Y; Wang, H; Zhang, W; Zhang, Y; Zhao, Y, 2016) |
| "The effect and recurrence rate were compared before and after treatment." | ( Fang, F; Hong, Z; Meiling, L; Yan, Z, 2015) |
| "At present there is no satisfactory treatment against relapse of drug-seeking behavior." | ( Castagné, V; Froger-Colléaux, C, 2016) |
| "One patient experienced a partial recurrence 5 months after the procedure and was successfully retreated with curettage + aminolevulinic acid PDT." | ( Cohen, LM; Kroumpouzos, G; Kuhn, H; Yang, CS, 2016) |
| "It has been suggested that recurrence after continuous terbinafine treatment may be less common than with intermittent or continuous itraconazole therapy, probably due to the fungicidal activity of terbinafine, although these differences tended not to be significant." | ( Bhatia, N; Caldwell, B; Elewski, BE; Gupta, AK; Kircik, LH; Pariser, DM; Rosen, T; Tosti, A, 2016) |
| "The overall recurrence rate of stones depends on factors such as previous stone history and type of treatment." | ( Curhan, GC; D'Addessi, A; Ferraro, PM; Gambaro, G, 2017) |
| "Factors that might contribute to tumor recurrence and treatment failure such as clinical factors, tumor features, and molecular biomarkers were included in our analysis." | ( Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J, 2016) |
| "Compared to surgical treatment of recurrences, laser depilation is an efficient and cost-effective method of preventing recurrence and reducing morbidity and loss of man-hours." | ( Baker, L; Govindan, KS; Javed, AA; Kenealy, J; Khan, MA; Rafiq, S; Thomas, K, 2016) |
| "There is no evidence of recurrence seven months after the chemotherapy." | ( Arai, H; Honda, M; Kobayashi, Y; Ueda, N; Yoshida, K, 2016) |
| "Known recurrence risk factors, such as inotrope administration, cardiac disease indices, Charlson Comorbidity Index, magnesium concentrations, fluid balance, and potassium concentrations, were also included in adjusted analysis using forward stepwise logistic regression modelling." | ( Bandeshe, H; Boots, R; Clement, P; Mitrić, G; Udy, A, 2016) |
| "Reductions in the cost of treating recurrence with fidaxomicin ranged from -€574." | ( Johal, S; McCrea, C; Nazir, J; Posnett, J; Watt, M, 2016) |
| "An 80-year-old man with a local recurrence of gastric cancer was treated with S-1 monotherapy leading to a complete response(CR)." | ( Hasegawa, M; Ichikawa, K; Kokado, Y; Koshiba, T; Kusama, T; Sone, N; Yamagami, K, 2016) |
| "Secondary outcomes are ulcer recurrence, wound pain, quality of life and wellbeing, adherence to study medication, adherence to compression therapy, serum inflammatory markers, hospitalisations, and adverse events at 24 weeks." | ( Aldons, P; Barker, A; Dapiran, E; Darby, I; Haines, T; Loveland, P; Madan, JJ; McNeil, J; Sinha, S; Underwood, M; Vicaretti, M; Ward, S; Weller, CD; Wolfe, R; Woodward, M, 2016) |
| "However, both recurrence and progression to MD after treatment were observed in some patients during the long-term follow-up." | ( Fujiwara, K; Fukuda, A; Fukuda, S; Homma, A; Iizuka, K; Masuya, M; Morita, S; Nakamaru, Y, 2016) |
| "Malaria recurrences after an initially successful therapy and malarial fever occurring a long time after infection are well-known problems in malariology." | ( Franken, G; Holtfreter, MC; Labisch, A; Mehlhorn, H; Richter, J; Walter, S, 2016) |
| "GD is an active treatment for relapsed high-grade osteosarcoma, especially for ECOG 0 patients, and should be included in the therapeutic armamentarium of metastatic osteosarcoma." | ( Asaftei, S; Cesari, M; Coccoli, L; Fagioli, F; Ferrari, S; Grignani, G; Jones, RL; Longhi, A; Marchesi, E; Meazza, C; Paioli, A; Palmerini, E; Picci, P; Pollack, SM; Tamburini, A, 2016) |
| "Usually, these post-treatment recurrences occur only once and a second course of the same treatment is sufficient to cure patients." | ( Domergue, A; Duru, V; Khim, N; Kim, S; Menard, D; Witkowski, B, 2016) |
| "The mainstay of therapy for recurrences is physical restriction and anti-inflammatory therapy based on aspirin or NSAID plus colchicine." | ( Adler, Y; Charron, P; Imazio, M, 2016) |
| "Three patients had HD recurrence after a previous suboptimal invasive treatment [PAIR (2), unroofing (1)] and all had to undergo a major liver resection for the complete removal of parasites." | ( Ettorre, GM; Goletti, D; Guglielmo, N; Laurenzi, A; Manfredelli, S; Vennarecci, G, 2016) |
| "Forty-four previously untreated and 53 relapsed patients were enrolled." | ( Afanasyev, B; Barker, AM; Chang, CN; Domnikova, N; Doubek, M; Flinn, IW; Grosicki, S; Gupta, IV; Homenda, W; Janssens, A; Kuliczkowski, K; Offner, F; Panayiotidis, P; Smolej, L; West, SL; Wright, OJ, 2016) |
| "There was no other recurrence at 6 months off treatment." | ( Gao, Y; Liu, J; Lu, YG; Wang, HL; Wang, WS, 2016) |
| "Successful treatment of relapse helps patients with MS obtain a vital sense of being able to gain control over the disease." | ( Berkovich, RR, 2016) |
| "However, rates of pericarditis recurrence, symptoms persistence, and pericarditis-related hospitalization were significantly decreased with colchicine treatment." | ( Chen, YJ; Cheng, YJ; Deng, XL; Huang, CB; Huang, J; Mu, BY; Wang, MX; Wang, Q; Zhou, RW, 2016) |
| "Retreatment criteria for recurrence were: gain in sub-retinal fluid (SRF) of more than 25 % plus/or increase of central retinal thickness (CRT) of more than 50 μm plus visual symptoms compared to last visit." | ( Herold, TR; Priglinger, SG; Rist, K; Ulbig, MW; Wolf, A, 2017) |
| "Evaluation of recurrence rates and retreatments showed good results in patients who responded to spironolactone primarily." | ( Herold, TR; Priglinger, SG; Rist, K; Ulbig, MW; Wolf, A, 2017) |
| "We describe the recurrence of cardiac abnormalities in a patient treated during the acute phase of Chagas disease after outpatient follow-up of 5 years." | ( Antunes, AF; Barbosa, Md; Ferreira, JM; Guerra, JA; Maduro, SG; Pereira, BV, 2016) |
| "In addition, the recurrence rate of diarrhea and the incidence of severe diarrhea within 3 months after treatment in the zinc supplement group were significantly lower than in the conventional treatment group (P<0." | ( Jiang, CX; Xu, CD; Yang, CQ, 2016) |
| "We hypothesised that recurrence of syncope and presyncope can be reduced by discontinuing/reducing vasoactive therapy without increasing the risk of cardiovascular and neurological events." | ( Brignole, M; Gaggioli, G; Solari, D; Tesi, F; Tomaino, M; Ungar, A; Unterhuber, M, 2017) |
| "Whole-genome comparison of pretreatment and relapse isolates of M." | ( Alexander, DC; Benwill, JL; Brown-Elliott, BA; Cameron, AD; Griffith, DE; Perry, BJ; Philley, JV; Vasireddy, R; Vasireddy, S; Wallace, RJ, 2017) |
| "Hepatitis C virus (HCV) recurrence after liver transplantation (LT) used to be a serious problem in the era of interferon-based treatment." | ( Eurich, D; Globke, B; Pratschke, J; Raschzok, N; Schott, E; Teegen, EM, 2017) |
| "Because of its high recurrence, the treatment of auricularis keloids is troublesome to ENT doctors." | ( Liu, K; Wang, PH; Wu, XL, 2016) |
| "Treatment failures and recurrences are frequently associated with multiple genotypes, suggesting reinfection." | ( Choi, YS; Daley, CL; Huh, HJ; Jeon, K; Jeong, BH; Jhun, BW; Ki, CS; Kim, CK; Kim, DH; Kim, H; Kim, HK; Kim, J; Kim, SY; Koh, WJ; Kwon, OJ; Lee, H; Lee, NY; Lee, SH; Park, HY; Park, KU; Shin, SJ, 2017) |
| "Thirty eyes had recurrence around the primary lesion; 27 eyes had recurrence within 12 months after treatment." | ( Dong, Y; Ren, J; Xie, L; Zhang, Y, 2017) |
| "The cumulative risk of first recurrence at 4 years after treatment was 28." | ( Dong, Y; Ren, J; Xie, L; Zhang, Y, 2017) |
| "New drugs emerged in the treatment of relapse or refractory HL (brentuximab vedotine [BV], immunological checkpoint inhibitor anti-PD1)." | ( Casasnovas, RO; Rossi, C, 2017) |
| "Following recurrence of cancer of the sigmoid colon, the patient received a course of XELOX plus bevacizumab(Bmab)to treat peritoneal dissemination and lung metastases." | ( Fujii, T; Funahashi, K; Kaneko, H; Kaneko, T; Katayanagi, T; Koda, T; Koike, J; Kurihara, A; Masuhara, H; Sawaguchi, Y; Shimada, H; Shiokawa, H; Suzuki, T; Ushigome, M; Watanabe, Y, 2016) |
| "Chemotherapy is performed for the recurrence of gastric cancer in many cases." | ( Iijima, S; Nishioka, K; Oshima, S; Takachi, K; Takemoto, H; Tsujimura, N; Uemura, Y, 2016) |
| "The high recurrence rate of keloids has lead to the use of multiple treatment adjuncts to improve cosmetic outcomes after surgery." | ( Dyachenko, A; Kanevsky, J; Luc, M; Mankowski, P; Tomlinson, J, 2017) |
| "Patients with recurrences may benefit from combined treatment with steroids and azathioprine." | ( Darlong, J; Govindharaj, P; John, AS; Kurian, R; Lockwood, DN; Sundarrao, P, 2017) |
| "Significant variables associated with recurrence were the presence of a hematological malignancy or receiving recent corticosteroid therapy." | ( McCarthy, KL; Paterson, DL, 2017) |
| "The primary endpoint was clinical recurrence of Crohn's disease (Crohn's Disease Activity Index >150 plus 100-point increase in score) and the need for anti-inflammatory rescue treatment or primary surgical intervention." | ( Ahmad, T; Arebi, N; Arnott, I; Bloom, S; Cahill, A; Campbell, S; Collie, M; Creed, T; Cummings, F; Dhar, A; Dunlop, MG; Edwards, C; Ennis, H; Gaya, DR; Goh, J; Hamlin, J; Hawkey, C; Keerie, C; Kennedy, NA; Lal, S; Lewis, S; Lewis, SJ; Lindsay, JO; McKinley, AJ; Morris, J; Mowat, A; Mowat, C; Murray, C; Naismith, GD; Nwokolo, C; Potts, L; Prescott, RJ; Satsangi, J; Sebastian, S; Sen, S; Smith, M; Subramanian, S; Thomas, L; Thomson, JM; Todd, JA; Travis, S; Winter, J; Yousif, M, 2016) |
| "malariae infection with clinical recrudescence after directly observed administration of artemether/lumefantrine." | ( Anstey, NM; Auburn, S; Berriman, M; Huang, GKL; Marfurt, J; Marr, I; Newbold, CI; Otto, TD; Price, RN; Rutledge, GG; Sanders, M; White, NJ, 2017) |
| "However, recurrence occurred and the patient achieved complete response following tegafur/gimeracil/oteracil-based chemotherapy." | ( Ikeyama, M; Ishizone, S; Nakayama, J; Yoshizawa, J, 2017) |
| "Given the high recurrence, rehospitalization and mortality rate, careful monitoring and long-term follow-up including controls of serum sodium, education and behavioural therapy are needed." | ( Arici, B; Bally, M; Christ-Crain, M; Mueller, B; Nigro, N; Sailer, CO; Schuetz, P; Suter-Widmer, I; Winzeler, B, 2017) |
| "191 attacks occurred during any of the treatments (annual relapse rate=0." | ( Aktas, O; Angstwurm, K; Berthele, A; Borisow, N; Faiss, J; Fischer, K; Friede, T; Gahlen, A; Geis, C; Hartung, HP; Havla, J; Hellwig, K; Hemmer, B; Hofstadt-van Oy, U; Jarius, S; Kleinschnitz, C; Kleiter, I; Krumbholz, M; Kümpfel, T; Lauda, F; Linker, RA; Marziniak, M; Mayer, C; Neuhaus, O; Pache, F; Paul, F; Ringelstein, M; Ruprecht, K; Schuster, S; Schwab, M; Stangel, M; Stellmann, JP; Then Bergh, F; Trebst, C; Tumani, H; Wildemann, B; Young, KL; Zeltner, L; Zettl, U; Ziemann, U, 2017) |
| "Multiple recurrences should be treated with vancomycin or fidaxomicin; if necessary, a vancomycin taper regimen may also be used." | ( Bachmann, O; Dersch, P; Solbach, P, 2017) |
| "Our primary prespecified outcome was recurrence of cellulitis when on treatment and after treatment." | ( Dalal, A; Days, W; Eskin-Schwartz, M; Hodak, E; Leibovici, L; Mimouni, D; Paul, M; Ray, S, 2017) |
| "In terms of recurrence, incidence, and time to next episode, antibiotic is probably an effective preventive treatment for recurrent cellulitis of the lower limbs in those under prophylactic treatment, compared with placebo or no treatment (moderate-certainty evidence)." | ( Dalal, A; Days, W; Eskin-Schwartz, M; Hodak, E; Leibovici, L; Mimouni, D; Paul, M; Ray, S, 2017) |
| "High recurrence has previously been reported in the treatment of melasma with low-fluence 1,064-nm Q-switched neodymium-doped yttrium aluminium garnet (QS-Nd:YAG) laser." | ( Balevi, A; Ozdemir, M; Ustuner, P, 2017) |
| "To evaluate the recurrence prevention efficacy of lurasidone for the maintenance treatment of bipolar I disorder, patients received up to 20 weeks of open-label lurasidone (20-80mg/d) combined with lithium or valproate during an initial stabilization phase." | ( Calabrese, JR; Cucchiaro, J; Loebel, A; Mao, Y; Pikalov, A; Streicher, C, 2017) |
| "Overall, the best results in preventing recurrences were achieved by combining three different treatments." | ( Hoffmann, TK; Rotter, N; Scheithauer, MO; Thierauf, J; Veit, JA; Walther, M, 2017) |
| "The median time to first and second recurrence after treatment were 43 and 121 days in patients receiving acyclovir and 33 and 118 days in patients receiving probiotic (HR 2." | ( Ghobadi, N; Keyvani, H; Mohseni, AH; Taghinezhad-S, S, 2018) |
| "Fidaxomicin treatment results in lower recurrence rates than vancomycin and metronidazole, but has higher acquisition costs in Europe and the USA." | ( Burton, HE; Mitchell, SA; Watt, M, 2017) |
| "The median time to recurrence was significantly longer in patients treated with anti-TNFs than in those who received thiopurines or mesalazine (37." | ( Allocca, M; Armuzzi, A; Bonovas, S; Danese, S; Fiorino, G; Furfaro, F; Landi, R; Papa, A; Peyrin-Biroulet, L; Spinelli, A, 2017) |
| "The mechanisms underlying IH recurrence after propranolol treatment have not been completely elucidated." | ( Chang, L; Chen, H; Gu, Y; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Ying, H; Yu, Z, 2018) |
| "There were neither recurrences nor relevant major adverse effects in all the five KFD cases treated with hydroxychloroquine." | ( Chen, YY; Chiou, YH; Huang, HH; Huang, YF; Lee, HS; Lin, YC; Liu, PY; Nong, BR, 2019) |
| "We examined the treatment, recurrence and prognosis of PVT in cirrhotic patients." | ( Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y, 2017) |
| "The cumulative recurrence rates at 1 and 2 posttreatment years were 26 and 30%, respectively." | ( Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y, 2017) |
| "Secondary outcome measures included recurrence of endometrial hyperplasia, progression of endometrial hyperplasia to endometrial cancer, hysterectomy rate, abnormal uterine bleeding, health-related quality of life, and adverse effects during treatment." | ( Atiomo, W; Clement, NS; Mulvaney, CA; Oliver, TR; Sanner, JR; Shiwani, H, 2017) |
| "The best adjuvant treatment to prevent recurrence after primary pterygium surgery is the association of conjunctival autograft and ciclosporin 0." | ( Arruda, GV; Fonseca, EC; Rocha, EM, 2018) |
| "We here describe a new paradigm for the treatment of relapsed multiple myeloma." | ( Lokhorst, HM; Nijhof, IS; van de Donk, NWCJ; Zweegman, S, 2018) |
| "Few data exist on recurrence rates, treatment response, and long-term outcomes in kidney transplant recipients (KTR) with primary focal segmental glomerulosclerosis (FSGS)." | ( Budde, K; Halleck, F; Khadzhynov, D; Staeck, O, 2017) |
| "The frequency of recurrence in patients hospitalized for acute idiopathic pericarditis in a tertiary medical center in 2004-2014 who were treated with glucocorticoids or with non-steroidal therapy was assessed from the computerized hospital database." | ( Chezar Azzerad, C; Hasdai, D; Iakobishvili, Z; Kornowski, R; Mager, A; Porter, A; Talmor, Y, 2018) |
| "Treatment response and recurrence were analyzed with uni- and multivariate statistics, as well as internal validation and propensity score matching of factors known to affect recurrence to assess independent effects of DEB-TACE response on recurrence." | ( Albar, AA; Arndt, SE; Bohorquez, HE; Cohen, AJ; DeVun, DA; Galliano, GA; Gilbert, PJ; Gimenez, JM; Gulotta, PM; Kay, D; Kirsch, DS; Nunez, KG; Sandow, TA; Thevenot, PT, 2018) |
| "The developed model to predict recurrence was found to be of good accuracy and could be a useful tool in targeting patients at a higher risk for recurrence for closer monitoring during follow-up, after treatment with primaquine." | ( Islahudin, F; Kumolosasi, E; Makmor-Bakry, M; Mat Ariffin, N, 2017) |
| "Patients with endoscopic recurrence detected by either ileocolonoscopy or CE received pharmacologic therapy with azathioprine or infliximab." | ( Ai, XY; Bai, Y; Chen, ZY; Feng, XC; Han, ZM; Li, AM; Li, MS; Liu, SD; Qiao, WG; Wan, TM; Xu, ZM; Zhang, J; Zhi, FC, 2018) |
| "She suffered from peritoneal recurrence with ascites after 1 year and 4 months of the operation and RAM(8mg/kg; day 1 and 15)plus PTX(80mg/m2; day 1, 8 and 15)therapy was administrated as second-line chemotherapy." | ( Fujita, J; Furukawa, H; Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kimura, Y; Makari, Y; Mikami, J; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T, 2017) |
| "Relapses were defined as recurrence of GPA of sufficient severity to require treatment or increase in the dose of treatment on a patient who was previously stable." | ( Fathima, S; Prakash, R; Shobha, V, 2018) |
| "At the fifth recurrence of pseudomembranous colitis, the patient received vancomycin taper treatment, dietary counseling, and repeat instructions regarding hand hygiene and house cleaning." | ( Abe, K; Furukawa, K; Ishida, Y; Sakamoto, T; Shiba, H; Yanaga, K, 2018) |
| "Parents reported that recurrences of adhesions after last prescribed/performed treatment were frequent: in total 25% of patients still had adhesions corresponding to 8/29 (29%) of those whose last treatment was oestrogen and 1/9 (11%) of those whose last treatment was manual separation." | ( Ekmark, AN; Stenström, P; Wejde, E, 2018) |
| "At 1 year following initiation of DMF treatment, the relapse rate was lower for patients who did not experience a relapse during 1 year following initiation of natalizumab treatment than for those who did (rate ratio for relapse rate, 0." | ( Calkwood, J; Cohan, SL; Hotermans, C; LaGanke, C; Mann, MK; Meka, V; Meltzer, LA; Mendoza, JP; Moses, H; Okwuokenye, M; Smoot, KE; Tornatore, C, 2018) |
| "Percutaneous PFO closure to reduce the recurrence of stroke compared to medical therapy has been intensely debated." | ( Al-Khadra, Y; Alraies, MC; Darmoch, F; Fanari, Z; Soud, M, 2018) |
| "This work provides a VT recurrence IVC model that will help to improve the current understanding of the biological mechanisms and directed treatment of recurrent VT." | ( Andraska, EA; Diaz, JA; Elfline, MA; Henke, PK; Henke, SP; Hoinville, ME; Luke, CE; Madapoosi, SS; Metz, AK; Wakefield, TW, 2018) |
| "Transcatheter PFO closure reduces the recurrence of stroke compared with medical therapy alone, with no significant safety concerns." | ( Abdelaziz, HK; Abuomara, HZ; Madmani, ME; Mahmud, E; Nairooz, R; Pothineni, NVK; Roberts, DH; Saad, M, 2018) |
| "Cancer recurrence after initial diagnosis and treatment is a major cause of breast cancer (BC) mortality, which results from the metastatic outbreak of dormant tumour cells." | ( Green, JE; Hunter, KW; Nini, R; Vera-Ramirez, L; Vodnala, SK, 2018) |
| "He was treated for relapsed neurosyphilis with daily penicillin G injections without improvement." | ( Asano, A; Nishina, T; Satou, T; Uemori, M, 2018) |
| "Thyrozol was used to treat the recurrence of Graves' disease after pituitary surgery." | ( Huang, H; Huang, J; Li, J; Luo, D; Tan, H; Tang, Y; Yu, R, 2018) |
| "Absence of recurrence was achieved by 55% of sides receiving combined treatment and 35% of control sides." | ( Abdel Azim, AA; Abdelghani, R; Salem, RT, 2018) |
| "At diagnosis and before treatment, the relapse group had higher serum TSH-receptor antibody and free thyroxine levels and larger goiters than the remission group, with no differences in Graves' orbitopathy prevalence and severity." | ( Bartalena, L; Bianconi, E; Chiovato, L; Cusini, C; Gallo, D; Ippolito, S; Masiello, E; Piantanida, E; Premoli, P; Rosetti, S; Sabatino, J; Tanda, ML; Veronesi, G; Wiersinga, WM, 2018) |
| "We aimed to determine the rate of recurrence at a minimum of 6 months after completion of maintenance therapy." | ( Crouss, T; Nyirjesy, P; Smith, K; Sobel, JD, 2018) |
| "To estimate TB recurrence among newly diagnosed PTB patients who have successfully completed treatment and to document endogenous reactivation or re-infection." | ( Bajaj Bhalla, B; Bansod, R; Bhalla, M; Bhat, J; Chadha, VK; Dawale, A; Gangadhar Rao, V; Jawahar, MS; Jayabal, L; Jayasankar, SP; Joseph, B; Khaparde, SD; Khayyam, K; Kumar Sharma, R; Mathuria, K; Mrithunjayan, SK; Murali, L; Myneedu, VP; Nair, S; Narang, P; Narang, R; Narayanan Sivaramakrishnan, G; Natrajan, M; Pachikkaran, P; Ponnuraja, C; Ramalingam, S; Rao, R; Sanker, P; Sarin, R; Sebastian, G; Selvaraju, S; Shanmugam, S; Shivashankara, BA; Singh, N; Singla, N; Singla, R; Tiwari, CP; Tumane, KB; Velayutham, B; Viswambharan, R; Viswanathan, K; Yadav, R, 2018) |
| "Overall, 16 patients developed a recurrence of the endometrioma (12 in the nontreatment group, three in the OC group and one in the DNG group)." | ( Akiyama, K; Ito, F; Kataoka, H; Kitawaki, J; Koshiba, A; Kusuki, I; Matsushima, H; Mori, T; Okimura, H; Takaoka, O, 2018) |
| "DNG therapy early after recurrence of postsurgical endometrioma appears to be viable for reducing the risk of repeated surgery." | ( Akiyama, K; Ito, F; Kataoka, H; Kitawaki, J; Koshiba, A; Kusuki, I; Matsushima, H; Mori, T; Okimura, H; Takaoka, O, 2018) |
| "Effectiveness was evaluated by the recurrence rate at 1 year after treatment." | ( Clotet, B; García-Cuyás, F; Ornelas, A; Piñol, M; Revollo, B; Sirera, G; Vela, S; Videla, S, 2018) |
| "There was no recurrence of thrombocytopenia during 10 months of follow-up during treatment for MDR-TB with a regimen without LZD." | ( He, JQ; Wang, D; Wang, MG, 2018) |
| "Levamisole was effective in reducing recurrences of recalcitrant recurrent EMM and can thus be considered an alternative or add-on therapy for this disorder." | ( Chen, CB; Chung, WH; Hui, RCY; Kuan, YZ; Liu, RF, 2018) |
| "The efficacy and safety of treating such relapsers using ledipasvir/sofosbuvir (LDV/SOF) with/without ribavirin (RBV) has been limited." | ( Aqel, B; Keaveny, AP; Leise, M; Pungpapong, S; Vargas, HE; Watt, KD; Zhang, N, 2018) |
| "Lenalidomide, a critical agent in the treatment of relapsed multiple myeloma, is renally cleared." | ( Dueck, AC; Hayman, S; Kanate, AS; Lonial, S; Manola, J; Mikhael, J; Oettel, K; Rajkumar, SV, 2018) |
| "Investigate the risk of recurrence and of new skin malignant neoplasms, after treatment of BCC." | ( Guevara-Gutiérrez, E; Hernández-Torres, M; Ledesma, GS; Ruiz-González, JF; Tlacuilo-Parra, A, 2018) |
| "Eight of the strains caused recurrence more than 40 days after the treatment." | ( Hirose, M; Ichinose, H; Saito, M; Villanueva, SYAM; Yoshida, SI, 2018) |
| "To determine the late recurrence rate of appendicitis after antibiotic therapy for the treatment of uncomplicated acute appendicitis." | ( Aarnio, M; Grönroos, JM; Hurme, S; Jartti, A; Mecklin, JP; Nordström, P; Paajanen, H; Rantanen, T; Rautio, T; Salminen, P; Sand, J; Tuominen, R; Virtanen, J, 2018) |
| "Uveitis recurrence was treated as needed." | ( Foster, CS; Jaffe, GJ; Paggiarino, DA; Pavesio, CE; Riedel, GE, 2019) |
| "Tuberculosis (TB) recurrence observed to be an important event in its treatment and has future implications under national TB control efforts." | ( Bansal, AK; Bhardwaj, AK; Goel, C; Kumar, D, 2018) |
| "The most important agreements were: recurrence is a risk criterion per se; fidaxomicin is effective and safe for the treatment of infections caused by C." | ( Almirante, B; Bouza, E; Cobo, J, 2019) |
| "The pediatric literature regarding recurrence of instability is difficult to interpret because of the variable treatment protocols and varying ages." | ( Bastrom, TP; Edmonds, EW; Hughes, JL; Kruk, P, 2019) |
| "Because of ventricular arrhythmia recurrences, implantable cardioverter-defibrillator implantation is still mandatory in patients treated in secondary prevention and with high risk." | ( Abugattas, JP; Brugada, P; Capulzini, L; Chierchia, GB; Coutiño, HE; de Asmundis, C; Guimarães Osório, T; Iacopino, S; La Meir, M; Maj, R; Paparella, G; Poelaert, J; Salghetti, F; Sieira, J; Stroker, E; Terasawa, M; Umbrain, V; Van Dooren, S; Varnavas, V, 2019) |
| "Ten (26%) patients had disease recurrence requiring a new course of treatment." | ( Deguine, O; Fraysse, B; Fraysse, ME; Kmeid, M; Mansour, C; Marx, M; Nicolas, S, 2019) |
| "Given the increased risk of TTC recurrence, the question on reinitiation of ECT treatment after remission of the heart disease is also addressed." | ( Hartmut Schoels, W; Kudling, R; Kuhn, J, 2018) |
| "There was no difference in time to recurrence or recurrence frequency between patients treated with 14-day or 7-9 day primaquine regimens (HR = 1." | ( Daher, A; Fontes, CJ; Lalloo, DG; Marchesini, P; Silva, JCAL; Stevens, A; Ter Kuile, FO, 2019) |
| "vivax recurrences, associated risk factors and impact of treatment." | ( Daher, A; Fontes, CJ; Lalloo, DG; Marchesini, P; Silva, JCAL; Stevens, A; Ter Kuile, FO, 2019) |
| "A biopsy of first recurrence or metastatic disease is recommended to re-evaluate oestrogen receptor status in patients with breast cancer and to select appropriate treatment." | ( Ahn, JH; Ahn, SH; Chae, SY; Choi, WJ; Gong, G; Han, S; Jung, KH; Kim, HJ; Kim, J; Kim, JE; Kim, SB; Kim, SY; Ko, BS; Lee, HS; Lee, JB; Lee, JW; Lee, SH; Lee, SJ; Moon, DH; Oh, SJ; Shin, HJ; Son, BH, 2019) |
| "However, recurrence was more likely to occur in the oral SPRL group than in the half-dose photodynamic therapy group (P = 0." | ( Kim, DY; Kim, JY; Lee, EK; Lee, JY, 2020) |
| "KEY POINTS: • Gout flare recurrences were common within the first 3 months after starting urate-lowering therapy in gout patients." | ( Janssen, CA; Oude Voshaar, MAH; Ten Klooster, PM; van de Laar, MAFJ; Vonkeman, HE, 2019) |
| "Recidivism of cholesteatoma (recurrence and residual disease), variations in the average of bone conduction threshold after treatment, and complications." | ( de la Torre, C; Villamor, P, 2019) |
| "A number of recurrences after 3 months of therapy was assessed." | ( Gyaurgiev, TA; Kuzmenko, AV; Kuzmenko, VV, 2019) |
| "The risk of recurrence of venous thromboembolism (VTE) persists after interruption of the initial anticoagulation therapy." | ( Imberti, D; Mastroiacovo, D; Pomero, F, 2020) |
| "Since the risk of recurrence after treatment is particularly high, a combination of different methods is proposed." | ( Modarressi, A; Petrou, IG; Pittet-Cuénod, B; Rüegg, EM, 2019) |
| "58 patients with biochemical recurrence of PCa after definitive primary therapy were included." | ( Aigner, RM; Gstettner, C; Kulnik, R; Kvaternik, H; Pernthaler, B; Salamon, S, 2019) |
| "Lenalidomide is FDA-approved for treatment of relapsed/refractory mantle cell lymphoma as a single agent, as well as in combination with rituximab for R/R follicular lymphoma and marginal zone lymphoma." | ( Ruan, J; Yamshon, S, 2019) |
| "Age; success rate; aglepristone treatments number; relapse, pregnancy rates; diagnosis-relapse, -first, -last litter intervals; litters number after treatment, and LS were analyzed by ANOVA." | ( Alonge, S; Majolino, G; Melandri, M; Pisu, MC; Veronesi, MC, 2019) |
| "There were no recurrences of HCC, but there was one rejection episode and one cirrhosis decompensation episode, both 12 weeks after treatment." | ( Ataíde, EC; Boin, IFSF; Santos, AG; Stucchi, RSB; Zanaga, LP, 2019) |
| "We compared the risk of death or AIS recurrence over 1 year in patients treated with anticoagulants, antiplatelets, and/or other cardiovascular drugs." | ( Bégaud, B; Castilloux, AM; Faure, M; Lillo-Le-Louet, A; Moride, Y, 2020) |
| "Treatment aimed at prevention of recurrence of urinary stone disease allows to correct detected metabolic disturbances." | ( Amosov, AV; Amosova, MV; Demidko, LS; Demidko, YL; Enikeev, ME; Fadeev, VV; Grigoryan, VA; Kuzmicheva, GM; Rudenko, VI, 2019) |
| "vivax recurrence between days 7 and 42 after starting treatment were investigated by Cox regression analyses according to an a priori analysis plan." | ( Abreha, T; Adam, I; Anstey, NM; Assefa, A; Awab, GR; Baird, JK; Barber, BE; Chu, CS; Commons, RJ; Dahal, P; Daher, A; Davis, TME; Dondorp, AM; Grigg, MJ; Guerin, PJ; Hien, TT; Humphreys, GS; Hwang, J; Karunajeewa, H; Laman, M; Lidia, K; Moore, BR; Mueller, I; Nosten, F; Pasaribu, AP; Pereira, DB; Phyo, AP; Poespoprodjo, JR; Price, RN; Sibley, CH; Simpson, JA; Stepniewska, K; Sutanto, I; Thriemer, K; Thwaites, G; White, NJ; William, T; Woodrow, CJ, 2019) |
| "vivax recurrence at day 42 to be significantly lower following treatment with DP compared with AL, reflecting the longer period of post-treatment prophylaxis; this risk was reduced substantially by coadministration with PQ." | ( Abreha, T; Adam, I; Anstey, NM; Assefa, A; Awab, GR; Baird, JK; Barber, BE; Chu, CS; Commons, RJ; Dahal, P; Daher, A; Davis, TME; Dondorp, AM; Grigg, MJ; Guerin, PJ; Hien, TT; Humphreys, GS; Hwang, J; Karunajeewa, H; Laman, M; Lidia, K; Moore, BR; Mueller, I; Nosten, F; Pasaribu, AP; Pereira, DB; Phyo, AP; Poespoprodjo, JR; Price, RN; Sibley, CH; Simpson, JA; Stepniewska, K; Sutanto, I; Thriemer, K; Thwaites, G; White, NJ; William, T; Woodrow, CJ, 2019) |
| "Some patients have recurrence of flares, or become antibiotic-dependent, and require repeated courses or prolonged periods of antibiotic therapy." | ( Bar, N; Dotan, I; Dubinsky, V; Godny, L; Golan, N; Gophna, U; Keizer, D; Rabinowitz, K; Reshef, L; Tulchinsky, H; Yadgar, K; Zonensain, K, 2020) |
| "Univariate predictors of recurrence included treatment with metronidazole (40." | ( Allegretti, JR; Bry, L; Gerber, GK; Kennedy, K; Marcus, J; Sitko, J; Storm, M, 2020) |
| "Vancomycin treatment for CDI endangers recurrence in IMC patients." | ( Atamna, A; Avni, T; Ayada, G; Babitch, T; Ben-Zvi, H; Bishara, J; Hijazi, R, 2020) |
| "We compared rates of CDI recurrence and reinfection in Crohn's disease and ulcerative colitis (UC) patients receiving long-duration (LD) and short-duration (SD) oral vancomycin therapy, defined as 21-42 days and 10-14 days, respectively." | ( Andersen, M; Lei, DK; Ollech, JE; Rubin, DT; Sossenheimer, P; Weisshof, R; Zmeter, N, 2019) |
| "Azathioprine was used as a maintenance treatment." | ( Anagnostouli, M; Andreadou, E; Boutzios, G; Evangelopoulos, ME; Fragoulis, GE; Kilidireas, C; Koutsis, G; Stefanis, L; Toulas, P; Tzanetakos, D; Tzartos, J; Vakrakou, AG; Velonakis, G, 2020) |
| "MCT HSV lesions recurrence after treatment was reported in 33." | ( Cintra, ML; de Souza, EM; Florence, MEB; Magalhaes, RF; Sasso, BM; Stelini, RF; Velho, PENF, 2020) |
| "Metronidazole was associated with low recurrence rates at minimal costs in patients with uncomplicated CDI, but had relevant shortcomings in patients with severe CDI and/or a high risk of recurrence, suggesting that these vulnerable patients might better be treated with oral vancomycin and fidaxomicin, according to the latest guidelines." | ( Bartlomé, N; Bucheli Laffer, E; Fankhauser, H; Fux, CA; Haubitz, S; Spelters, C, 2020) |
| "Rates of recurrence remained high during treatment of a wound (0." | ( Armstrong, DG; Bloom, JD; Lakhani, PJ; Linders, DR; Petersen, BJ; Rothenberg, GM; Wood, KA; Zhou, M, 2020) |
| "Tamoxifen- treated patients with recurrence or non-recurrence were selected using a matched case-control design." | ( Andersson, G; Göthlin Eremo, A; Lagergren, K; Montgomery, S; Othman, L; Tina, E, 2020) |
| "They also discuss treatment for relapsed disease including targeted therapies." | ( Al-Juhaishi, T; Mckay, J; Sindel, A; Yazbeck, V, 2020) |
| "To compare recurrence between the second-generation HES and bare platinum coil (BPC) in the new-generation Hydrogel Endovascular Aneurysm Treatment Trial (HEAT)." | ( Abi-Aad, KR; Ansari, SA; Aoun, RJN; Aoun, SG; Bendok, BR; Dabus, G; Dashti, SR; Delgado Almandoz, JE; DeNardo, AJ; El Ahmadieh, TY; El Tecle, NE; Fiorella, D; Kniss, JF; Kwasny, MJ; Milot, G; Patra, DP; Rahme, RJ; Raymond, J; Scott, JA; Ward, JD; Woo, HH; Zammar, SG, 2020) |
| "Data on recurrence of IgG4-RD symptoms, laboratory and image findings were recorded, along with information on treatment in the serologically unstable condition." | ( Chen, D; Gao, J; Li, ZG; Liu, Y; Shen, D; Wang, K; Wang, Y; Wang, Z; Xia, C; Yang, F; Yu, G; Zeng, Q; Zhang, S; Zhu, L, 2020) |
| "Mixed DME eyes were treated with DEX-I relapse later and more frequently without subretinal fluid than IRC eyes." | ( De Geronimo, D; Eandi, CM; Giannini, D; Le Mer, Y; Neri, G; Parravano, M; Polito, MS; Tosi, GM; Varano, M, 2020) |
| "To compare recurrence rates for keloids treated with surgery plus one adjuvant intervention (dual therapy) versus surgery plus 2 or more adjuvant interventions (triple therapy)." | ( Ellis, MM; Jones, LR; Ozog, DM; Siddiqui, F; Sunkara, PR, 2020) |
| "The difference in recurrence rates between dual (19%) and triple therapy (11." | ( Ellis, MM; Jones, LR; Ozog, DM; Siddiqui, F; Sunkara, PR, 2020) |
| "Early detection of type 3 MNV recurrence by OCT-A characterisation may prompt retreatment and potentially prevent progression to late stages of the disease." | ( Bandello, F; Battista, M; Borrelli, E; Capuano, V; Corbelli, E; Miere, A; Querques, G; Querques, L; Sacconi, R; Souied, EH, 2021) |
| "Relapse was defined as the recurrence of GCA symptoms requiring treatment intensification." | ( Fernandes, AD; Matza, MA; Stone, JH; Unizony, SH, 2021) |
| "Post-treatment virologic relapse was defined as a serum HBV DNA level greater than 2000 IU/mL, and clinical relapse was defined as an alanine aminotransferase level greater than 80 U/L and a HBV DNA level greater than 2000 IU/mL." | ( Chen, CH; Hu, TH; Hung, CH; Jeng, WJ; Kuo, YH; Lu, SN; Tseng, TN; Wang, JH, 2020) |
| "There is no standard treatment for relapsed follicular lymphoma (FL)." | ( Baumann, T; Caballero, AC; Canet, M; Escoda, L; García, O; Iserte, L; López-Guillermo, A; Magnano, L; Mercadal, S; Muntañola, A; Salar, A; Sánchez-González, B; Sancho, JM; Soler, A; Sorigué, M; Villalobos, MT, 2020) |
| "To evaluate the recurrence rate after surgical excision, the pterygium patients were further subdivided into three groups according to the adjuvant therapy used to prevent recurrence." | ( Bayomy, NR; Elgouhary, SM; Elmazar, HF; Naguib, MI, 2020) |
| "The number of recurrences per eye was significantly lower in the FAi-treated compared with the sham-treated group (mean 1." | ( Jaffe, GJ; Pavesio, CE, 2020) |
| "Risk of recurrence did not differ significantly by subtype between treatment groups." | ( Ameriso, SF; Arauz, A; Berkowitz, SD; Chamorro, Á; Connolly, SJ; Hankey, GJ; Hart, RG; Kasner, SE; Korompoki, E; Lindgren, A; Muir, KW; Mundl, H; Ozturk, S; Pearce, LA; Perera, K; Rudilosso, S; Sharma, M; Shoamanesh, A; Shuaib, A; Tatlisumak, T; Toni, D; Veltkamp, R, 2020) |
| "On-treatment recurrence was observed in 30." | ( Abello, MS; Díaz, CJ; Doiny, DG; Falconi, EC; Majdalani, MG; Moltedo, JM; Nicastro, ES, 2020) |
| "Among 1,750 patients who completed treatment, 79 had relapse and 104 PKDL." | ( Alvar, J; Alves, F; Bern, C; Das, P; Das, VNR; Goyal, V; Hightower, A; Pandey, K; Rijal, S; Singh, RS; Singh, SN; Verma, N, 2020) |
| "After the first discharge, she got a recurrence of COVID-19 during her home isolation, and then returned to hospital and continued the previous therapy." | ( Cao, J; Fan, L; He, F; Hu, K; Lei, M; Luo, Q; Qin, S; Shao, X; Yang, L; Yu, N, 2020) |
| "However, our study reports recurrence at this rare site in an immunocompetent patient despite early suitable TB treatment and good adherence with therapy." | ( Abid, A; Amchich, Y; Boucaid, A; El Ouazzani, H; Rhorfi, IA; Rouihi, A; Souhi, H; Zegmout, A, 2020) |
| "Once clinical recurrence (CR) occurs, ETV treatment will be restarted." | ( Chen, G; Du, H; Gan, D; Gong, M; He, J; Huang, Y; Jiang, Y; Li, X; Li, Z; Lin, H; Long, F; Lu, B; Lu, W; Qiu, M; Sun, F; Sun, J; Sun, X; Wang, L; Wu, Q; Xiao, H; Xu, W; Yang, X; Ye, Y; Zhang, L; Zhang, M; Zhu, X, 2020) |
| "Six months after discharge due recurrence of symptoms, ranolazine was added to therapy." | ( Bosco, B; D'Andrea, D; Di Chiara, G; Iodice, P; Uran, C, 2020) |
| "TQ 300 mg single dose reduces P vivax recurrences compared to no antihypnozoite treatment during a six-month follow-up, but there is moderate uncertainty around effect size (RR 0." | ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020) |
| "One case showed recurrence 1 year 7 months after treatment, and chemotherapy was re-administered." | ( Hijikata, Y; Hirata, Y; Kobayashi, M; Lim, LA; Matsubara, Y; Ota, Y; Tojo, A; Yotsuyanagi, H, 2020) |
| "However, she experienced recurrence with positive T790 M, and osimertinib (80 mg/day) was administered as the 2nd line therapy." | ( Ishikawa, K; Kagamu, H; Kaira, K; Shinomiya, S; Yamaguchi, O, 2020) |
| "After contemporary treatment of ES-HL, relapse mostly occurred > 12 months after first diagnosis." | ( Baues, C; Behringer, K; Borchmann, P; Bröckelmann, PJ; Engert, A; Fuchs, M; Guhl, T; Moccia, AA; Müller, H; Pabst, T; Rank, A; Soekler, M; Vieler, T; von Tresckow, B, 2021) |
| "Treatment failures, which can be due to recrudescence or re-infection, are categorized as 'clinical' or 'parasitological' failures, the former indicating that symptoms have returned." | ( Challenger, JD; Mumtaz, R; Okell, LC, 2020) |
| "Disease recurrence is a common finding for those who undergo successful treatment." | ( Guo, W; Silverstein, D; Stevens, G; Zhu, C, 2021) |
| "Moreover, the main risk factors of recurrence after treatment with fidaxomicin remain unknown." | ( Castro Hernández, I; Cobo, J; Cuéllar Tovar, S; Escudero-Sánchez, R; García Fernández, S; Giner, L; Gutiérrez-Rojas, Á; Merino-de Lucas, E; Ramos-Martínez, A; Salavert Lletí, M; Valencia-Alijo, A, 2021) |
| "In consideration of the recurrence of the Henoch Schönlein Purpura and the gastrointestinal involvement, we decided to start Mycophenolate Mofetil treatment." | ( Cuomo, G; Del Giudice, EM; Gicchino, MF; Iafusco, D; Marrapodi, MM; Melone, R; Olivieri, AN; Zanfardino, A, 2021) |
| "This study aims to identify the rate of recurrence after surgical resection and radiotherapy on patients with chest keloids." | ( Fua, T; Miles, OJ; Paleri, S; Ramakrishnan, A; Zhou, J, 2021) |
| "Recently, corticosteroid dosing to treat relapses has been questioned, with data suggesting lower doses may be as effective." | ( Christian, MT; Maxted, AP, 2022) |
| "Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse." | ( Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR, 2021) |
| "A severe recrudescence was detected and attributed to hyperparasitaemia, monotherapy and a polyclonal infection without Kelch 13 gene mutation." | ( Abraham, P; Argaud, L; Becker, A; Bienvenu, AL; Bonnot, G; Chidiac, C; Conrad, A; Kouakou, YI; Landre, S; Leboucher, G; Miailhes, P; Picot, S; Rimmelé, T; Simon, M, 2021) |
| "The main factors in preventing recurrence include optimal surgical treatment by an excision combined with a free conjunctival autograft, consistent postoperative treatment with preservative-free artificial tears and topical steroids as well as long-term UV protection." | ( Cursiefen, C; Heindl, LM; Rokohl, AC, 2021) |
| "The VTE recurrence composite was lower for patients treated with anticoagulants (7." | ( Casanegra, A; Daniels, P; Froehling, D; Hodge, D; Houghton, D; Kuczmik, W; Lang, T; Macedo, T; McBane, RD; Meverden, R; Vlazny, D; White, L; Wysokinski, WE, 2021) |
| "The major drawback of this treatment is the relapse of hyperthyroidism in half of the patients after discontinuation of the recommended conventional 12-18 months of MMI treatment." | ( Abdi, H; Amouzegar, A; Azizi, F, 2021) |
| "Although the standard treatment for relapsed DLBCL is high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT), the efficacy of this approach for primary refractory DLBCL is not well understood." | ( Fukuhara, S; Hatta, S; Ito, Y; Izutsu, K; Kobayashi, Y; Makita, S; Maruyama, D; Miyagi-Maeshima, A; Munakata, W; Nomoto, J; Suzuki, T; Tajima, K; Taniguchi, H; Tobinai, K; Yuda, S, 2021) |
| "However, the high recurrence rates have led to the use of adjuvant therapy after surgical keloid excision." | ( Lee, JW; Seol, KH, 2021) |
| "We correlated the localization of recurrence with the panel-based IF-RT plan, which was drawn up for all patients prospectively, blinded to treatment allocation." | ( Baues, C; Borchmann, P; Celik, E; Eich, H; Engert, A; Fuchs, M; Goergen, H; Kobe, C; Marnitz, S; Rosenbrock, J; Voltin, CA, 2021) |
| "DMF is associated with lower risk of treated relapse for patients with RRMS than other first-line RRMS agents (TERI and IIM)." | ( Abouelfath, A; Blin, P; Bosco-Lévy, P; Brochet, B; Debouverie, M; Diez, P; Droz-Perroteau, C; Guillemin, F; Heinzlef, O; Lassalle, R; Lignot, S; Louapre, C; Maillart, E, 2022) |
| "We sought to describe the risk of recurrence at 1 month after the end of treatment for FUTI due to ESBL-E according to the oral relay therapy used." | ( Andriantahina, I; Angoulvant, F; Birgy, A; Bonacorsi, S; Cixous, E; Cohen, R; Craiu, I; De Pontual, L; Dommergues, MA; Dubos, F; Gajdos, V; Georget, E; Gillet, Y; Grimprel, E; Jung, C; Launay, E; Levy, C; Lignieres, G; Madhi, F; Pinquier, D; Rybak, A; Soussan-Banini, V; Vignaud, O, 2021) |
| "Glucocorticoids (GCs) are the main treatment of relapse in multiple sclerosis (MS)." | ( Evangelopoulos, DS; Evangelopoulos, ME; Kassi, E; Moutsatsou, P; Nasiri-Ansari, N; Papadopoulou, A, 2021) |
| "Through regular visits, the recurrence of aspergillus infection, quality of life, lung function indicators, safety of antifungal therapy and other indicators were recorded to evaluate the recurrence risk of aspergillus infection and safety of antifungal agents." | ( Chen, X; Liang, S; Xu, J; Zhang, L; Zhou, Y, 2021) |
| "With notable recurrence of FSGS noted on kidney transplant biopsy, she was initially treated with additional plasmapheresis sessions leading to downtrend in proteinuria." | ( Bomback, AS; Chen, JK; Jain, NG; Kehoe, J; Mahajan, R; Singer, P; Whyte, D, 2022) |
| "To evaluate the efficacy, safety, and recurrence rates with polidocanol sclerotherapy in the treatment of pyogenic granulomas (PGs)." | ( Khurana, A; Mathachan, SR, 2022) |
| "The risk of recurrence after a venous thromboembolism (VTE) related to estrogen-containing contraceptives is a key driver to guide anticoagulant treatment decisions." | ( Coppens, M; Klok, FA; Knijp, J; Middeldorp, S; Moll, S; van Es, N; Wiegers, HMG, 2022) |
| "The primary outcome was intention-to-treat relapse-free survival at day 210, defined as absence of signs and symptoms of VL or, if symptomatic, negative parasitological investigations." | ( Alexander, N; Alves, F; Burza, S; Das, P; Das, VNR; de Lima Pereira, A; Gill, N; Goyal, V; Harshana, A; Kazmi, S; Kumar, D; Kumar, V; Lal, CS; Lasry, E; Mahajan, R; Pandey, K; Rewari, B; Rijal, S; Verma, N, 2022) |
| "Venetoclax is used to treat relapsed/refractory chronic lymphocytic leukemia (r/r CLL)." | ( de Lemos, M; Gerrie, A; Ladha, F; Lee, C; Markarian, A; Nakashima, L; Schaff, K; Woo, S, 2022) |
| "Response to treatment, relapse rate, complications, and results of serological tests were compared in both groups." | ( Emami, K; Hashmi, SH; Majzoobi, MM; Soltanian, AR, 2022) |
| "The proportion of recurrences was numerically lower in those treated with bezlotoxumab, although the propensity analysis did not find significant differences between the two drugs." | ( Armiñanzas Castillo, C; Cano Yuste, A; Cobo Reinoso, J; De La Torre Cisneros, J; Díaz Pollán, B; Escudero-Sanchez, R; Fernández Fradejas, J; García Basas, L; García Fernández, S; Giner, L; Gutierrez Rojas, A; Gutiérrez, B; López Medrano, F; Martín Segarra, O; Merino De Lucas, E; Muriel García, A; Olmedo Sampedrio, M; Ramos Martínez, A; Rodríguez Hernández, MJ; Rodríguez-Pardo, D; Ruíz Ruigomez, M; Sáez Bejar, C; Salavert Lletí, M; Tasias Pitarch, M; Valencia Alijo, A, 2022) |
| "Results of recurrence rate varied by specific treatment modality; keloid excision yielded a rate of only 54%, keloid excision with postoperative radiation yielded a rate of 83%, keloid excision with intraoperative triamcinolone injection yielded a rate of 33%, and keloid excision with a combination of intraoperative triamcinolone injection and postoperative radiation yielded a rate of 33%." | ( Margiotta, E; Ramras, S; Shteynberg, A, 2022) |
| "We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020." | ( Balieiro, PCDS; Brito-Sousa, JD; Cordeiro, JSM; Lacerda, M; Melo, GC; Mendes, M; Monteiro, W; Phanor, J; Sampaio, VS; Silva-Neto, AV; Vitor-Silva, S, 2022) |
| "Postoperative recurrence rates were compared between surgical treatment groups: CAU + MMC, CAU, AMG + MMC, and AMG." | ( Kim, YJ; Lee, HJ; Rao, R, 2023) |
| "The primary end point was CDI recurrence after treatment with fidaxomicin or vancomycin." | ( Appaneal, HJ; LaPlante, KL; Liao, JX; Vicent, ML; Vyas, A, 2022) |
| "Tumour recurrences after treatment of head and neck squamous cell carcinoma (HNSCC) are more likely to originate from regions of high-baseline FDG-PET uptake." | ( Aren, E; Berry, M; Deshpande, S; Estall, V; Fowler, A; Jameson, MG; Johnston, M; Lee, M; Trada, Y, 2023) |
| "To compare the recurrence rate and risk factors between conservative surgery followed by medical treatments and conservative surgery-only in patients with focal adenomyosis." | ( Ma, X; Wang, S; Wang, W; Wu, Z; Xiang, T; Zhang, M, 2023) |
| "The KAAS can predict recurrence in patients with chest keloids after surgery and radiotherapy." | ( Hao, Y; Liang, Z; Liu, H; Shan, M; Song, K; Wang, Y; Xia, Y, 2023) |
| "The KAAS can be used to predict the recurrence and we developed a nomogram for predicting the recurrence of chest keloids after surgery and adjuvant radiotherapy." | ( Hao, Y; Liang, Z; Liu, H; Shan, M; Song, K; Wang, Y; Xia, Y, 2023) |
| "The KAAS can predict recurrence in patients with chest keloids after surgery and radiotherapy." | ( Hao, Y; Liang, Z; Liu, H; Shan, M; Song, K; Wang, Y; Xia, Y, 2023) |
| "The KAAS can be used to predict the recurrence and we developed a nomogram for predicting the recurrence of chest keloids after surgery and adjuvant radiotherapy." | ( Hao, Y; Liang, Z; Liu, H; Shan, M; Song, K; Wang, Y; Xia, Y, 2023) |
| "The KAAS can predict recurrence in patients with chest keloids after surgery and radiotherapy." | ( Hao, Y; Liang, Z; Liu, H; Shan, M; Song, K; Wang, Y; Xia, Y, 2023) |
| "The KAAS can be used to predict the recurrence and we developed a nomogram for predicting the recurrence of chest keloids after surgery and adjuvant radiotherapy." | ( Hao, Y; Liang, Z; Liu, H; Shan, M; Song, K; Wang, Y; Xia, Y, 2023) |
| "Keloid is a benign tumor with high recurrence rate; accordingly, complete surgical excision with adjuvant radiotherapy is one of the most effective treatments." | ( Chen, F; Chiang, CH; Huang, CJ; Huang, MY; Kuo, YR; Tang, JY, 2022) |
| "The end points were recurrence rate and local recurrence-free interval (LRFI), defined clinically as palpable gross tumor over the treatment site and duration from the last day of radiotherapy to disease recurrence." | ( Chen, F; Chiang, CH; Huang, CJ; Huang, MY; Kuo, YR; Tang, JY, 2022) |
| "Keloid is a benign tumor with high recurrence rate; accordingly, complete surgical excision with adjuvant radiotherapy is one of the most effective treatments." | ( Chen, F; Chiang, CH; Huang, CJ; Huang, MY; Kuo, YR; Tang, JY, 2022) |
| "The end points were recurrence rate and local recurrence-free interval (LRFI), defined clinically as palpable gross tumor over the treatment site and duration from the last day of radiotherapy to disease recurrence." | ( Chen, F; Chiang, CH; Huang, CJ; Huang, MY; Kuo, YR; Tang, JY, 2022) |
| "Keloid is a benign tumor with high recurrence rate; accordingly, complete surgical excision with adjuvant radiotherapy is one of the most effective treatments." | ( Chen, F; Chiang, CH; Huang, CJ; Huang, MY; Kuo, YR; Tang, JY, 2022) |
| "The end points were recurrence rate and local recurrence-free interval (LRFI), defined clinically as palpable gross tumor over the treatment site and duration from the last day of radiotherapy to disease recurrence." | ( Chen, F; Chiang, CH; Huang, CJ; Huang, MY; Kuo, YR; Tang, JY, 2022) |
| "The primary outcome was the late recurrence after treatment." | ( Çam, N; Çınar, T; Durmuş, G; Gökalp, M; Gürkan, K; Hayıroğlu, Mİ; Karataş, MB; Zengin, A, 2022) |
| "One of the biggest challenges to treat OUD is the relapse to drug seeking after prolonged abstinence." | ( Li, G; Singh, A; Wang, Y; Wang, ZJ; Yue, S, 2023) |
| "However, 30% of patients treated with IST relapse." | ( Aggarwal, N; Durrani, J; Groarke, EM; Lotter, J; Manley, AL; Patel, BA; Rios, O; Shalhoub, R; Wu, CO; Young, NS, 2023) |
| "Adapted systemic treatment of relapsed disease considering the initial risk group and initial treatment is reasonable." | ( Ebinger, M; Fuchs, J; Heinz, AT; Klingebiel, T; Koscielniak, E; Kratz, CP; Ljungman, G; Münter, MW; Pajtler, KW; Rößler, J; Schönstein, A; Seitz, G; Sparber-Sauer, M; Stegmaier, S; Timmermann, B; Vokuhl, C; von Kalle, T, 2023) |
| "However, no effective prevention or treatment for drug relapse is available." | ( Huang, D; Ma, YY, 2023) |
| "every day) and baseline and post-treatment alcohol relapse status (relapser vs." | ( Abduljaleel, JK; Ahamed, R; Augustine, P; Philips, CA; Rajesh, S; Tharakan, A, 2023) |